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Abréviations 
 
AA anisamide 
AD aerodynamic diameter 
AS-ODN antisense oligodeoxynucleotides 
C3, C4, C5 complement components 3, 4, 5 
CAM cell adhesion molecules 
CAP calcium phosphate 
CD24 / CD44 cluster of differentiation number 24 / 44 
CD44v variant isoforms of CD44 
CE capillary electrophoresis 
CF cystic fibrosis 
CTGF connective growth factor 
DAPI 4′,6-diamidino-2-phenylindole 
DE [2-(2-3didodecyloxypropyl)hydroxyethyl] ammonium bromide 
DEAPA diethylaminopropylamine 
DiPhPE diphytanoyl glycerophosphatidylethanolamine 
DOPE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
DOTAP 1,2-dioleyl-3-trimethylammonium-propane 
DOTMA n-[1-(2,3-dioleyloxy) propyl]-n,n,n-trimethylammonium chloride 
DPPE dipalmitoyl phosphatidylethanolamine 
DSC differential scanning calorimetry 
DSGLA n,n-distearyl-nmethyl-n-2[n’-(n2-guanidino-l-lysinyl)] aminoethyl ammonium chloride 
DSRNA double-stranded RNA 
EDC ethyl-dimethyl-aminopropyl-carbodiimide 
EHV-1 equine herpes virus type 1 
EPR enhanced permeability and retention 
ErbB2 receptor tyrosine-protein kinase 
ERK1/2 extracellular signal regulated kinases 
FITC fluorescein isothiocyanat 
GFP green fluorescent protein 
HA hyaluronic acid 
HA-LCS-NPs hyaluronic-acid lipid-chitosan nanoparticles 
HARE HA receptor for endocytosis 
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HAase hyaluronidase 
HMW high molecular weight 
ICAM-1 intracellular adhesion molecule-1 
IgG / IgM immunoglobulin G / M 
LMW low molecular weight 
LUC luciferase 
LYVE-1 lymphatic vessel endocytic receptor 
MLV multilamellar vesicle 
MPP mucus-penetrating particles 
MPT multiple particle tracking 
MSD mean square displacement 
MW molecular weight 
MβCD methyl-β-cyclodextrin 
NLC nanostructured lipid carriers 
PCL poly(ɛ-caprolactone) 
PCR polymerisation chain reaction 
PdI polydispersity index 
PE phosphatidylethanolamine 
PEG poly(ethylene glycol) 
PEI polyethylenimine  
PIV  parainfluenza virus 
PLGA poly(lactic-co-glycolic) acid 
PS polystyrene nanoparticles 
PSA poly(sebacic acid) 
PVA poly(vinyl alcohol) 
qPCR quantitative polymerisation chain reaction 
RHAMM receptor for hyaluronan-mediated motility 
RISC RNA induced silencing complex 
RPMI medium Roswell Park Memorial Institute 
RSV respiratory syncytial virus 
SCLC small cell lung cancer 
SAXS small-angle X-ray scattering 
siRNA small interfering RNA 
SLN solid lipid nanoparticles 
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SPARC secreted protein, acidic and rich in cysteine 
SPR surface plasmon resonance 
SUV small unilamellar vesicle 
TEM transmission electron microscopy 
TNF tumor necrosis factor 
VEGF vascular endothelial growth factor 
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Des progrès récents dans l’utilisation préclinique et clinique des petits ARN interférents (siRNA) ont 
montré leur potentiel en tant qu’inhibiteur de la synthèse protéique, et cela dans de nombreuses 
pathologies comme le cancer. L’administration des siRNA rencontre un certain nombre de problèmes 
liés à leur dégradation rapide dans les milieux biologiques, ainsi qu’à leur difficulté à pénétrer au sein 
des cellules cibles en raison de leur hydrophilie et de leur charge négative. Une des clés de 
l’amélioration de l’efficacité thérapeutique de ces molécules repose sur l’emploi de vecteurs. De 
nombreux vecteurs ont été formulés sur la base de systèmes colloïdaux que l’on dénomme 
aujourd’hui communément nanovecteurs ou nanomédicaments. Au cours de cette thèse, nous avons 
développé et optimisé des lipoplexes capables de protéger les siRNA contre la dégradation et de 
favoriser leur transport jusqu’aux cellules cibles. Ces lipoplexes, fonctionnalisés par de l’acide 
hyaluronique (HA), ont été conçus avec plusieurs objectifs, qui sont : (i) une complexation optimale 
des siRNA ; (ii) une toxicité limitée ; (iii) une capacité à cibler des cellules surexprimant le récepteur 
CD44, fortement impliqué dans les processus de développement tumoral et métastatique ; et (iv) un 
ciblage tumoral après administration par voie intraveineuse ou par voie intratrachéale. Pour ce faire, 
des lipolexes recouverts d’HA ont été formulés, caractérisés d’un point de vue physico-chimique mais 
aussi du point de vue de leur efficacité in vitro et in vivo, pour la vectorisation active de siRNA vers 
des cellules tumorales surexprimant le récepteur CD44. 
 
Le mémoire de la thèse comprend plusieurs parties. La première partie est bibliographique et se 
présente sous la forme de deux articles de revue, selon le plan suivant :  
 
1. Le premier article, rédigé en tout début de la thèse, porte sur les caractéristiques des 
formulations de nanoparticules encapsulant les siRNA et les effets résultant de leur 
administration pulmonaire. La revue se concentre sur le transport de siRNA au sein de l’arbre 
pulmonaire, décrivant les différents obstacles à cette administration et la manière dont ils 
peuvent être contournés. Ce chapitre a été publié dans Journal of Drug Delivery Science and 
Technology en 2012.  
2. Le deuxième chapitre concerne les nanoparticules à base de lipides (dont les liposomes) qui 
ont été utilisés pour le ciblage des récepteurs CD44. Dans cet article, nous décrivons le rôle 
de l’interaction entre l’HA et les récepteurs CD44 dans la prolifération et la migration 
cellulaire ainsi que l'inflammation et la croissance tumorale. L'effet de la modification de ces 
nanoparticules, par l’insertion d’HA, sur leurs propriétés physico-chimiques, leur activité 
biologique, leur interaction avec les récepteurs CD44, les voies d’internalisation cellulaire, la 
toxicité, l’activation du système complément/macrophages ainsi que la pharmacocinétique 
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est discutée. Ce chapitre a été soumis comme article de revue dans le journal Nanomedicine 
en 2015.  
 
La seconde partie décrit les travaux expérimentaux sous la forme d'articles de recherche, organisés 
selon le plan suivant : 
 
1. Dans un premier article, les lipoplexes vecteurs de siRNA ont été conçus et caractérises. Pour 
atteindre le ciblage des récepteurs CD44, la structure des lipoplexes a été modifiée avec 
l’aide d’un conjugué entre l’HA et le lipide L-alpha-dioléylphosphatidyléthanolamine (DOPE). 
Une étude de la structure/morphologie de ces vecteurs a été réalisée en utilisant une 
combinaison de techniques telles que la diffusion dynamique de la lumière, l’électrophorèse 
capillaire, la cryomicroscopie et la résonance plasmonique de surface. L’organisation 
structurale du vecteur a été étudiée par diffusion des rayons X aux petits angles. Ce chapitre 
a été soumis comme article de recherche dans le journal Soft Matter en 2015. 
2. L’activité in vitro et in vivo de la formulation optimisée de lipoplexes a été ensuite testée. La 
présence d’HA sur la surface des lipoplexes, et les effets de cette modification sur 
l'internalisation cellulaire ont été évalués. La capacité des lipoplexes à délivrer les siRNA a été 
démontrée en testant l'inhibition de l’expression génique de la luciférase sur lignée cellulaire 
de cancer du poumon A549-Luc, aussi bien in vitro qu’in vivo chez la souris par voie 
intraveineuse. Ce chapitre a été soumis comme article de recherche au journal 
Nanomedicine NBM en 2015. 
3. Enfin, la diffusion des lipoplexes modifiés par l’HA au sein du mucus a été étudiée au cours 
d’un séjour au John Hopkins University dans l’équipe du Pr. Justin Hanes dans le but 
d’évaluer la faisabilité de l'administration locale (intratrachéale) de ces formulations pour le 
traitement de maladies pulmonaires. La diffusion des lipoplexes dans le mucus a été mesurée 
en utilisant la technique de ‘multiple particle tracking’. Une étude in vivo chez la souris a 
aussi permis d’examiner la distribution des lipoplexes modifies par l’HA, dans les poumons 
après administration intratrachéale. Ce travail sera soumis pour publication. 
 
À la fin du manuscrit, une discussion générale reprend et développe tous les résultats obtenus au 
cours de cette thèse, et discute les perspectives scientifiques issues de ce travail.  
Cette thèse de doctorat a été réalisée à l'Institut Galien Paris-Sud, sous la direction du Professeur 
Elias Fattal et du Docteur Hervé Hillaireau, grâce à l’octroi d’une bourse de la Fondation CAPES, du 
Ministère Brésilien de l’Education. 
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Travaux antérieurs - Chapitre 1 
 
Nanoscale particles for lung delivery of siRNA 
 
 
Résumé  
 
Les petits ARN interférents (siRNA) sont des molécules puissantes capables de bloquer l'expression des 
gènes après avoir atteint le cytoplasme de la cellule. Malgré leur grande efficacité, ils doivent être 
transportés par des nanovecteurs afin de les protéger contre la dégradation dans les fluides 
biologiques, accroître leur internalisation cellulaire et favoriser leur distribution subcellulaire. Plusieurs 
études ont mis en évidence le potentiel de l'administration locale de siRNAs dans les poumons pour le 
traitement de maladies pulmonaires. A cet effet, différents nanovecteurs ont été conçus pour le 
ciblage passif ou actif des cellules d’intérêt. Cette revue discute des possibilités de transporter les 
siRNA dans les poumons par ces nanosystèmes.  
 
Chapitre publié sous forme d’article de review dans Journal of Drug Delivery Science and Technology, 
volume 22, 2012, 99-108. Auteurs : Thais Leite Nascimento, Hervé Hillaireau, Elias Fattal. 
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Literature review – Chapter 1 
 
Nanoscale particles for lung delivery of siRNA 
 
 
Abstract  
 
Small interfering RNAs (siRNAs) are potent molecules capable of blocking gene expression after 
entering cell cytoplasm. Despite their strong efficacy, they need to be carried by nanoscale delivery 
systems that can protect them against degradation in biological fluids, increase their cellular uptake 
and favor their subcellular distribution. Several studies have highlighted the potential of local 
pulmonary delivery of siRNAs for the treatment of lung diseases. For this purpose, nanoscale delivery 
systems were addressed to target passively or actively the target cell. This review discusses the 
possibilities of approaching lung delivery of nanoscale particles carrying siRNAs. 
 
Chapter published as a review article in Journal of Drug Delivery Science and Technology, volume 22, 
2012, 99-108. Authors: Thais Leite Nascimento, Hervé Hillaireau, Elias Fattal. 
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Introduction 
 
Since its discovery, the mechanism of RNA interference via small interfering RNA (siRNA) has 
developed rapidly into a powerful tool in molecular biology for studying the downregulation of gene 
expression. Due to their high efficiency and selectivity, siRNAs became rapidly interesting for medical 
applications like the treatment of severe diseases. There are a number of potential applications for 
targeted local delivery of siRNA to the lungs including the treatment of inflammatory, immune and 
infectious diseases, cystic fibrosis (CF), and cancer [1]. However, siRNAs face the same obstacles for a 
successful application as other nucleotide-based therapeutics like plasmid DNA or antisense 
oligonucleotides i.e., a poor cellular uptake and stability in serum and the lack of selectivity for the 
target tissue [1-4]. Therefore, carrier features of nanoparticulate delivery systems have been applied 
to address these limitations. Encapsulation and specific targeting of lung cancer cells thus offer the 
possibility of improving the treatment of lung diseases. This review focuses on the local delivery of 
siRNA to the lungs, describing the different barriers and the state-of-the-art ways they can be 
circumvented.  
 
I. Mechanism of action of siRNA 
 
siRNAs were discovered by showing that the introduction of long double-stranded RNA (dsRNA) into a 
variety of hosts could induce post-transcriptional silencing of all homologous host genes and/or 
transgenes [5-8]. Within the intracellular compartment, the long dsRNA molecules are metabolized to 
small 21-23 nucleotide interfering RNAs by the action of an endogenous ribonuclease: dsRNA-specific 
Rnase III enzyme Dicer [6, 9-12]. The siRNA molecules then assemble into a multiprotein complex, 
termed RNA-induced silencing complex (RISC) (Figure 1). Functional RISC contains four different 
subunits, including helicase, exonuclease, endonuclease, and homology searching domains. When 
siRNA binds to RISC, the duplex siRNA is unwound by helicase, resulting in two single strands (Figure 1) 
[13], allowing the antisense strand to bind to the targeted RNA molecule (Figure 1) [7, 14]. The 
endonucleases hydrolyze the target mRNA homologous at the site where the antisense strand is 
bound. RNA interference has an antisense mechanism of action as, ultimately, a single strand RNA 
molecule binds to the target RNA molecule by the Watson-Crick base pairing rules. Following binding, 
a cleavage enzyme present in RISC called argonaute 2, degrades the target RNA [15]. This mechanism 
makes feasible the use of small double stranded siRNA in therapeutics instead of AS-ODNs. When 
siRNA-mediated silencing occurs, the products are cleaved, released and degraded, allowing RISC 
complex to interact with other molecules from the mRNA pool [16]. It was also shown that small RNAs 
(called miRNAs for microRNAs) cause gene silencing in humans as well as in Caenorhabditis elegans, 
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Drosophila melanogaster, and plants [17, 18]. miRNAs are processed from extended RNA hairpins, 
whereas siRNAs are produced from a range of RNA precursors, such as viral, transposon RNAs and 
transgenes [19]. The mechanisms of siRNAs and miRNAs for RNA interference have some similarities, 
for example, the synthesis of both of them is related to the activity of Dicer, although there are 
significant differences between them, such as siRNAs cleaving mRNA, whereas miRNAs in some cases 
translationally repressed mRNA [20, 21]. 
 
 
Figure 1. Mechanism of action of intracellular siRNA. 
 
  
siRNA 
RNA-induced silencing 
complex (RISC) 
siRNA unwinding by helicase 
contained in Risc 
Activated RISC 
Association with target 
mRNA 
Target mRNA cleavage by 
argonaute 2 enzme  
contained in Risc 
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II. Barriers to siRNA delivery by inhalation  
 
Direct instillation of siRNA into the lung offers several important benefits. As for any drug [22], the 
desired effect can be achieved with a total dose considerably lower than that required for systemic ad- 
ministration, resulting in a lower risk of toxicity and reduced adverse effects [23-24]. Also, instillation 
of siRNA (for instance as aerosol by intratracheal administration) offers direct access to lung epithelial 
cells, important cell types in a variety of pulmonary disorders and virus infections [22] and to the 
malignant cells on the respiratory tract, that cannot be achieved via systemic administration [25]. 
Finally, in the case of cancer treatment, the specificity of the siRNA would also result in much lower 
side effects when compared to conventional chemotherapy. 
In this review, we will focus on local delivery to the airways of siRNA, which are large molecular weight 
molecules, both ionized and hydrophilic [4]. Despite a large interest, they present some hurdles for 
their in vivo administration (Table I). Indeed, even by lung administration, if the aerosolized solution 
reaches sites close to the target, the in vivo applicability of siRNA will be limited by the apparent siRNA 
instability in biological fluids and their inadequate cellular uptake (Table I). In biological fluids, the 
siRNA half-life is very short and varies from seconds to minutes [26]. This is predominately due to their 
rapid degradation by endogenous RNases and their rapid clearance [26]. To reach their cellular target, 
siRNAs need to cross the cellular membrane, but because of their negative charge and size [2], the 
incubation of unmodified free siRNA with mammalian cells does not result in effective knockdown of 
the target gene [27]. This is the reason why the most challenging innovation that is required for 
effective siRNA-mediated therapy in lung diseases is the targeting of siRNA to specific lung cell 
populations, using adequate delivery systems that will allow their delivery into the relevant 
intracellular compartment and further guarantee its protection against degradation. These systems 
should combine adequate intracellular delivery and permit lung delivery either by aerosol or dry 
powders. 
The first obstacle to such a delivery is the resistance by respiratory mucus and alveolar fluids such as 
lung surfactant (Table I). Indeed, in the large airways, a continuously renewed mucus layer constitutes 
a barrier to assure the defence against inhaled materials [28, 29]. Mucus is composed mainly of water 
and mucins, long flexible highly glycosylated proteins that constitute around 1-5 % of the total weight 
of the whole mucus [30, 31]. Mucus traps the inhaled materials which are then effectively removed 
from the respiratory tract toward the upper end of the tracheal tube via the mucociliary clearance 
process [31]. This complex mechanism, which guarantees lung integrity in physiological conditions, can 
undergo important changes associated with pathological diseases or in the case of inhalation of 
various toxic compounds. Chronic disorders of the respiratory tract, such as asthma and cystic fibrosis 
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as well as exposure to cigarette smoke, pollutants and urban particular matter, are associated with 
impaired barrier function and changes in the composition of the mucus layer [32-36]. 
 
Table I - Tissue and cellular barriers for lung delivery of siRNA 
 Barriers to siRNA 
delivery to the lung  
Consequences SiRNA delivery strategies 
Tissue 
level 
Aerodynamic 
properties 
Modulate the biodistribution 
in the different regions of the 
lung 
Aerosol formulation 
 
Liquid droplets (nebulization) 
Dry powders (spray-drying) 
Muco-ciliary 
clearance 
Limits the period of time the 
carrier has to cross the mucus 
barrier and reach the 
epithelial cells 
Stability in the 
bronchoalveolar 
fluids 
Degradation of the carrier or 
the siRNA 
Cellular 
Level 
Intracellular 
penetration  
Insufficient amount of siRNA 
internalized 
Nanocarrier formulation 
 
Lipid-based 
Polymer-based 
Virus-like vectors 
Intracellular stability 
Quick endo-lysosomal 
degradation of siRNA, 
reduction of siRNA amount in 
the cytoplasm  
Subcellular 
distribution 
SiRNA must be delivered to 
the cytoplasm in order to be 
active 
  
 
One other barrier is the size of the inhaled material [37]. For lung delivery, the geometric diameter, 
particle shape and density are taken into account resulting in the so called aerodynamic diameter (AD). 
The AD of the particles affects the magnitude of forces acting on them. While inertial and gravitational 
effects increase with increasing particle size, diffusion produces larger displacement as particle size 
decreases (Figure 2). Large particles (> 5 μm AD) usually impact on airway wall at bifurcations. They are 
usually deposited higher up in the airway such as the back of the throat or pharynx [38]. When the AD 
of particles ranges from 1 to 5 μm, they are subject to sedimentation by gravitational force that occurs 
in smaller airways and respiratory bronchioles (Figure 2). The optimal particle size for efficient 
Travaux antérieurs – Chapitre 1 
23 
 
deposition at the lower respiratory tract is considered to be between 1 and 3 μm [39, 40] (Figure 2). 
The movement of smaller particles (< 1 μm aerodynamic diameter) is controlled by Brownian motion. 
And as the particle size further decreases, deposition in the lung increases again due to the increasing 
mobility through diffusion [37]. However, only nanoparticles that are less than 100 nm appear to settle 
effectively to the alveolar region with a fractional deposition of around 50 % [41, 42]. When the 
diameter gets larger in the nanoscale range, a high proportion, up to 80 %, can be exhaled [43, 44]. 
 
 
Figure 2. Particle deposition along the pulmonary tract as a function of the aerodynamic diameter. 
 
III. Lung delivery of siRNA by nanoscale delivery systems 
 
In the effort to enhance gene silencing, various non-viral nanoscale delivery systems have been 
developed for siRNA delivery, and a large part, summarized in Table II, are based on liposomal or 
polymeric delivery systems [3, 4, 45, 46]. Most systems developed for this purpose have a size of one 
to several hundreds of nanometers, and should thus be termed “sub-micron particles” rather than 
“nanoparticles” according to the latest European Commission recommendation of 18 October 2011 on 
the definition of nanomaterials. 
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1. Lipid-based delivery systems 
 
Several commercially available cationic lipids, including Lipofectamine2000, DOTAP (N-[1-(2,3-
dioleoyloxy)propyl]-N,N,N-tri-methylammonium methylsulfate) and DOTMA(N-[1-(2,3-dioleyloxy) 
propyl]-N,N,N-trimethylammonium chloride), have been selected and applied to the delivery of nucleic 
acids from all types: plasmid, antisense oligonucleotides and siRNA [47]. At the same time, researchers 
are still designing and synthesizing new lipids [48, 49] mostly to reduce the adverse effects described 
for the first cationic lipids [50, 51]. Cationic lipids added in excess to nucleic acids form positively 
charged lipoplexes which strongly interact with the negatively charged cell membrane facilitating their 
endocytosis and further cytoplasmic delivery [52]. Dioleylphosphatidylethanolamine (DOPE), a lipid 
helper, is generally associated with cationic lipids since it participates on the formation of the 
complexes with nucleic acids [53] and facilitates endosomal membrane disruption by forming 
hexagonal phases at the acidic pH of the endosomes [54]. Strategies involving the covalent attachment 
of a targeting ligand at the extremity of poly(ethylene glycol) (PEG) chains grafted onto liposomes have 
also been explored. Ligands specifically promote intracellular accumulation of the nucleic acid-
containing lipid particle into the target cells and further lead to improved gene silencing [55]. 
Regarding lung delivery, cationic liposomes carrying siRNA have the ability to be aerosolized [56] and 
they have shown, in vitro, to deliver intracellularly siRNA in the human lung cancer cell lines A549 and 
H661 [57], human bronchial epithelial cells [58] or type II rat alveolar epithelial cells [59]. 
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Table II: In vitro and in vivo intranasal or intratracheal delivery of siRNA by nanoscale organic and non viral carriers 
 
Target Delivery Technology Model Biological action (in vivo or in vitro) Reference 
In vitro experiments 
Human telomerase 
reverse transcriptase  
Hyaluronic acid-bearing 
DOTAP/DOPE liposomes 
 
A549 lung cancer 
cells 
Transfection of siRNA cells was markedly 
improved with HA-modified liposomes targeting 
the CD44 receptor. Telomerase activity was 
successfully inhibited after a treatment with 
lipoplexes prepared with antihTERT siRNA. 
[64] 
BCL-2 Antagonist G-bearing 
DOTAP/HSPC/CHOL/ 
DSPE-PEG 
Human variant 
small cell lung 
cancer (SCLC) cell 
Increased internalization in SCLC. 
No enhanced down regulation of Bcl-2. 
[69] 
Cyclin B1 Linear Polyethyleneimine (PEI) H460 lung cancer 
cell line 
Higher apoptotic effect  [105] 
Enhanced green 
fluorescence protein 
(EGFP) 
Poly(b-amino ester)s (PAEs), 
composed of low molecular 
weight PEI and poly(ethylene 
glycol) (PEG)  
A549 lung cancer 
cells 
79% silencing is obtained by PAE  [106] 
Enhanced green 
fluorescence protein 
(EGFP) and Protein 
kinase B (Akt1) 
Chitosan-graft-polyethylenimine 
copolymer composed of chitosan 
and low molecular weight 
polyethylenimine  
A549 lung cancer 
cells 
Silencing of EGFP expression is approximately 2.5 
folds more than that of PEI25K  
[107] 
Enhanced green 
fluorescence protein 
(EGFP) 
Chitosan nanoparticles H1299 human lung 
carcinoma cells 
Silencing up to 80% is obtained [115] 
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Enhanced green 
fluorescent protein 
(EGFP) and TNF-α 
(tumour necrosis 
factor) 
Freeze-dried chitosan/siRNA 
nanoparticles 
H1299 human lung 
carcinoma cell line 
expressing EGFP 
and TNF-α 
expressing RAW 
murine 
macrophage cell 
line 
EGFP knockdown efficiency increases with the 
siRNA concentration and depends on the presence 
of sucrose as lyoprotectant. Chitosan particles 
yielded more specific TNF-α knockdown than 
particles formed with lipid. 
[116] 
Luciferase pHPMA-MPPM (poly((2-
hydroxypropyl) methacrylamide 1-
methyl-2-piperidine methanol))  
TMC (O-methyl-free N,N,N-
trimethylated chitosan) 
Human lung 
cancer cells 
(H1299) 
Luficerase expression was silenced by 30–40% 
increasing up to 70–80% in the presence of an 
endosomolytic peptide or a photochemical 
internalizing agent 
[122] 
Luciferase PVA/PLGA nanoparticles human lung 
cancer H1299 luc 
cells 
Luciferase knockdown of 80–90% with minor to no 
cytotoxicity 
[118] 
In vivo experiments 
BCL-2 Cationic DOTAP lipid 
 
Mice 
Intratracheal 
Higher peak concentrations and longer retention 
of siRNA in the lungs when compared with 
systemic administration 
[75] 
Β-galactosidase Cationic lipid Genzyme (GL) 67 Mice 
Intratracheal 
Reduced βgal mRNA levels in the airway 
epithelium but no protein expression 
[76] 
SPARC (matricellular 
protein)  
Cationic lipid Dharma-FECT™  Mice-induced 
fibrosis 
Intratracheal 
SPARC siRNA reduced gene and protein expression 
of collagen type 1 in fibroblasts  
Lung fibrosis induced by bleomycin is reduced 
with SPARC siRNA and was accompanied by an 
inhibition of connective tissue growth factor 
expression in these same tissues 
[77] 
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Highly conserved 
regions of the 
nucleoprotein or 
acidic polymerase in 
Influenza viruses 
Cationic lipid oligofectamine 
(Invitrogen)  
Mice 
Intravenous 
followed by 
Intranasal 
Delivery of the siRNAs reduced lung virus titers in 
infected mice. Protection is specific and not 
mediated by an antiviral IFN response 
[78] 
Respiratory syncytial 
virus (RSV)-P protein 
and parainfluenza 
virus (PIV) type 3 
(HPIV3) P protein 
TransIT-TKO™ (Mirus Bio Corp) Mice 
Intranasal 
Specific reduction of pulmonary RSV and PIV titer. 
SiRNAs free of transfection reagent, also inhibited 
pulmonary viral titers. 
[79] 
Severe acute 
respiratory syndrome 
(SARS) coronavirus 
Infasurf® (calfactant) 
Extract of natural surfactant from 
calf lungs which includes 
phospholipids, neutral lipids, and 
hydrophobic surfactant-associated 
proteins B and C 
Mice 
Intranasal 
The siRNAs provided relief from SCV infection–
induced fever, diminished SCV viral levels and 
reduced acute diffuse alveoli damage 
[80] 
GAPDH protein Infasurf® (calfactant) 
Extract of natural surfactant from 
calf lungs which includes 
phospholipids, neutral lipids, and 
hydrophobic surfactant-associated 
Mice 
Intranasal 
Reduction of lung concentration of GAPDH protein 
50% at 24 h and 67% at 7 days. 
[81] 
Protein kinase B 
(Akt1) 
Poly(ester amine)  Mice Silencing of Akt1 in the lungs without affecting 
Akt2 and Akt3 or affecting the protein expression 
of Akt1 in other organs 
[109] 
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Nevertheless, liposome-based carriers still face some challenges for optimal siRNA delivery. These 
particles may be inadequate as they are associated after systemic administration with an intrinsic 
problem of non-specific interactions with blood components [51]. Some improvements were tested, 
such as the inclusion of anionic charges in PEG, which gives a greater colloidal stability in presence of 
serum [60]. However, when covering lipoplexes with PEG to reduce aggregation, a decrease of 
transfection efficiency is observed in vitro [61, 62]. Therefore it is important to find other ways to 
achieve targeting of lung cells. We have designed hyaluronic acid (HA)-coated lipoplexes for the 
targeted delivery to cancer cells that overexpress the HA binding receptor CD44 [63, 64]. This 
approach is based on the properties of HA, that, besides being an endogenous polymer, fulfills 
important mechanical or structural functions [65], interacting with its principal cell surface receptor 
CD44. The latter plays an important role on cell-cell/cell-matrix interaction, cell adhesion and 
migration and signal transduction from the extracellular to the intracellular compartment [66-68]. 
SiRNA transfection was improved with HA-modified liposomes, in CD44 positive A549 cells but not in 
Calu-3 cells that do not display the receptor. Santos et al. [69] have designed lipoplexes bearing as 
targeting ligand antagonist G, a substance P analogue that competitively inhibits basal and 
neuropeptide-stimulated growth of different small-cell lung cancer (SCLC) [70]. The targeted vesicles 
showed increased internalization in SCLC, as well as in other tumor cells and HMEC-1 microvascular 
endothelial cells, but the improved cellular association did not correlate with enhanced 
downregulation of the targeted Bcl-2. This absence of Bcl-2 downregulation was due to an 
inadequate release of the nucleic acids from the endocytic pathway, because of the presence of 10 
mol% of PEG incorporated in the SLP formulation and/or to the absence of membrane destabilizing/ 
fusogenic lipids. 
To improve siRNA delivery, Chen et al. [71] developed a promising novel non-glycerol based cationic 
lipid, DSGLA (N,N-distearyl- N-methyl-N-2[N’-(N2-guanidino-L-lysinyl)] aminoethyl ammonium 
chloride) that was formulated in lipid-polycation-DNA (LPD) nanoparticles containing DOTAP and 
targeted with PEG tethered with anisamide (AA). This new lipid contained both guanidinium and 
lysine residues as a cationic head group, that were chosen due to the fact that guanidinium groups 
are capable of forming hydrogen bonds with nucleic acid bases, thus further enhancing the capacity 
to deliver plasmid siRNA [71]. The lysine groups were selected for decreasing the cytotoxicity 
observed with the commercial lipid DOTAP contained in the LPD nanoparticles previously described 
by the authors [72, 73]. The presence of 10 μM DSGLA in AA-bearing LPD was found to decrease 
extracellular signal-regulated kinases (ERK1/2) activation in H460 cells. The lipids without guanidine 
group did not cause the inhibition of ERK1/2 activation, and on the contrary, due to the 
antiapoptopic effect of DOTAP, an increased ERK1/2 activation was observed. 
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Among all lipid systems developed for treating lung cancer or other pulmonary diseases only a few 
have been administered in animal models by local administration, either intranasally or 
intratracheally. Garbuzenko et al. [74, 75] compared intratracheal v/s intravenous delivery of DOTAP-
siRNA lipoplexes in mice. Intratracheal administration led to higher siRNA peak concentrations and a 
much longer retention of liposome-siRNA in the lungs when compared with systemic administration. 
In another experiment, GL67, a cationic lipid from Genzyme, mediated the uptake of siRNAs into 
airway epithelium in vivo in mice. siRNAs were complexed to GL67 and the resulting suspension was 
placed as a single bolus into the nasal cavity and rapidly sniffed into the lungs [76]. Following in vivo 
lung transfection, siRNAs were visible only in alveolar macrophages. SiRNAs targeted to β-
galactosidase reduced βgal mRNA levels in the airway epithelium of K18-lacZ mice by 30 % as shown 
by RT-PCR. However, this was insufficient to reduce protein expression [76]. In another experiment, 
C57BL/6 mice were induced for skin and lung fibrosis by bleomycin and followed by SPARC siRNA 
treatment through subcutaneous injection and intratracheal instillation, respectively using 
DharmaFECT 1 as transfection reagent. SPARC (secreted protein, acidic and rich in cysteine), is a 
component of the extracellular matrix which has been reported as a bio-marker for fibrosis in 
interstitial pulmonary fibrosis. After treatment, it was shown that lung fibrosis induced by bleomycin 
was markedly reduced by treatment with SPARC siRNA. The anti-fibrotic effect of SPARC siRNA in vivo 
was accompanied by an inhibition of connective growth factor (CTGF) expression in these same 
tissues. The lung distribution of intratracheally injected fluorescent siRNA showed that intense 
fluorescence was distributed within epi- thelial cells of bronchi and bronchioles, and only weak 
fluorescence was detected in the parenchyma [77]. It is unclear so far why such a difference of lung 
distribution was observed in both studies. Physico-chemical properties of complexes such as size, 
charge or other surface properties might play an important role in their distribution. 
Complexes comprised of Oligofectamine and a siRNA specific for highly conserved regions of the 
nucleoprotein or acidic polymerase were found to inhibit influenza A virus replication in vivo after 
intranasal administration to mice [78]. The same inhibition was obtained on respiratory syncytial 
virus (RSV) and parainfluenza virus (PIV) using siRNAs against viral genes, instilled intranasally in 
mouse, associated or not with the transfection reagents TransIT-TKO. [79]. Finally, suspensions of 
siRNAs, with or without the transfection reagent Lipofectamine were administered intranasally in an 
in vivo murine model of Equine Herpes Virus Type 1 (EHV-1) infection using an EHV-1-specific siRNA. 
Although the administration of free siRNA induced protection against clinical signs like weight loss, 
no significant difference could be observed between the effectiveness of siRNA complexed with the 
transfection reagent Lipofectamine or with buffer (PBS). This agrees with some reports where the 
activity of intranasally administered free siRNA in various animal models has been clearly 
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demonstrated, and was in some cases superior to that of lipoplexes [80, 81]. Finally, a more recent 
study has demonstrated the inflammatory properties of lipoplexes carrying siRNA [82]. 
 
2. Polymeric nanoparticles 
 
Nanoparticles are among the various siRNA delivery systems considered for pulmonary application 
[4, 83-85]. These nanoscale carriers present several advantages for the treatment of respiratory 
diseases, such as prolonged drug release, cell specific targeted drug delivery or modified biological 
distribution of the therapeutic agent, both at the cellular and organ level [86]. Nanoparticles 
composed of polymers show assurance in fulfilling the stringent requirements placed on these 
delivery systems, such as targeting of specific sites or cell populations in the lung, release of the drug 
in a predetermined manner, and degradation within an acceptable period of time [87]. Moreover, 
studies using inhaled nanoparticles dispersed in aqueous droplets suggest that the mucus clearance 
can be overcome by nanoparticles, and the drug efficiently transported to the respiratory epithelium 
[88]. 
 
2.1. Association of siRNA to cationic polymer systems by complexation 
 
Several polymer nanoparticle systems have been developed to enhance intracellular delivery of 
nucleic acids [3, 4, 89]. As for cationic lipids, at physiological pH, siRNA can electrostatically interact 
with cationic charges from polymers to form polyplexes simply by mixing the components in optimal 
conditions. The positive charges can either come from soluble cationic polymers or cationic 
nanoparticles. As the complex generally possesses a global positive surface charge, they get easily 
attached to the negatively charged cell surface and subsequently undergo endocytosis [90]. 
One of the main polymers used is polyethyleneimine (PEI), a branched polymer with high cationic 
potential. The complexes formed between nucleic acids and PEI are usually stable, dispersible, non- 
covalent and have a net positive charge, which allows interaction with negatively charged cell 
membranes, followed by internalization by endocytosis [4]. The delivery of the nucleic acid to the 
cytoplasm occurs by the “proton sponge effect” [91], in which the protonation of the numerous 
amino groups in the polymer causes osmotic rupture of the endosome and a cytosolic release of the 
nucleic acid [92-95]. Additionally, after complexation, siRNA is efficiently protected from degradation 
both in vitro in the presence of RNase and in vivo in the presence of serum nucleases [99]. 
Consequently, PEI has been employed in several studies for efficient siRNA delivery in vitro and in 
vivo [4, 100]. Lin et al. [105] tested linear PEIs forming cationic complex with siRNA to target Cyclin 
B1, an indispensable protein for cell mitosis. After treatment with siRNA alone, lung cancer cells 
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population in the G2/M phase of the cell cycle increased to around 5 % (compared with control) 
whereas cells treated with PEI-siRNA complex had a significant increase to around 13 %, indicating 
better arrest of the cell mitosis in the G2/M phase of cell cycles by treatment with the complex. 
Bolcato-Bellemin et al. [110] used linear PEI for the formation of complexes, and modified the siRNA 
structure adding short complementary A5-8/T5-8 overhangs to make the siRNA bind to each other, 
forming a large “gene-like” structure. With these new sticky overhangs, the PEI-siRNA complex 
showed increased stability and improved RNase protection and gene silencing in lung cancer cells. 
While linear PEI is capable of providing a high efficiency of systemic gene delivery to the lungs, 
branched PEI has been associated with higher levels of acute toxicity [101]. Indeed, higher molecular 
weight PEIs are related to increased cytotoxicity, due to aggregation of the polymer on the outer cell 
membrane, which thereby induces necrosis [102]. Also, PEI toxicity might be caused by the rapid 
adsorption of plasma proteins onto the positively charged polymers, which can lead to aggregation. 
Regarding siRNA, Beyerle et al. [103] showed that the toxicity is also dependant on cell type, and 
Thomas et al. [104] found that linear fully deacylated PEI of 25 kDa and 87 kDa were the most 
effective for lung delivery. Cytotoxicity and transfection efficiency of PEI are directly proportional to 
its molecular weight [96]. Efforts to reduce the toxicity or improve stability of the polyplexes have 
been made by synthesis of PEI with graft copolymers such as linear PEG [97, 98]. A modified PEI 
system, poly (β-amino ester) (PAE) composed of low molecular weight PEI and PEG was complexed 
with siRNA [106]. The complex was shown to transfect A549 lung cancer cells with a siRNA targeting 
the enhanced green fluorescence protein (EGFP) achieving 79 % silencing, higher than the standard 
25 kDa PEI complex. In a subsequent study, the authors combined the advantages of chitosan 
(another cationic polymer: for more details see below) and of a modified PEI system. They 
synthesized a chitosan-graft-PEI (CHI-g-PEI) copolymer, composed of chitosan and low molecular 
weight PEI [107]. The CHI-g-PEI carrier complexed with siRNA silenced EGFP expression 
approximately 2.5 times more than that of 25kDa PEI in A549 cells. The carrier was also used to study 
the silencing of Akt1 protein expression. Such protein has a vital role in lung cancer, since its 
overexpression is related to the mechanisms of cancer cell survival, proliferation, and metastasis 
[108, 109]. Efficient knockdown of Akt1 mRNA as well as the decrease in Akt1 protein expression was 
observed using the new carrier. Also the addition of peptides such as HIV-TAT to cationic PEG-PEI 
copolymers has been studied to enhance transfection efficiency in bronchial cells in vitro [111]. 
Recently, non-invasive aerosolized siRNA delivery systems were developed for lung cancer 
treatment. A degradable PEI-PEG copolymer was synthesized by reaction of low-molecular weight PEI 
with PEG diacrylate [112]. An aerosol of poly(ester amine)/Akt1-targeting siRNA complex was 
delivered into mice with urethane-induced lung cancer through a nose-only inhalation system. 
Following aerosol delivery twice weekly for 4 weeks, Akt1 siRNA delivered in complexes with 
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poly(ester amine) showed down-regulation of Akt related signals and inhibited the progression of 
tumors in the lung cancer model of K-rasLA1 mice [109]. 
Beside PEI, chitosan is a natural polysaccharide both mucoadhesive and mucopermeable, two 
qualities that are advantageous for targeted delivery of siRNA to the respiratory tract [113, 114]. 
Additionally, it is well tolerated, biodegradable, and forms cationic complexes with nucleic acids. 
Chitosan has been effective for siRNA delivery and gene silencing with low toxicity [22, 113]. In an 
interesting study, the high degree of deacetylation and high chitosan molecular weight were 
identified by Liu et al. [115] as important parameters for efficient siRNA-mediated knockdown, thus 
highlighting the importance of polymer chemical properties for the optimization of gene silencing 
using chitosan/siRNA nanoparticles. Andersen et al. [116, 117] delivered chitosan/siRNA 
nanoparticles targeting the enhanced green fluorescent protein (EGFP). They found that EGFP 
knockdown efficiency increased with siRNA concentration and that it could be achieved using freeze-
dried nanoparticles, lyophilized directly within the cell culture dishes or onto surfaces, and used later 
by simply adding the cell suspension directly. At low siRNA concentration (< 25 nM) the highest 
knockdown was obtained at relatively high sucrose concentrations used as cryoprotectant (60 % 
knockdown at 10 % sucrose) whereas, at high siRNA concentration (50 nM), 5 % sucrose was 
sufficient to reach maximum knock down efficiency (70 %). Compared with lipoplexes using (TransIT-
TKO), freeze-dried TransIT-TKO/siRNA were more effective than chitosan/siRNA at all concentrations 
tested, although chitosan particles yielded more specific TNF-α knockdown than particles formed 
with lipid, which also exhibited significantly lower viability of approximately 60 %, compared to 90-
100 % of the chitosan/siRNA nanoparticles. 
Other cationic polymers have been used. Nguyen et al. [118] designed a branched biodegradable 
polyester consisting of tertiary-amine-modified PLA backbones grafted to PLGA. This polymer was 
previously found to show high transfection efficiency [119], superior biocompatibility compared to 
PEI [120], rapid degradation rates [120] and low acute toxicity and inflammatory response after 
pulmonary application [121]. Nguyen et al. [118] found that small siRNA dosages (of 5 and 10 pmol) 
were necessary to achieve the aimed luciferase knockdown of 80-90 % in H1299 human lung 
carcinoma cell with minor to no cytotoxicity. Also, at a polymer ratio of 10:1 the nebulized 
nanoparticles displayed comparable knockdown efficiency to the non-nebulized samples. Varkouhi et 
al. [122] evaluated the gene-silencing activity of two enzymatically-degradable designed polymers: 
trimethylated chitosan (TMC) and pHPMA-MPPM (poly((2- hydroxypropyl) methacrylamide 1-methyl-
2-piperidine methanol)). Both compounds showed a rather important silencing effect (higher than 
current surfactants) with less toxicity, reaching 30 to 40 %. These values increased up to 70-80 % in 
the presence of an endosomolytic peptide or a photochemical internalizing agent. 
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2.2. Encapsulation of siRNA within polymer nanocapsules 
 
Another established approach for lung delivery of siRNA involves poly (lactic-co-glycolic acid) (PLGA) 
nanoparticles. PLGA is approved for human use by the Food and Drug Administration (FDA), and 
several PLGA-based formulations have received worldwide marketing approval [123]. This synthetic 
biodegradable polymer was shown to be useful for drug delivery formulations with good 
biocompatibility, cellular uptake and controlled release characteristics [124-126], but also a high 
stability during nebulization [127]. According to Campolongo and Luo [128], PLGA nanoparticles have 
attracted much attention since they are assumed to meet the criteria required for successful siRNA 
delivery: i) they are sufficiently small for efficient tissue penetration and cellular uptake, ii) the siRNA 
can be entrapped into the PLGA matrix, which offers physical protection against RNase activity as 
well as a favorable colloidal stability of the system, and iii) the PLGA particles generally possess an 
excellent controllable and alterable degradation profile, allowing drug release to span from days to 
years depending on the molecular weight, the composition of the block copolymer and the structure 
of the nanoparticles [129]. Even though, regarding nucleotide encapsulation, formulation of PLGA 
nanoparticles also presents some challenges. One of them is that it is difficult to load smaller nucleic 
acid molecules like siRNA into PLGA nanoparticles and obtain a high loading and encapsulation 
efficiency with the use of classical preparation methods. As other low molecular weight compounds, 
siRNA easily leaks from the inner water phase into the outer water phase during preparation due to 
its relatively low molecular weight, its hydrophilic character and the electrostatic repulsion forces 
present between the phosphate groups in the siRNA backbone and the anionic acid groups in the 
PLGA polymer [118]. Also, the degradation of PLGA leads to the formation of acidic products, lactic 
and glycolic acid, which can cause DNA degradation and damage [130]. 
The optimal parameters for preparation of siRNA-loaded PLGA nanoparticles by the double emulsion 
solvent evaporation method were studied by Cun et al. [129]. The formulation and preparation 
process parameters were rationally optimized by an understanding of the effect of the parameters: i) 
the volume ratio between the inner water phase and the oil phase, ii) the PLGA concentration, iii) the 
sonication time for the primary emulsification, iv) the siRNA load and v) the amount of acetylated 
bovine serum albumin (Ac-BSA) added to the inner water phase to stabilize the primary emulsion. 
PLGA concentration and the volume ratio were the only significant main effects. Surprisingly, siRNA 
load was found not to contribute significantly to the encapsulation efficiency. The suggested 
explanations for the individual effects were that the increased PLGA concentration resulted in a 
further stabilization of the primary emulsion and limited the diffusion of siRNA through and out of 
the organic phase due to the increased viscosity of the organic phase, and that a higher inner water 
phase volume reduced the concentration gradient between the inner and the outer water phase. 
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2.3. Mineral nanoparticles 
 
Calcium phosphate (CaP) nanoparticles have also been studied to improve nucleotide transfection 
[131-136]. CaP is a well used non-viral vector for in vitro transfection due to the fact that it is rapidly 
dissolved in the cytoplasm’s acidic pH, and that it presents little cell toxicity [134, 135, 137]. Recently, 
Li et al. [138] combined the advantages of a core/shell nanoparticle structure and CaP nanoparticle 
to achieve a prolonged circulation time and an elevated endosome release mechanism. The authors 
studied nanoparticles with a CaP core and PEG-phospholipid coating to target luciferase in human 
lung cancer H460 cells, and an improvement in the gene-silencing effect was observed. CaP dissolved 
at a low pH, causing nanoparticle de-assembly, the dissolved calcium and phosphate ions increased 
the osmotic pressure and caused endosome swelling to release the encapsulated siRNA. 
 
2.4. Viral-like synthetic vectors 
 
Lastly, virus-like synthetic vectors as influenza virus envelopes [139] or virosomes have been applied 
to deliver siRNA in vitro. The use of virosomes has some advantages for antiviral siRNA delivery in the 
lung, such as the fact that they are expected to be taken up by the cells infected with the virus [140] 
and their relatively high efficiency. For certain types of viral vectors, a relatively long duration of gene 
expression can also be achieved [101]. However, progress in virosome research is hampered by the 
difficulty in manufacturing viral envelopes [140], inefficiency, impossibility of repeated 
administration and severe complications associated with their immunogenicity and oncogenic 
potential [101, 114, 141-143]. The well-documented case of the death of Jesse Gelsinger due to 
complications associated with an adenoviral vector highlights this problem [144]. 
 
IV. Means to deliver nanoscale carriers as dry powders 
 
The study of the nanoparticle delivery into the respiratory system is also important, whether they are 
administered as aerosol droplets or dry powders. As mentioned earlier in this review, the study of 
the aerodynamic diameter of the particles containing nanoparticles is crucial to an optimized delivery 
to the lower respiratory tract. Also, the characteristics of the liquid media or solid excipients that 
surround the nanoparticles will influence their release kinetics after deposition in the airways, and 
thus the time it will take until the nanoparticles themselves are in contact with epithelial cells or 
macrophages. 
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Our group has designed multistage or “trojan” delivery system that combines the advantages of 
microspheres (i.e, long term release) and polyplexes (i.e., enhanced nucleic acid intracellular 
penetration) [145-148]. Indeed, solid nanoparticulate complexes made of PEI and nucleic acids were 
encapsulated into a polymer matrix [146, 148]. ODN complexation with PEI improved the 
encapsulation efficiency probably by an electrostatic interaction between the cationic ODN/ PEI 
complex and the anionic PLGA [145, 146, 148]. Release rate was shown to be dependent on the 
porosity of the microparticles: the higher the porosity, the faster the release. Low porous particles 
were shown to delivery constantly the nanoparticles with the consequence of improving the 
intracellular penetration once reaching the target. Microparticles consisting of aggregates of PLGA 
nanoparticles surrounding a hollow core were developed using non-biodegradable [39] and 
biodegradable PLGA polymers [149] because of their high aerodynamic properties, these particles 
seem very promising for lung delivery of nanoparticles. 
 
Conclusion 
 
Although lung delivery of siRNA represents an important field for therapeutic applications, the need 
of nanoscale carriers is essential to allow their delivery. A variety of systems have shown efficiency in 
vitro, as the systems based on cationic lipids. Other cationic polymers were able to complex siRNA, 
and biodegradable polymers were able to encapsulate siRNA, and they can be further surface-
modified and functionalized to enhance targeting properties. Nevertheless, in vivo delivery also 
requires the control of aerosol formulation of the nanoparticles. And despite some successful 
experiments reported here, the studies carried out in vivo do not all show a real benefit of lung 
inhaled nanoparticulate systems. Further research is needed in order to better understand the 
distribution of such particles after lung administration. 
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Lipid based nanosystems for CD44 targeting in cancer treatment: recent 
significant advances, ongoing challenges and unmet needs 
 
 
Résumé 
 
De nombreuses preuves expérimentales obtenues dans des modèles cellulaires et animaux 
démontrent l’importance de l'interaction entre l’acide hyaluronique (HA) et le récepteur CD44 dans 
la prolifération et la migration cellulaire, l'inflammation et la croissance des tumeurs. Afin de tirer 
profit de cette interaction, la conception de nanomédicaments modifiés par l’HA a été exploitée au 
cours de la dernière décennie pour le ciblage de cellules surexpriment les récepteurs CD44, dans le 
but de transporter des médicaments aux cellules cancéreuses ou inflammatoires. La modification des 
particules par l’HA offre la possibilité de cibler sélectivement ces cellules et améliorer ainsi l'efficacité 
des médicaments. L'efficacité de ce ciblage est cependant influencée par plusieurs facteurs, dont le 
poids moléculaire de l‘HA, sa conformation et disponibilité sur la surface des nanoparticules, la 
densité de son recouvrement ainsi que la charge et taille de ces nanomédicaments. Dans ce chapitre, 
nous nous concentrons sur l'impact de la modification par l’HA de nanomédicaments à base de 
lipides sur ces caractéristiques. Nous discutons comment cette modification influence les propriétés 
physicochimiques de ces systèmes, leur activité biologique, l'interaction avec des récepteurs CD44, 
les voies d’internalisation cellulaire, leur toxicité, l'activation du système complément et des 
macrophages et leur pharmacocinétique.  
 
Chapitre rédigé sous forme d’article de review pour poublication dans Nanomedicine en 2015. 
Auteurs: Thais Leite Nascimento, Hervé Hillaireau, Elias Fattal. 
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Literature review – Chapter 2 
 
Lipid based nanosystems for CD44 targeting in cancer treatment: recent 
significant advances, ongoing challenges and unmet needs 
 
 
Abstract 
 
Extensive experimental evidence in cells and animal models demonstrate the important role of 
hyaluronic acid (HA)-CD44 interaction in cell proliferation and migration, inflammation and tumor 
growth. Taking advantage of this interaction, the design of HA-modified nanocarriers has been 
investigated in the past decade for the targeting of CD44-overexpressing cells with the purpose of 
delivering drugs to cancer or inflammatory cells. Particle modification with HA offers the possibility of 
selectively targeting those cells and improving drug efficacy. The effect of such a modification on 
targeting efficacy is however influenced by several factors, including HA molecular weight (MW), 
conformation and availability on the surface of the carriers, grafting density and particle charge and 
size. In this review, we focus on the impact of HA-modification of lipid-based nanoparticles on their 
characteristics. We discuss how modification of their structure induced by HA influences particle 
physicochemical properties, biological activity, interaction with CD44 receptors, intracellular 
trafficking pathways, toxicity, complement/macrophage activation and pharmacokinetics. Our aim is 
to give an overview on how to control nanocarrier functionalization by HA to design more efficient 
CD44-targeting lipid nanocarriers. 
 
Chapter written in review article form and submitted for publication to the journal Nanomedicine in 
2015. Authors: Thais Leite Nascimento, Hervé Hillaireau, Elias Fattal. 
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Introduction 
 
Much effort has been devoted over the past few decades to improve the treatment of cancer, and 
advances in nanotechnology and tumor biology have enabled the development of efficient 
nanocarriers to deliver therapeutic agents to the tumor tissue [1-4]. These nanocarriers have offered 
unique possibilities to overcome cellular barriers in order to improve the delivery of various drugs 
and drug candidates, including promising therapeutic biomacromolecules (i.e., nucleic acids, 
proteins) [5]. In this context, one of the main adhesion/homing molecules involved in tumor 
progression and metastasis, CD44, has attracted much attention. Targeting these molecules is a 
promising approach in the treatment of cancer. These receptors are expressed on many types of 
tumors and accumulate numerous functions, such as supporting cell migration and transmitting 
survival signals through interactions with its numerous ligands [6-8].  
The main ligand of CD44 receptors is hyaluronic acid (HA, hyaluronate, hyaluronan). The interaction 
between these two molecules is influenced by several factors. The conformation and availability of 
the ligands on the surface of nanoparticles, HA molecular weight, grafting density, particle charge 
and size, and the stability of the nanocarrier in physiological environment are examples of factors 
that should be considered when studying the targeting of CD44 receptors by HA-containing 
nanocarriers.  
In this review, based on the design of lipid-based nanosystems, we have addressed these important 
issues, which are crucial for the rational design and optimization of CD44-targeted, hyaluronan-based 
nanotherapeutics for improved intracellular delivery. The influence of these modifications on their 
structure and physicochemical properties is discussed, as well as in their biological activity, including 
interaction with CD44 receptors, intracellular trafficking pathways, toxicity and 
complement/macrophage activation as well as the pharmacokinetics changes. Our aim is to give an 
overview on how to control the HA-particle modification to help designing more efficient CD44-
targeting lipid nanocarriers. 
 
CD44: structure and role 
 
The cluster of differentiation 44 (CD44) is a single chain glycoprotein encoded by a gene located on 
the short arm of chromosome 11 [9]. This gene is composed of 20 exons, and alternate splicing of the 
10 central exons [10] and post-translational modifications are responsible for the existence of variant 
isoforms (CD44v). Molecular mass of the different CD44 isoforms range from ∼80 kDa to ∼250 kDa 
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[6]. The most abundant isoform of human CD44 protein, CD44s, is the smallest one and lacks any 
variant exons. CD44E, a large isoform, is also abundant and expressed mainly in epithelial cells [11], 
while other CD44 isoforms are rarely present on normal tissues. In particular, CD44s is abundantly 
expressed by both normal and cancer cells, whereas the variant CD44 isoforms are expressed mostly 
by cancer cells [12]. 
CD44 belongs to the cell adhesion molecules family (CAM), together with integrins, selectins and 
cadherins. These molecules are involved in the contact between cells and between cells and the 
extracellular matrix. They are critical to the maintenance of tissue integrity, regulating growth, 
survival, differentiation and cell migration. Under pathological disorder, CD44 is involved in the 
tumor progression as well as the metastatic process [13]. An increasing number of studies [14-17] 
have evidenced that a small population of tumor cells (less than 0.1%) exhibit an indefinite 
proliferation potential, and are responsible for maintaining the tumor and, possibly, for the 
formation of new tumors at metastatic loci. These are referred to as cancer stem cells or cancer-
initiating cells, in which CD44 has been identified as an important marker due to its interaction with 
different growth factor receptors [18]. 
Several types of tumors overexpress CD44 receptors, such as lung [19], ovarian [20], pancreatic [21], 
colon [22], prostate [23] and acute leukemia [24]. The level of expression depends on the cell type 
and the differentiation degree. The CD44 extracellular domain can interact with innumerous 
components of the extracellular matrix, including collagen, fibronectin, fibrinogen and laminin 
[25,26], and its principal ligand is hyaluronic acid (HA, hyaluronate, hyaluronan) (Figure 1). 
 
 
Figure 1: Structure of the CD44 receptor 
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Hyaluronic acid: a natural ligand of CD44 
 
HA is a negatively charged hydrophilic linear polymer composed of repeating disaccharide units of D-
glucuronic acid and N-acetyl-D-glucosamine linked by alternating β -1,4 and β -1,3 glycosidic bonds. It 
is biocompatible, being the major component of the extracellular matrix. In the matrix, HA plays a 
structural role, which depends on its hydrodynamic properties as well as on its interaction with other 
components of the matrix. HA influences intracellular signaling mainly by binding to its main cell-
surface receptors CD44 and RHAMM (receptor for hyaluronan-mediated motility), but it also 
interacts with other cell surface receptors such as ICAM-1 (intracellular adhesion molecule-1), TLR-4 
(toll-like receptor-4), HARE (HA receptor for endocytosis), and LYVE-1 (lymphatic vessel endocytic 
receptor) [27]. 
Since it is also concentrated in regions of high cell division and invasion (during embryonic 
morphogenesis, inflammation, wound repair, and cancer) [28], HA is involved in tumorigenesis. Its 
biological properties are dependent on its molecular weight [29]. Native high molecular weight 
(HMW) HA has been shown to be non-toxic and non-immunogenic [30]. It also does not induce 
expression of genes involved in proliferation or inflammation [31] and counteracts proangiogenic 
effects of the HA oligomers [32]. When HA fragments from 2 to 100 kDa (about 4 to 250 disaccharide 
units) bind to CD44, they induce angiogenic effects that have been described in vitro, contributing to 
tumor growth [33,34]. 
HA-CD44 binding affinity is dependent on the size of the polysaccharide. The specific binding domain 
of CD44 to HA comprises 160 amino acid residues. Hexamers and decamers are considered the 
shortest length able to bind CD44, and larger oligomers (over 20) have more affinity for the receptors 
because they have the ability to bind several CD44 at the same time [35]. CD44 proteins exist in three 
states with respect to HA binding: nonbinding; nonbinding unless activated by physiological stimuli; 
and constitutively binding [18]. To date, receptor mediated endocytosis of HA and macropinocytosis 
of bulk phase HA have been reported (Figure 2). CD44-mediated endocytosis can occur via lipid rafts 
or by the clathrin-coated pit pathway. Receptors for HA endocytosis may be recycled to the cell 
surface or turned-over. HA saccharides are further digested to HA oligosaccharides by hyaluronidases 
(HAses) in the endosome into fragments that could have several biological functions [36]. Different 
signaling pathways can be triggered after HA-CD44 interaction occurs, depending on cell type and HA 
molecular weight. The participation of HA in CD44 signaling for different cell activities including 
proliferation, migration, and inflammation in normal tissues and in organ pathology illustrates the 
important and complex role of HA in modulating cell behavior [37] . 
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Figure 2: Mechanism of cellular internalization of hyaluronic acid. 
 
Lipid-based CD44-targeting nanocarriers 
 
Lipid-based nanocarriers have attracted increasing scientific and commercial attention in the context 
of drug delivery for in vivo applications due to their overall low toxicity [41]. Presently, many lipid-
based colloids are approved and commercialized for clinical use. Shortcomings frequently 
encountered with active compounds, such as poor solubility, normal tissue toxicity, poor specificity 
and stability are expected to be overcome through the use of lipid-based nanocarriers. Surface-
modification of these carriers offers moreover the possibility to overcome biological barriers so that 
they will preferentially accumulate in disease target cells [42]. The present review focuses on the 
surface modification of solid lipid nanoparticles, nanostructured lipid carriers and liposomes with HA 
for CD44 targeting. After a short description of the nanocarriers, the influence of these modifications 
on their activity will be discussed. 
 
Solid lipid nanoparticles 
 
Solid lipid nanoparticles (SLN) are nanocarriers made from lipids that are solid at room temperature 
[43]. They have been introduced in the 1990’s as an alternative to polymeric nanoparticles and have 
been explored since then due to their low toxicity [44] and relatively simple and cost-effective large 
scale production using high pressure homogenization, for instance [45]. The major driving force for 
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SLN drug carriers is the perception that these particles may have superior in vitro and in vivo stability 
compared to other colloidal carrier systems [46]. Surface modification of SLN has been used to 
improve the cell penetrating capacity of these particles. Namely, protamine [47,48], cell penetrating 
peptides [49,50], among others, have been investigated. HA-modified SLN have been recently used 
by Apaolaza et al. [51] for the targeted delivery of DNA to overexpressing ARPE-19 compared to HEK-
293 cells. Complexes prepared with HA of either 150, 500 or 1630 kDa, protamine and DNA were 
obtained by electrostatic interactions with SLN. The incorporation of HA in these SLN formulations 
induced a 7-fold increase in the transfection capacity of SLNs on ARPE-19 cells, regardless of the 
amount and molecular weight of HA. CD44 inhibition studies suggested the participation of the CD44 
receptors in the internalization of the vectors. Besides increasing transfection efficiency, modification 
of the vectors with HA also increased cell viability after treatment, compared to the plain SLN. SLN 
coated with HA by electrostatic interactions were also tested by Tran et al. [52] (Figure 3A). In their 
study, 3 kDa HA-decorated SLNs were used for the tumor-targeted delivery of vorinostat, a histone 
deacetylase inhibitor. Surface modification of SLNs increased cellular uptake of these vectors in CD44 
overexpressing A549 and SCC-7 cells. Moreover, competitive binding assays with a pretreatment with 
HA confirmed the receptor-mediated internalization of the particles. The coating by HA also 
increased SLN cytotoxicity compared to the free drug and the non-modified SLNs. These nanocarriers 
increased the circulation time of vorinostat and reduced its clearance in rats, resulting in higher 
plasma concentration than the free drug. 
 
 
Figure 3: Assocation of hyaluronic acid A) by adsorption to solid lipid nanoparticles or nanostructured 
lipid carriers; B) by association to a phospholipid inserted in phospholipid bilayer of liposomes. 
 
Nanostructured lipid carriers 
 
Nanostructured lipid carriers (NLC) consist in a new generation of lipid NPs that were introduced in 
the late 1990’s. These nanocarriers are characterized by a core consisting of a mixture of solid and  
liquid lipids, where the resulting matrix has a lower melting point than the original solid lipid, while 
still solid at body temperature [53,54]. Compared to SLN, NLC have the advantage of offering 
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increased drug loading and decreased drug leakage, although the drug loading capacity for 
hydrophilic drugs of both type of particles is still low compared, for example, to liposomes. They have 
been mostly used for chemotherapeutic drug delivery, and surface modification has been carried 
with biotin [55], anti-VEGFR-2 antibody [56] and transferrin [57] in order to improve the in vitro and 
in vivo efficacy of these carriers. HA-modified nanostructured lipid carriers loaded with paclitaxel 
were studied by Yang et al. [58] for the treatment of tumors overexpressing CD44. In their report, the 
authors described a more prolonged paclitaxel release from HA-coated particles, attributed to the 
increase in the diffusion distance of the drug from the nanocarriers due to the HA coating on the 
surface of NLC. HA-coating also promoted an increase in cell cytotoxicity of NLC compared to 
commercially available Taxol® against B16 murine melanoma cells, CT26 mouse colon cancer cells 
and HCT116 human colon cancer cell lines. In vivo, HA-NLC showed an increased antitumor activity 
and were better tolerated than Taxol by B16-bearing Kunming mice, as observed by animals’ weight 
loss. HA-coated NLC also prolonged paclitaxel plasma circulation time, and increased its 
accumulation in the tumor.  
 
Liposomes 
 
Liposomes have been studied for decades as drug delivery carriers to diseased cells, and great 
advances in cancer treatment and other diseases were achieved. For example, Doxil® improved 
therapeutic efficacy of doxorubicin in cancer treatment by enhancing selective drug accumulation in 
tumors [59,60] and leaded a breakthrough developments in the area. Another very successful case is 
AmBisome®, which improved the treatment of fungal infections in immunocompromised patients 
[61-63]. Presently, a number of liposome-based products are on the market for the treatment of 
Kaposi sarcoma [64], breast cancer [65], aspergillosis [66,67], meningitis [68] and leukemia [69], and 
many more are in clinical testing [70].  
The popularity of liposomes is explained by several advantages offered by these nanocarriers as 
drug-delivery systems. They are able to encapsulate both lipophilic compounds, in the lipid bilayer, 
and hydrophilic compounds, in their aqueous core. They usually have good biocompatibility, low 
toxicity and immunogenicity, and are biodegradable [71]. Besides, they are very versatile vesicles, 
and their structure can be modified to adjust their in vivo fate. The choice of specific lipids can for 
example control the release of the encapsulated drug in the targeted tissue by overheating [72-74]. 
Using cationic lipids in the liposome formulation allows the complexation of nucleotides by ionic 
interactions, a strategy that has been extensively used for nucleotide delivery and gene therapy 
[75,76]. Ligands, such as antibodies [77,78], folate [79], aptamers [80-84] or peptides [85] can be 
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attached to liposome surface to bind specific receptors on the cell surface. Particularly, liposomes 
modified with HA have been largely explored for the drug targeting to CD44-expressing cells. 
Ongoing work on modification of liposomes with HA has focused mainly on specifically delivering 
antitumor drugs (small or large molecules) to CD44-overexpressing tumor cells. HA-liposomes were 
proven as effective carriers of miR-34a, a prognostic biomarker, to MDA-MB-231 breast tumors 
overexpressing hyaluronan receptors [86]. They were also used by Qhattal et al. [87,88] to target 
these cells in vitro and in vivo. In these studies, it was observed that the cellular targeting efficiency 
of HA-liposomes depended strongly upon HA MW, grafting density, and cell-surface CD44 density. A 
liposome formulation coated with HA was also developed for MDA-MB-231 targeted delivery of an 
anticancer agent and MR imaging of breast cancer [89]. In this study, HA-modification reduced the 
toxicity of liposomes, increased serum stability and promoted tumor-accumulation of these vesicles. 
In our investigations on HA-liposomes carrying either DNA or siRNA, higher transfection efficiencies 
of CD44-overexpressing MDA-MB-231 [90] and A549-luc cells [91,92] were also observed. These HA-
modified lipoplexes presented good biocompatibility and low complement activation [90]. 
Landesman-Milo et al. [93] also used HA-coated liposomes prepared with neutral phospholipids and 
cholesterol to target A549 CD44-overexpressing cells. The authors observed specific binding and 
internalization of HA-modified particles. Liposomes were shown to be non-toxic and efficient in 
delivering siRNAs to the targeted cells [93]. Dalla Pozza et al. [94] and Arpicco et al. [95] designed HA-
liposomes prepared with low MW HA to target highly CD44-expressing MiaPaCa2 pancreatic 
adenocarcinoma cells. In the first study, the authors demonstrated a selective uptake of HA-
liposomes by MiaPaCa2 cells compared to CD44-non expressing VIT1 cells. In the second study, the 
cellular uptake ability and the in vitro and in vivo anti-tumoral activity of HA-liposomes carrying 
gemcitabine (GEM) were investigated. An increased cellular internalization of liposomes covered 
with HA and increased in vitro and in vivo sensitivity towards GEM-containing HA-liposomes were 
observed. Dual-function liposomes with HA targeting and pH-responsive cell-penetrating peptide 
were prepared by Jiang et al. [96] for tumor-targeted drug delivery to hepatocellular carcinoma cells. 
HA was utilized to decrease liposomes interaction with plasma proteins, and once at the tumor site, 
its degradation by HAses exposed the R6H4 peptide. These paclitaxel-containing liposomes 
presented stronger cytotoxicity, efficient intracellular trafficking and preferential tumor 
accumulation.  
HA-modified liposomes have also been used to target macrophages, in the context of the treatment 
of inflammatory diseases. Glucksam-Galnoy et al. [97] investigated the interactions between non-
modified and HA-modified unilamellar (HA-ULV) and multilamellar (HA-MLV) liposomes and 
macrophages, and describe a substantially favored binding of the MLV species over the ULV species. 
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Internalization of exclusively  non-modified MLV was observed in this study, and the authors 
suggested that smal HA-ULV provide stealth properties and are suitable for delivering anti-
inflammatory drugs to the macrophage surface, while HA-MLV would be suitable for delivering anti-
inflammatory drugs inside macrophages and reducing inflammation cell-signaling TNF-α production. 
Gan et al. [77] used HA-modification for the treatment of retinal inflammation, a common process of 
posterior ocular diseases that can lead to severe vision loss. The authors developed core-shell lipid 
nanoparticles, consisting of chitosan nanoparticles covered with a lipid layer modified with HA, to 
target retinal pigment epithelium (RPE) cells, generally considered as the therapeutic target of 
inflammation pathogenesis. As commonly described for liposomes after intravitreal administration 
[98] these vesicles had a longer residence time in vivo and in addition could efficiently pass through 
the vitreous barrier being preferentially internalized by the CD44-expressing RPE cells.  
The reports about HA-liposomes for drug delivery to CD44 positive cells clearly established their 
advantages over the non-targeted liposomes. The characteristics of the nanocarriers related to the 
density and size of HA influence directly their ability to interact with the receptors on the targeted 
cells, and therefore impact on their biological activity. Taking into consideration the large amount of 
studies related to liposomes compared to all other types of nanocarriers, we discuss below how their 
modification with HA influences their physicochemical characteristics and their efficacy in vitro and in 
vivo.  
 
Functionalization of liposomes with HA 
 
Basically, two different preparation methods are used for inserting HA within the liposomal 
membrane. In one of them, HA is linked to the surface of preformed liposomes by a covalent 
conjugation. In this method, first described by Yerushalmi and Margalit in 1998 [99], carboxylic 
residues of HA are pre-activated by incubation with the condensing agent ethyl-dimethyl-
aminopropyl-carbodiimide (EDC) in aqueous acid medium. The activated HA is then added to the 
nanocarrier suspension at basic pH, where an amidic bond will be formed with the lipids amine 
groups. This method seems to yield coating efficiencies that allow efficient CD44-binding [12,77,86-
88,93,97,100], which is desirable since a minimal amount of HA is necessary to target the receptors 
[101]. The inconvenience of this technique is that post-conjugation must be made for every 
preparation of liposomes, which is time consuming since the reaction lasts for more than 24 h [99]. In 
the second approach, liposomes are prepared in the presence of HA conjugated to a lipid anchor 
(Figure 3B). Low molecular weight (LMW) HA can be linked to an aminated lipid such as 
phosphatidylethanolamine (PE) [102], dipalmitoyl phosphatidylethanolamine (DPPE) [94], 
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diphytanoyl glycerophosphatidylethanolamine (DiPhPE) [103] by reductive amination, using a sodium 
borohydride as reducing agent, providing a conjugate in which only one lipid molecule is linked to HA 
which will interact with other lipid within the bilayer structure (Figure 4A). HMWHA can be coupled 
to 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) by means of an amidation reaction in 
which the amino group is randomly linked to the carboxylic residues of the polymer and then 
introduced into liposomes bilayer [90,92] (Figure 4B). Using this approach allows a faster preparation 
of HA-vesicles, since the HA-lipid conjugate can be synthesized previously and stored to be used for 
multiple formulations. It also yields coating efficiencies that allow efficient CD44-binding 
[89,90,92,95,103]. Unfortunately, association efficiency of HA to liposomes is not systematically 
quantified, which renders the comparison of these two methods rather difficult. Nevertheless, 
chemical conjugation of HA has been proved to be more efficient than the functionalization of 
liposomes with unconjugated HA [92,104], since in this case, HA is not anchored on the liposome 
structure but merely attached to liposomes by electrostatic interactions. Instead of being conjugated 
to phospholipids, HA has been also chemically coupled to other lipids such as ceramide [89] or 
sterarylamine [104]. In both cases, liposomes were efficiently targeting CD44 positive cells. 
Since many aspects related to the presence of HA on vesicle surface are important in determining 
their biological effect, a better comprehension of particle structure after modification with HA is an 
important step of the formulation characterization. For instance, the arrangement of HA on liposome 
surface will have an important influence on their biological activity. In principle, linear HA polymer 
can behave just like polyethylene glycol (PEG), another hydrophilic polymer frequently used for the 
modification of liposome surface. This means that depending on the HA molecular weight and 
grafting density, HA chains grafted on the lipid bilayers can show brush, mushroom, or pancake 
conformation [87]. Also, because HA is linked with several anchors, the conformation of the HA 
around the liposomes might be different from these conformations [92] and therefore, each 
conformation will have its own thickness of hydration layer, steric hindrance and disposition of 
binding moieties [105]. 
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Figure 4: Coupling reaction of aminated phospholipids to HA by (A) by reductive amination on the extremity of LMW-HA or (B) amidation on carboxylic 
residues of HMW-HA. 
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Effect of HA molecular weight and grafting density on nanoparticle physicochemical properties 
 
The most common route of administration of nanocarrier suspensions is the intravenous one. This 
administration pathway allows a maximum amount of particles to circulate and find their cell targets 
immediately after administration. Cells are able to internalize nanocarriers by either phagocytosis or 
receptor-mediated endocytosis, meaning that particle size may affect internalization depending on cell 
type. However, the diameter of capillaries is the most limiting factor for nanocarriers size when 
administered through the intravenous route. A size of 200 nm is considered as optimal for 
nanocarriers to circulate in the narrowest vessels avoiding embolization [5,106]. Therefore, liposomes 
of around 100 nm are usually preferred. Since HA is a hydrophilic polymer, its placement on 
nanoparticle surface increases nanoparticle mean hydrodynamic diameter. This increase is generally 
used to characterize particle coverage and reflects the presence of HA on their surface. Several 
authors have demonstrated that particle size progressively increases with HA MW [87,95,107]. For 
example, in one of the above-mentioned studies [95], HA-liposomes had a mean diameter of 160 ± 5 
and 208 ± 7 nm when prepared with HA of molecular weights of 80 and 1000 kDa, respectively. A 
progressive increase in particle diameter with increasing concentrations of grafted polymer chain units 
is also commonly observed. 
Besides the measurement of hydrodynamic diameter, microscopy can be used to give extra 
information on the structure of the particles. For instance, Arpicco et al. [95] demonstrate that 
hyaluronated liposomes revealed a particulate surface coating, which was absent in plain liposomes, 
and were decorated by fluffy dark structures, confirming that HA molecules were exposed on liposome 
surface. Gan et al. [77] described similar observations, where the analysis of HA-liposomes (named 
liponanoparticles) by transmission electron microscope (TEM) exhibited black spots surrounded by 
gray rims, confirming the core-shell structure of the particles. Tiantian et al. [107] used TEM to 
describe the change in liposome shape caused by the presence of HA, and reported the formation of 
more spherical structures than for non-coated liposomes. 
Exploring nanoparticle surface charge modification by measuring the zeta potential can be used to 
describe surface coating of nanoparticles by HA. Whether the initial liposomes display a neutral 
[97,108], negative [95,107] or positive charge [90-92], a clear change in the zeta potential is 
systematically observed after insertion of HA on these structures. Since HA is an anionic polymer, 
when present on the surface of the vesicles, it causes a decrease in zeta potential, and for this reason, 
HA-modified lipid vesicles are usually neutral or negative. This is beneficial when stability in serum and 
vesicle toxicity are considered, since HA decreases particle interaction with serum proteins and masks 
the surface charge of cationic particles as discussed in more details below. 
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Another important aspect of the physicochemical characterization of nanoparticles is the evaluation of 
their stability under conditions that resemble the in vivo environment. Particle stability is a complex 
function of nanoparticle surface characteristics and components of surrounding medium [109]. In 
physiological conditions, nanoparticles may interact with biological components, which leads to the 
formation of a protein corona [110]. Coating with proteins may induce conformational changes [111-
113] or modification in size and zeta potential [114-116]. These changes can dramatically affect 
particles’ stability, interaction with membrane and cells, and clearance [117]. For liposomes, as for 
many other particle types, immediate aggregation can occur when particles interact with blood 
components [117-119]. However, when particles are modified with HA, the decreased charge and 
additional steric hindrance caused by the hydrophilic coating can improve their stability [40,120]. For 
instance, Park et al. [89] describe that, while conventional liposomes formed large aggregates 
immediately after incubation in 50% FBS, particle size of the HA-coated liposomes was maintained for 
at least 24 h. We have also observed that the presence of HA results in an improvement of lipoplexes 
stability in the presence of serum. The diameter of lipoplexes (lipids:DNA ratio of 2) did not differ 
significantly in the serum-containing cell culture media, while non-modified lipoplexes aggregated 
immediately upon dilution [92]. These observations support the idea that HA-modification, while 
improving in vivo stability, could potentially ameliorate the pharmacokinetic performance of HA-
modified particles [89]. 
Alteration of encapsulation efficiency after modification of lipid vesicles with HA has not been 
frequently described. Modification of the entrapment of drugs in the hydrophilic core or in the 
lipophilic bilayers of liposomes is unlikely, assuming that the addition of HA does not alter in a great 
extent, for example, the liposome structure or the fluidity of the lipid bilayers. On the other hand, 
when active drug encapsulation depends on the interaction with the lipids for their association, it is 
plausible to imagine that steric hindrance or the negative charge of HA could represent barriers for this 
association. This is the case for complexation of nucleic acids to liposome surface during the formation 
of lipoplexes. A possible competition between the negative charges of DNA and RNA molecules with 
the ones of HA for the binding to cationic lipid could take place. This competition can be influenced by 
the binding strength of each component with the cationic lipids. HA molecules may also represent a 
barrier to the binding of the nucleic acids. This steric hindrance has been observed for DNA lipoplexes 
that presented PEG on their surface [121]. Similar observations have however not been reported for 
HA-modified liposomes. In our recent studies with HA-modified lipoplexes, even for preparations using 
HA of 1,600 kDa [90,92], its presence did not prevent nucleic acid association but reduced the amount 
of HA that was initially attached on liposomes surface before lipoplex formation [92]. 
Although alterations in the encapsulation efficiency properties of liposomes have not been reported, 
authors described changes in the drug release properties from vesicles caused by the insertion of HA in 
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their structure. Tiantian et al. [107] observed, for example, that the release profile of docetaxel was 
prolonged after liposome coating with HA. This observation was not related to the molecular weight of 
HA, but rather to the decrease of the bilayer fluidity upon association of HA [122]. Moreover, drug 
release from HA-liposomes can be altered due to different degradation ratios of HA occurring at 
different pH. Park et al. [89] observed an increase in doxorubicin release from liposomes with 
decreasing pH values. Kim also observed an accelerated release of miRNA from liposomes at acidic 
compared to neutral pH. This pH-dependent release from HA liposomes reflects the physiological 
breakdown of HA. The degradation of HA in aqueous solution is caused by hydrolysis attributed to the 
random scission of its polymer chains, and its degradation rate strongly depends on pH. HA is indeed 
more labile in acidic than neutral conditions [123,124]. Jiang et al. [96] used this characteristic to 
design pH-responsive HA/cell-penetrating peptide decorated-liposomes for tumor-targeted paclitaxel 
delivery. Indeed, it was shown that the degradation of HA by HAase-rich tumor microenvironment 
allowed exposure of the cell penetrating peptide and cell internalization  [96]. 
 
Effect of HA molecular weight and density on the interaction with CD44 receptors 
 
Overall, the previous observations confirm that it is important to understand the physicochemical 
characteristics of the formulated HA-liposomes. It is however not enough to have HA on the surface of 
liposomes since HA moieties should also be available for interaction with the CD44 receptors. Affinity 
of liposomes for CD44 receptors strongly depends on the molecular weight of the HA oligomers, 
hexamers and decamers being the smallest sequences of HA that can interact with CD44 receptors. As 
they have the ability to bind simultaneously to several CD44 units, HMW HA has more affinity to these 
receptors than LMW HA [35].  
The measurement of CD44-HA interaction is often related to chemical techniques such as NMR [125] 
or biological techniques such as SDS-PAGE, Western blot, immunostaining, or finally cellular 
localization by techniques adjacent to cell culture such as flow cytometry or fluorescence microscopy 
[25,126,127]. Particularly, the importance of the interaction between free HA or HA-functionalized 
liposomes with CD44 receptors is often determined using surface plasmon resonance (SPR). In this 
technique, the extracellular moieties of CD44, CD44-Fc, are attached to a gold surface, and HA 
molecules of different molecular weights, non-modified or HA-particles are put in contact with the 
receptors. The amount of ligands that interact with the surface is then measured in real time, since 
this experiment is performed in a continuous flow. Mizrahy at al. [100] evaluated the correlation 
between the lengths of HA oligomers and their binding affinity to CD44 receptors using SPR. The 
authors analyzed the interaction with CD44 receptors of HA of 6.4, 31, 132, 700 and 1500 kDa, and 
confirmed the interaction with multiple receptors for HA with MW of 132 kDa and higher. A small 
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library of liposomes distinguished only by the MW of their surface anchored HA was then prepared, 
and it was observed that the affinity towards CD44 was controlled solely by adjusting the HA MW on 
the surface of NP. The results from these experiments showed the same trend observed in the 
experiments with free HA, clearly indicating stronger binding of HMW HA to the receptor. Controlling 
the molecular weight of HA attached on the surface of liposomes can be used as an approach to 
selective target the right receptors. Ruhela et al. [103] used this strategy to optimize CD44 receptor 
targeting and reduce liposome interaction with the HARE receptor in the liver. The authors assumed 
that HA oligomers of 10−20 units are long enough to bind to the CD44 receptor but shorter than the 
HA length required to tightly bind to the HARE receptor of liver endothelial cells. Indeed, HA oligomers 
of 10-18 monosaccharides were used to prepare the diphytanoyl glycerophosphatidylethanolamine 
(DiPhPE)-HA conjugates inserted into liposomes and were shown to strongly bind to COS7 cells 
overexpressing CD44.  
 
Cellular binding, uptake and trafficking pathways 
 
Competitive binding assays are performed in vitro to observe CD44-mediated internalization and to 
understand the intracellular trafficking pathways involved in the uptake of HA-particles. A simple 
method to test the binding of these particles to the receptors is pre-treating cells with an excess of 
free HA or anti-CD44 antibody. For example, upon blocking of CD44 receptors with free HA, Kim et al. 
[86] observed a complete uptake suppression in MCF-7 and MDA-MB-231 cell lines. Gan et al. [77] also 
observed that ligand pretreatment did not change the cellular uptake of plain and lipid nanoparticles 
prepared with LMW HA, while the cellular uptake of particles prepared with HMW HA was significantly 
reduced in CD44-expressing ARPE-19 cells. In the work of Arpicco et al. [95], MiaPaCa2 cells were pre-
incubated with a saturable amount of free HMW HA (51 kDa) before treatment to validate the 
specificity of HA-liposome uptake through the CD44 receptor. A 75% reduction of the uptake, in 
comparison with the control (without incubation with free HMW HA), was observed in cells treated 
with liposome-bearing HMW HA (2000 kDa) at 24 h [95]. Dalla Pozza et al. [94] reported that the ability 
of MiaPaCa2 cells (CD44+) to incorporate both 4.8 or 12 kDa HA-liposome formulations was 
significantly higher than that of VIT1 cells (CD44-), suggesting that liposome internalization in 
MiaPaCa2 cells was mainly mediated by HA. Surace et al. [90] observed that the transfection of DNA 
HA-lipoplexes on the CD44-expressing MDA-MB-231 cells was highly inhibited by anti-CD44 Hermes-1 
antibody [128] but not by the nonspecific anti-ErbB2 antibody. Meanwhile, the transfection of MCF-7 
cells was not altered whether they were transfected in the presence of Hermes-1 antibody or not. A 
concentration-dependent activity was observed, with a maximum gene inhibition efficiency reaching 
70% in comparison with the control when cells were treated with 1 μg/mL of anti-CD44 Hermes-1 
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before transfection. In another experiment, Dufay-Wojcicki et al. [92] tested the intracellular pathway 
for green fluorescent protein (GFP)-expressing DNA-cationic lipoplexes modified by HA. Cells were pre-
treated with HA to saturate CD44, or HA was blocked using CD44 antibody, and in both cases a 
decrease of 40% in GFP expression was observed [92]. The incubation of HA-liposomes with cells at 4 
°C, a temperature which inhibits all the active energy-mediated processes, significantly reduced the 
uptake in MiaPaCa2 cells, suggesting that HA-liposomes entered cells via an endocytic pathway. These 
results were also confirmed by confocal laser scanner microscopy. In these experiments, MiaPaCa2 
cells treated with fluorescein-labeled HA-liposomes for 1 h at 37 °C were strongly fluorescent and VIT1 
cells showed in contrast a very low signal, as well as MiaPaCa2 cells treated with non-targeted 
liposomes or at 4 °C.  In one study [129], the authors also analyzed the effect of temperature on HA-
liposome uptake by incubating the A549 cells with HA-liposomes for 2 h at 4 °C. As expected, the 
incubation of HA-liposomes with cells at 4 °C inhibited the active energy-mediated processes, reducing 
uptake of 5-8 kDa and 175-350 kDa HA-liposomes by 68% and 53%, respectively, compared to uptake 
at 37 °C. This finding confirms that HA-liposomes are taken up inside the cells via an energy-dependent 
endocytosis pathway. 
The endocytic pathways involved in the internalization of nanoparticles are clathrin-mediated, 
caveolae-mediated, macropinocytosis and other clathrin- and caveolae-independent process [5]. The 
cellular uptake of liposomes, like for other types of particles, will depend on their surface charge, size, 
cell type and the molecular composition of the cell surface [130]. It is difficult to describe a consistent 
profile of liposomes matching each of these endocytic pathways. Indeed, unlike phagocytosis occurring 
primarily in professional phagocytes, other endocytic mechanisms may take place in virtually all types 
of cells and vary accordingly; differences will also occur between the apical and basolateral 
membranes of a polarized cell. Moreover, several endocytic mechanisms often take place 
simultaneously [5]. The study of the influence of these characteristics on the internalization of 
particles has an important impact in the drug delivery field. For instance, nanocarriers may be tailored 
in order to be metabolized into the lysosomes and release their content intracellularly as a 
consequence of lysosomal biodegradation after clathrin-mediated endocytosis [5]. They can also be 
designed to by-pass the lysosomal degradation pathway and reach the cytoplasm by caveolae-
mediated endocytosis when the carried cargo is highly sensitive to enzymes [5,131,132]. 
Qhattal et al. examined the effects of several membrane entry inhibitors on the uptake of HA-
liposomes by preincubating A549 cells with the inhibitors before treatment with HA-liposomes. 
Chlorpromazine was used to inhibit the assembly and disassembly of clathrin [133] and test the 
clathrin-mediated endocytosis. Amiloride was used as a specific inhibitor of the Na+/H+ exchange 
required for macropinocytosis. Filipin III and nystatin were used to inhibit caveolae-mediated uptake 
by partitioning into membranes and sequestering sterols [134]. None of these inhibitors showed any 
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effect on the uptake of HA-liposomes. When blocking lipid rafts (cell membrane microdomains rich in 
cholesterol, sphingolipids and cell surface receptors [129]) using methyl-β-cyclodextrin, the uptake of 
HA-liposomes was reduced by nearly 45% compared to untreated cells, suggesting that HA-liposomes 
are taken up into the cells via the lipid raft-mediated endocytosis which is cholesterol-dependent 
[133].  In a similar study, Dalla Pozza et al. [94] pre-treated MiaPaCa2 cells with increasing amounts of 
individual membrane entry inhibitors before incubation with 4.8 or 12 kDa HA-liposome formulations. 
The flow cytometry analysis also revealed that methyl-β-cyclodextrin (MβCD) strongly decreased the 
HA-liposome uptake, in a concentration dependent manner, while treatment with chlorpromazine, 
nystatin and amiloride (inhibitors of clathrin- or caveolae-mediated uptake or macropinocytosis, 
respectively), did not alter the fluorescence of the cells compared to controls. Incubation with 
caveolae-inhibitor filipin reduced by 60% the transfection efficiency of HMW hyaluronic acid-bearing 
DNA lipoplexes (using a plasmid coding for the GFP) in A549 cells. Moreover, when genistein, another 
inhibitor of this internalization pathway was used, GFP expression was lowered by 90% [92]. In 
contrast, using the clathrin-mediated endocytosis inhibitor chlorpromazine, transfection levels were 
not changed. Nevertheless, transfection efficiency was also blocked by an excess of HA or CD44 
antibody. Both caveolin [135] and CD44 [10] are present in lipid rafts domains, it is therefore likely that 
the inhibition of CD44 by an excess of HA or CD44 antibody is blocking one of the pathways for 
caveolin phosphorylation, which is necessary to start the caveolae-dependent endocytosis [136].  
 
In vitro and in vivo toxicity and inflammation of HA-liposomes 
 
An important concern regarding the use of nanoparticles for targeted delivery of active substances in 
vivo is the risk that they can cause adverse effects in the body. This is one of the key aspects in the 
development of nanocarriers for in vivo application, and although no conclusive guidelines have been 
made for preparing low immuno-stimulatory nanomedicines, all nanocarriers need to go through 
rigorous toxicology studies before regulatory approval [137].   
As previously discussed, it is well accepted that HA of different MW causes different effects on cellular 
functions after binding to CD44 receptors. HMW HA is present under homeostatic conditions, and 
plays a key role in the structural integrity of tissues. It is therefore considered to be biocompatible or 
bio-inert [138]. Under certain pathological inflammatory conditions, such as cancers, fragments of 
LMW HA are produced due to a reduction of the activity of HA synthases [139] and an increased 
activity of hyalurodinases [139]. These small fragments (from 2 to 100 kDa, about 4 to 250 
disaccharide units) have been shown to have an angiogenic effect in vitro, contributing to tumor 
growth [140]. It has also been described that LMW HA provoke immuno-stimulatory [141] and 
proinflammatory effects upon binding to CD44 [142]. Nevertheless, not all literature reports are 
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consistent [100], and a more complex behavior is observed when the toxicity of HA-modified 
liposomes particles is studied. Similarly as for the other aspects of nanoparticle activity, their 
interaction with the immune system will be controled not only by HA MW, but also by particle size, 
shape, surface and composition. 
In the study designed by Mizhary et al. [100], where liposomes with different MW HA were prepared, 
the authors report that none of the vesicles showed any apparent effect on the proliferation of highly 
CD44-expressing NCI/ADR-RES (for adriamycin-resistant cell line), TK-1 and RAW 264.7 cells. No 
macrophage activation or complement activation caused by these nanocarriers were detected. 
Additionally, no cytokine induction was observed regardless of the HA MW anchored to the surface of 
nanoparticles. These results were compared to a previous study where significantly higher amounts of 
free LMW HA but not HMW HA induced inflammatory gene expression in peritoneal and alveolar 
macrophages [143], providing a good example that toxicity is a dose-relative notion [144]. The authors 
discuss that covalently attaching HA to the surface of liposomes hurdles processing by cells, and may 
account for the lack of macrophage activation. HA-liposomes prepared by Kim et al. [86] with 1000 kDa 
HA also showed high biocompatibility on CD44-expressing (98.8%) MDA-MB-231 cells compared to low 
CD44-expressing (3.6%) MCF-7 cells. Similarly, uni- and multilamellar HA-liposomes prepared by 
Glucksam-Galnoy et al. [97] with 1500 kDa HA did not elicit any TNF-α response. The secretion level of 
three different inflammatory interleukins was tested by Landesman-Milo et al. [93] using IL-6 and TNF-
α as a model for the innate immune response and IL-10 as a model for the late immune response. In 
this study, where liposomes were coated with 700 kDa HA, neither the HA-modified nor the uncoated 
particles caused an elevate secretion of both innate and late cytokines response.  
An improvement of liposome biocompatibility by coating lipid bilayers with HA was even observed by 
Gan et al. [77], who described that HA-liposomes did not show cytotoxicity on CD44-expressing human 
retinal pigment epithelial (ARPE-19) cells, compared to the non-modified liposomes. Similarly, Park et 
al. [89] described a recovery of cell viability from around 40% to 100% upon coating the outer surface 
of liposomes with HA. The authors attributed this effect to a protection of HA against the disruption of 
cellular membrane by the liposome itself, which reduced cytotoxicity versus the plain liposomes. 
These results are not unexpected, not only considering HA MW, but also the type of nanoparticles. 
Liposomes are generally considered to be safe and non-immunogenic, since the lipids used in the 
formulation are quite often ubiquitous to the cellular composition. For cationic liposomes, though, it 
has been described that alterations of the net charge of cell membranes and adverse effects on the 
activity of ion channels, membrane receptors and enzymes can occur [145]. These alterations depend 
on the cationic nature of the lipid head group and its ratio with neutral lipid [144], and raise a concern 
about the safety of these vesicles. In our studies with cationic liposomes [90-92], lipoplexes presented 
good biocompatibility. DNA lipoplexes prepared with increasing lipids:DNA ratios (2, 4, and 6) and non-
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modified and HA-modified liposomes for the targeting of CD44-overexpressing A549 cells [92] showed 
low activation of the complement, as measured by the activation of the protein C3 that is also 
considered as a good indicator of the capacity of macrophages of the mononuclear phagocyte system 
(MPS) to phagocyte the drug carrier. 
 
Effect of HA-modification on liposome pharmacokinetics 
 
Almost immediately after entering the organism through the intravenous route, liposomes are 
recognized by opsonins. These specific serum proteins, mainly IgG and IgM immunoglobulins and 
complement components (C3, C4, C5) [146-148], adsorb onto particle surface inducing their 
recognition and binding by specific receptors present on the surface of cells from the MPS [149]. These 
cells will capture liposomes by endocytosis and remove them from the circulation [150]. Components 
that inhibit the phagocytosis of pathogens or particles, referred to as dysopsonins, are also present in 
the serum. Human serum albumin and IgA, for example, possess dysopsonic properties and their 
presence on particle surface has been shown to reduce recognition and phagocytosis [151]. The 
balance between blood opsonic proteins and suppressive proteins regulates therefore the extent and 
rate of liposome clearance, which will depend on particle size and surface properties [109,151].  
When it comes to regular liposomes, phagocytosis is enhanced for larger and multilamellar particles 
[5,152,153], as well as for charged or hydrophobic surfaces [154-156]. HA being a hydrophilic 
molecule, its presence on the surface of liposomes will increase vesicle stealth properties, resulting in 
longer circulation time. Tumor targeting can also be expected by modifying particles with HA, further 
improving accumulation of the nanocarrier in the tumor region and leading to improved activity in vivo 
[89]. 
Park et al. [89] observed an improved in vivo behavior of doxorubicin-encapsulating liposomes 
modified with the insertion of a HA-ceramide conjugate. While plain liposomes immediately 
aggregated in the presence of 50% FBS, the in vitro stability of HA-liposomes was maintained during 24 
h. However, the most important effect of HA insertion was tumor targeting. The in vivo diagnostic and 
tumor treatment capabilities of the formulation was evaluated in a MDA-MB-231 tumor-xenografted 
mouse model. Fluorescence signal on the tumor region, corresponding to the presence of the 
particles, was 2.6-fold higher than that of plain liposomes, and increased up to 89% 2 h after injection 
compared to the free drug distribution. The authors attributed the accumulation of the nanocarrier in 
the tumor region to the serum stability of the particles and more importantly to its slow clearance in 
vivo and prolonged circulation in the blood stream. Dalla Pozza et al. [94], comparing HA-liposomes 
prepared with LMW HA of 12 and 4.8 kDa, observed that the volume of tumors in mice treated with 12 
kDa HA-liposomes increased at a significant lower extent than that in mice treated with 4.8 kDa HA 
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liposomes or non-targeted liposomes. At the end of the treatment, free GEM did not inhibit the tumor 
growth in the drug-resistant pancreatic cancer xenograft model used, while liposome formulations 
displayed different levels of efficacy. 12kDa HA-liposomes determined a reduction in the mean tumor 
mass of about 50% compared to 4.8 kDa HA liposomes or non-targeted liposomes and about 65% 
compared to control or free GEM treatment. Kim et al. [86] used HA-coated liposomes to target breast 
cancer cells over expressing CD44, and achieved enhanced intracellular delivery and optical imaging of 
miR-34a beacons. The coating with HMW HA promoted a tumor-specific delivery of the imaging probe. 
1 h after the intravenous injection of non-modified and HA-liposomes, injection of the latest provided 
strong fluorescence signal in CD44-positive tumor bearing mice, while non-modified and blocking 
groups using excess HA as controls showed significantly reduced fluorescence signals. Using these 
nanocarriers, the authors achieved targeted optical imaging of miR-34a expression levels. 
These results suggest that modifying liposome surface with HA provides a hydrophilic shield that will 
reduce interaction with plasma proteins and increase particle circulation time. This has led to the 
proposition of HA as an alternative to PEG, when reduced opsonisation and MPS uptake combined 
with the targeting properties of HA are desired [108,157]. Qhattal et al. [88] tested this hypothesis 
with a systematic study of the pharmacokinetics of HA-liposomes with three different HA polymer 
lengths (5-8, 50-60 and 175-350 kDa) and compared with that of PEGylated liposomes. It was shown 
that the clearance of HA-liposomes was dependent on HA length. Indeed, the addition of HMW HA to 
the surface of liposomes accelerated the clearance of the particles from the blood compared to low 
MW HA. This finding was related to the high affinity of the particles for other HA receptors such as 
HARE and LYVE-1, which are abundantly expressed in normal sinusoidal endothelial cells of the liver, 
spleen, and activated tissue macrophages [88,158,159], that are responsible for active clearance of 
liposomes from the circulation. 
Changes in pharmacokinetics by HA are not strictly limited to intravenous administration. Gan et al. 
[77] described an increase in residence time after coating lipid-chitosan nanoparticles with 10-100 and 
200-400 kDa HA and administration by the intravitreal route. The authors observed that 7 days after 
injection, approximately one-third of the total fluorescence related to the non-coated particles was 
cleared from the targeted vitreous region, while for the 200-400 kDa HA-coated liposomes, 
approximately 75% of the fluorescence still remained in the retinal pigment epithelium/choroid. An 
improved penetration on the targeted site of action was also described after the in vivo treatment. 
While both non-coated and HA-particles passed through the vitreous barrier and reached the inner 
limiting membrane, red fluorescence of HA-liposomes was found in the RPE layer in the inflamed eyes, 
which was not observed in the non-coated group. 
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Conclusion and future perspective 
 
Modifying the surface of lipid-based nanoparticles with HA offers the possibility of targeting CD44-
overexpressing cells and takes advantage of the biological relevance of CD44-HA interaction on tumor 
growth and progression. HA-modification of nanoparticles can indeed change physicochemical 
properties, alter stability, toxicity, and influence particle distribution and efficiency in vitro and in vivo. 
The complexity of the structure of lipid-based nanocarriers displaying HA on their surface implicates 
that a thorough characterization of the nanocarrier is necessary to understand its activity.  
Although many studies conclude that LMW HA are more effective for inducing long circulating 
properties in lipid nanocarriers than HMW, the question is still opened regarding the angiogenic effect 
of these fragments. Furthermore, studies are still needed to better understand how the modification 
by HA influences in vivo distribution and tissue accumulation of these nanocarriers particularly in the 
case of cancer. Whether the improved efficacy is only due to pharmacokinetic modifications of the 
carriers added to an enhanced penetration and retention effect with or without targeting CD44 on 
tumor cells is still an open question. Within the tumor it would be important to determine what is the 
subpopulation of cells that is interacting with the carriers and whether these cells are cancer stem 
cells. Future perspectives include a comparison of the hyaluronic acid-coating strategy with more 
recent others that combine nanocarriers and apatmers or antibodies as ligands for CD44. 
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Table 1: Different types of liposomes associated to hyaluronic acid for targeting CD44 
Carrier Drug target HA MW 
Method of HA 
insertion on the 
formulation 
Reference 
HA-multilamellar 
liposomes  
 NCI/ADR-RES 
ovarian 
adenocarcino
ma, RAW 
264.7 
macrophages 
and TK-1T cell 
lymphoma 
cells 
6.4, 31, 132, 
700 and 1500 
kDa 
HA conjugated on  
preformed 
liposomes (by 
carbodiimide  
conjugation 
chemistry) 
[100] 
HA-liposomes  Mice liver 
endothelial 
cells 
500-700 kDa Eletrostatic 
attraction 
(incubation of 
preformed 
liposomes with 
HA-stearylamine 
conjugate) 
[104] 
HA-liposomes miR-34a (miRNA) MCF-7 and 
MDA-MB-
231breast 
cancer cells 
1000 kDa HA conjugated on 
DSPE-PEG2000 
amine on the 
surface of  
preformed 
liposomes 
[86] 
HA-liposomes 
(uni and 
multilamellar) 
 RAW264.7 
macrophages 
1500 kDa HA conjugated on  
preformed 
liposomes (by 
carbodiimide  
conjugation 
chemistry) 
[97] 
HA-liposomes  Gemcitabine PaCa44, 
PaCa3, Panc1, 
CFPAC1, 
PT45P1, 
T3M4, Suit-2, 
Mia-PaCa2, 
PC1J, HPAF II, 
and PSN1 
pancreatic 
adenocarcino
ma 
cell lines  
4.8 and 12 
kDa 
HA-DPPE 
conjugates 
inserted upon 
liposome 
preparation (thin 
lipid film 
hydration) 
[95] 
HA-modified core 
shell 
liponanoparticles 
 ARPE-19 
retinal 
pigment 
epithelial 
cells  
10-100 and 
200-400 kDa 
HA conjugated on  
preformed 
liposomes (by 
carbodiimide 
conjugation 
chemistry) 
 
 
[77] 
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HA-coated lipid-
based-
nanoparticles 
siRNA NCI/ADR-RES 
ovarian 
tumor and 
A549 lung 
carcinoma 
cells 
700 kDa HA conjugated on  
preformed 
liposomes (by 
carbodiimide  
conjugation 
chemistry) 
[93] 
HA-liposomes Docetaxel (model drug) 
/ lymphatic 
system 
80 and 1000 
kDa 
Electrostatic 
attraction 
(thermostat 
titration of  
preformed 
liposomes on HA 
solution) 
[107] 
HA-liposomes  A549lung 
carcinoma, 
MDA-MB-231 
and MCF7 
breast cancer 
cells 
5-8, 10-12, 
175-350 and 
1600 kDa 
HA conjugated on  
preformed 
liposomes (by 
carbodiimide 
conjugation 
chemistry) 
[87] 
HA-liposomes 
with or without 
PEG 
 MDA-MB-231 
breast cancer 
cells 
5-8, 50-60 
and 
175-350 kDa 
HA conjugated on 
preformed 
liposomes (by 
carbodiimide  
conjugation 
chemistry) 
[88] 
HA-liposomes Paclitaxel HepG2 
hepatocarcin
oma cells 
210 kDa Electrostatic 
attraction 
(incubation of 
preformed 
liposomes with 
HA solution) 
[96] 
HA-liposomes  COS-7 kidney 
fibroblas t 
cells 
HA oligomers 
(10-20 
monosacchar
ides) 
HA-DiPhPE 
conjugates 
inserted upon 
liposome 
preparation 
[103] 
HA-liposomes  Gadopentetate 
dimeglumine 
doxorubicin 
MDA-MB-231 
breast cancer 
cells 
4.7 kDa HA-ceramide 
conjugates 
inserted upon 
liposome 
preparation (thin 
lipid film 
formation) 
[89] 
HA-liposomes Gemcitabine Mia-Paca 
pancreatic 
carcinoma 
cells 
4.8 and 
12 kDa 
HA-DPPE 
conjugates 
inserted upon 
liposome 
preparation (thin 
lipid film 
hydration) 
 
 
[94] 
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HA-liposomes  DNA MDA-MB-231 
andMCF-
7breast 
cancer cells 
1500 kDa HA-DOPE 
conjugates 
inserted upon 
liposome 
preparation (thin 
lipid film 
hydration) 
[90] 
HA-liposomes  siRNA A549 lung 
carcinoma 
cells 
1500 kDa HA-DOPE 
conjugates 
inserted upon 
liposome 
preparation (thin 
lipid film 
hydration) 
[91] 
HA-liposomes DNA A549 lung 
carcinoma 
cells 
1600 kDa HA-DOPE 
conjugates 
inserted upon 
liposome 
preparation (thin 
lipid film 
hydration) 
[92] 
HA-solid lipid 
nanoparticles 
DNA / ARPE-19 
and HEK-293 
cells 
150, 500 and 
1630 kDa 
Electrostatic 
interactions (HA-
protamine-DNA 
complexes 
incubated with 
preformed SLN) 
[51] 
HA-solid lipid 
nanoparticles 
Vorinostat / SCC-
7squamousce
ll carcinoma, 
MCF-7 human 
breast 
adenocarcino
ma, A549 
human 
epithelial 
lung 
adenocarcino
ma  
3 kDa Electrostatic 
interactions (HA 
incubated with 
preformed SLN) 
[52] 
HA-
nanostructured 
lipid carriers 
Paclitaxel / B16 murine 
melanoma 
cells, CT26 
mouse colon 
cancer cells 
and HCT116 
human colon 
cancer cells 
300 kDa Electrostatic 
interactions (HA 
incubated with 
preformed NLC) 
[58] 
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Travaux expérimentaux - Chapitre 1 
 
Supramolecular organization and siRNA binding of hyaluronic acid-modified 
lipoplexes for targeted delivery to CD44 receptor 
 
 
Résumé 
 
La stabilité, la toxicité, les interactions avec les composants biologiques et l'efficacité in vitro et in vivo 
des lipoplexes sont directement influencés par leur structure. Dans ce chapitre, la formation de 
lipoplexes de siRNA obtenus par la complexation de liposomes modifiés avec de l'acide hyaluronique 
(HA) à des siRNA a été étudiée, ainsi que les paramètres influençant leur organisation 
supramoléculaire. L'insertion de l'HA dans la structure du liposome au moment de la formation des 
vésicules a entraîné une augmentation de la taille des liposomes en fonction de la concentration d’HA. 
Leur complexation avec les siRNA a encore augmenté la taille des particules obtenues. Ces lipoplexes 
présentent un diamètre autour de 110 nm lorsque le siRNA a été associé à des ratios de charge (+/–) 
de 266 à 50, et autour de 230 nm à ratios +/– de 4 à 1. Les potentiels zeta des lipoplexes modifiés par 
HA sont de l'ordre de + 50 mV à des ratios +/– de 266 à 50, et une diminution à des valeurs négatives 
de –30 à –45 mV à des ratios +/– de 4 à 1 a été observée. L’ajout du conjugué HA-DOPE n’a pas 
compromis l’association du siRNA à des liposomes, bien que l'ajout des acides nucléiques lors de la 
formation des lipoplexes ait provoqué un déplacement d'une partie du conjugué HA-DOPE de la 
structure des lipoplexes, comme montré par électrophorèse capillaire. La titration calorimétrique 
isotherme et les études de diffraction des rayons X ont démontré que, sous l’effet des interactions 
électrostatiques avec les siRNA, un réarrangement des bicouches lipidiques a lieu, conduisant à la 
formation de vésicules oligolamellaires. Ce phénomène est dépendant de la quantité de molécules de 
siRNA et du degré de modification par l'HA, comme observé par analyse de la diffraction des rayons-X 
et confirmé visuellement par cryo-microscopie. Ces images ont révélé la coexistence de vésicules 
sphériques unilamellaires et oligolamellaires dans la population de liposomes, et a confirmé la 
réorganisation des bicouches lipidiques et la formation de structures oligolamellaires denses. Enfin, le 
positionnement convenable de l’HA sur la surface des lipoplexes et sa capacité de se lier 
spécifiquement aux récepteurs de CD44 de manière concentration-dépendante ont été démontrés par 
la technique de résonance plasmonique de surface.  
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Experimental work – Chapter 1 
 
Supramolecular organization and siRNA binding of hyaluronic acid-modified 
lipoplexes for targeted delivery to CD44 receptor 
 
Abstract 
 
Lipoplexes stability, toxicity, interaction with biological components and efficiency in vitro and in vivo 
are directly influenced by their structure. In this work, the formation of siRNA lipoplexes from 
hyaluronic acid (HA)-modified liposomes and siRNA was studied, as well as the parameters influencing 
their supramolecular organization. The Insertion of HA in the liposome structure at the moment of 
vesicle formation increased liposome size, depending on HA concentration. Subsequent complexation 
with siRNA further increased the size of the resulting lipoplexes, reaching around 110 nm when siRNA 
was associated at charge ratios (+/–) from 266 to 50, and around 230 nm at +/– ratios from 4 to 1. HA-
modified lipoplexes’ zeta potentials were around + 50 mV at +/– ratios from 266 to 50, and decreased 
to negative values from –30 to –45 mV at +/– ratios from 4 to 1. The addition of the HA-DOPE 
conjugate did not compromise siRNA binding to liposomes, although the addition of nucleic acids upon 
lipoplex formation accounted for a displacement of part of the HA-DOPE conjugate from the lipoplex 
structure, as shown by capillary electrophoresis. Isothermal titration calorimetry and X-ray diffraction 
studies demonstrated that following electrostatic interactions with siRNA, a rearrangement of the lipid 
bilayers takes place resulting in the formation of condensed oligolamellar vesicles. This phenomenon is 
dependent on the amount of siRNA molecules and the degree of modification with HA, as observed by 
X-ray diffraction analysis and confirmed visually by cryo-TEM microscopy. These images revealed the 
coexistence of spherical unilamellar and oligolamellar vesicles on liposomes population, and confirmed 
the reorganization of the lipid bilayers and the formation of dense oligolamellar structures. Finally, the 
suitable positioning of HA on the lipoplex surface and HA ability to specifically bind to the CD44 
receptors in a concentration-dependent manner was demonstrated by surface plasmon resonance 
analysis.  
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Introduction 
 
Downregulation of gene expression using small interfering RNA (siRNA) has raised a broad interest for 
medical applications. siRNAs are short double-stranded RNA molecules of 19-21 nucleotides in length, 
that besides being highly efficient and selective, offer the possibility of a long-lasting therapeutic effect 
for gene-related diseases. One of the strands is entitled the guide, which is complementary to the 
coding region of the target mRNA, while the other is known as the passenger strand. Once in the 
cytoplasm, the guide strand binds to the target RNA molecule, which promotes the enzymatic cleavage 
of the mRNA and prevents the synthesis of the protein of interest. These molecules however face 
some impediments to a successful application, similarly to other nucleotide-based therapeutics like 
plasmid DNA or antisense oligonucleotides1. As a result of their small size, they are rapidly eliminated 
by the kidneys and show circulating half-lives of seconds to minutes2. They are also susceptible to 
degradation by nucleases in the plasma. Within the tissues, they do not cross cell membranes readily 
because of their negative charge, hydrophilicity and molecular size. Also, siRNAs are taken up by most 
mammalian cells in a way that does not preserve their activity3. Therefore, the future of this 
therapeutic approach heavily depends on the development of delivery systems able to carry these 
molecules from their administration site to their intracellular pharmacological target4.  
Complexes formed by electrostatic interactions between cationic liposomes and siRNA, called 
lipoplexes, are considered as the most suitable carriers for intracellular delivery of nucleic acids and 
particularly for siRNA5, 6. In addition, they are versatile systems, whose surface can be modified to 
increase their circulation time and improve their interaction with the target7. One of the key factors 
influencing siRNA delivery is the macromolecular shape of the lipoplexes8, 9. Their final structure has a 
significant impact on particle stability, interaction with biological components, cytotoxicity9, 10 and 
intracellular trafficking11, 12, and will therefore determine their efficiency in vitro and in vivo13. It is 
therefore important to consider an accurate and detailed understanding of lipoplex structure and 
physicochemical characteristics.  
Hyaluronic acid (HA) is a glycosaminoglycan polymer composed of disaccharide units of N-
acetylglucosamine and D-glucuronic acid linked together through alternating  -1,3 and  -1,4 glycosidic 
bonds14. It is biocompatible, being the major component of the extracellular matrix. The native high 
molecular weight HA is non-toxic and non-immunogenic15. It does not induce expression of genes 
involved in proliferation or inflammation16 and counteracts proangiogenic effects of the HA 
oligomers17, 18. Surface modification of cationic liposomes with high molecular weight HA can improve 
their efficacy by mediating active CD44 targeting in tumors and can also increase their circulation time, 
due to a possible dysopsonization effect due to the hydrophilic coating effect of HA19, 20, 21, 22.  
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In this study, we describe the design and physicochemical characterization of novel HA-lipoplexes 
entrapping siRNA. The lipoplex composition is based on the cationic lipid 2-(2-3-
didodecyloxypropyl)hydroxyethyl] ammonium bromide (DE), which has shown promising transfection 
efficiency in different cell lines compared to the cationic lipids currently available on the market23. To 
achieve the targeting of CD44 receptors, lipoplexes were surface-coated using a conjugate of HA and L-
alpha-dioleylphosphatidylethanolamine (DOPE)24. In previous studies, modification of lipoplexes with 
HA-DOPE conjugate demonstrated increased transfection of CD44-expressing cells using plasmid 
DNA18, 25 and siRNA24. The supramolecular organization and formation of these lipoplexes, however, 
remained an open question. Here, a study of the formation of these nanocarriers and the aspects 
influencing the organization of the lipid bilayers was performed using a combination of dynamic light 
scattering, capillary electrophoresis, cryo-TEM microscopy, surface plasmon resonance and small angle 
X-ray scattering techniques. 
 
Materials and Methods 
 
Materials 
 
The cationic lipid [2-(2-3-didodecyloxypropyl)hydroxyethyl] ammonium bromide (DE) was synthesized 
as described previously23. L-alpha-dioleylphosphatidylethanolamine (DOPE) and 
phosphatidylethanolamine conjugated to rhodamine (PE-rhodamine) were purchased from Avanti 
Polar Lipids distributed by Sigma Aldrich (Saint Quentin Fallavier, France). High molecular weight HA 
(sodium salt, 1600 kDa, purity of 95%) was provided by Acros organics (Geel, Belgium). SiRNA (19 bp) 
was purchased from Eurogentec (Angers, France) and diluted in RNAse-free water before use. The HA-
DOPE conjugate was synthesized as described previously25. In the following, water refers to 
ultrapurified MilliQ® water (Millipore, France) with a resistivity ≥ 18 MΩ∙cm. 
 
Liposomes and lipoplexes preparation 
 
Liposomes of DOPE/DE at 1:1 w/w ratio (equivalent to a molar ratio of 0.78:1) were prepared in water 
by the ethanol injection method24, 26. Separate solutions of DE and DOPE, stored in chloroform under 
nitrogen at -20°C, were dried under pressure in a rotary evaporator. The dried lipids were then 
dissolved in absolute ethanol at a concentration of 10 mg/mL. For liposome preparation, 0.06 to 0.9 
mL of the ethanolic lipid solution were rapidly injected into RNAse free water under magnetic stirring. 
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 HA-liposomes were prepared by diluting an aqueous stock solution of the HA-DOPE conjugate (1 
mg/mL) to different concentrations in RNAse free water before injection. Each conjugate have 3 μg of  
DOPE/mg of HA. The HA-DOPE content of liposomes is expressed as mass ratio of HA-DOPE to other 
lipids (DE + DOPE) (10% refers to 1:10 w/w). Liposome suspensions were dialyzed against 1 L of MilliQ 
water overnight in Spectra/Por CE dialysis tubes with a molecular weight cutoff of 50 kDa (Spectrum 
Laboratories, Breda, Netherlands) to eliminate ethanol. Lipoplexes were then prepared at different 
charge ratios (+/– ratios) by adding one volume of the 3 mM liposome suspension into two volumes of 
siRNA solution at different concentrations (0.11, 0.16, 0.22, 0.44, 5.52, 7.36, 11.05 and 22.10 µM for 
+/– ratios of 200, 134, 100, 50, 4, 3, 2 and 1) in an Eppendorf tube, and gently homogenizing by 
pipetting up and down. Suspensions of 15 µL – 2.5 mL of lipoplexes were usually prepared and 
incubated for 1 hour at room temperature before use.  
 
Hydrodynamic diameter and zeta potential measurement 
 
The mean hydrodynamic diameter, polydispersity index (PdI) and zeta potential were determined with 
a Zetasizer Nano Zs (Malvern Instruments Ltd, Malvern, UK). Before each measurement, liposomes and 
lipoplexes were diluted in 1 mM NaCl. Measurements were carried out in triplicate at 25 °C for at least 
three independent preparations.  
 
Colloidal stability of lipoplexes in isotonic media 
 
Non-coated, 10% HA-liposomes and HA-lipoplexes at various charge ratios were prepared as described 
above and diluted down to 66 μg/mL of lipids with 0.9% w/v NaCl or 5% w/v glucose. Changes in 
hydrodynamic diameter upon dilution were monitored at 25°C. The accuracy of measurements was 
verified by mixing each suspension thoroughly before each measurement. All experiments were 
performed at least in duplicate. 
 
Lipoplexes siRNA content 
 
siRNAs were labeled at the 5’-end with γ-33P-ATP (Perkin-Elmer Life Sciences, Courtaboeuf, France) 
catalyzed by T4 polynucleotide kinase (New England Biolabs, Frankfurt am Main, Germany) according 
to the manufacturer’s protocol. Lipoplexes were prepared with radiolabeled siRNA at various +/– 
ratios (2-134) from non-coated or 10% HA-liposomes. Suspensions were placed in the upper chamber 
of Amicon Ultra-0.5 ml filters (cutoff value 100 kDa; Millipore). After adding 200 μL of RNase-free 
water, samples were centrifuged (14,000 g, 30 min, 4°C). This procedure was repeated five times. 
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Binding efficiencies were determined by comparing the sum of specific radioactivity of the washings to 
the radioactivity of the siRNA solution used for the lipoplexes preparation. Experiments were 
performed in triplicate. 
 
Capillary electrophoresis 
 
A Beckman P/ACE System 5500 was used with an uncoated fused silica capillary of 57 cm of effective  
length and an  internal diameter of 75 µm. Electrophoresis conditions to analyze HA-DOPE conjugate 
were derived from Grimshaw et al.27 for the assay of HA. The capillary was first conditioned by four 
successive rinsing steps of 5 min each with water, 1 M NaOH, 0.1 M NaOH and back to water. Before 
each analysis, the capillary was washed at 20 psi with water for 2 min, 0.1 M NaOH for 3 min and 
finally equilibrated with the background electrolyte for 5 min. The separation buffer was 65 mM 
sodium tetraborate containing 20mM of sodium dodecyl sulfate (SDS) with pH 9.0. Sample injection 
was carried out at 0.5 psi for 5 s. All samples were adjusted to a concentration of 1 mg/mL of HA or 
HA-DOPE by evaporation under vacuum using an Eppendorf Concentrator® at 30 °C. This step was 
validated after verification by dynamic light scattering that no modification of the diameter and zeta 
potential occurred during the concentration. The free fraction of conjugate was determined using a 
HA-DOPE 1mg/ml solution as an internal standard. Samples containing 1 mg/mL HA-DOPE + HA-DOPE 
solutions at 0.25, 0.5, 1 and 2.5 mg/mL were analyzed and the peak areas obtained were used to form 
calibration curves. The peak areas found by extrapolation of the sample curves to the point [HA-
DOPE]=0 were used in the HA-DOPE calibration curve to determine the free amount of conjugate. 
Detection wavelength was 200 nm and the voltage applied was +25 kV. The capillary was maintained 
at 25 °C during electrophoresis. Experiments were performed at least in duplicate. 
 
Isothermal titration calorimetry  
 
The thermodynamics of the interaction between siRNA and the cationic liposomes, coated or not with 
HA, was evaluated by isothermal titration calorimetry (ITC) (Microcal Inc., USA). Aliquots of 10 μL of 
aqueous siRNA solution (19.7 µM) filled into a 283 μL syringe were used to titrate the aqueous 
suspension of liposomes (98 µM of total lipids) into the calorimetric sample cell accurately 
thermostated at 25°C. Agitation speed was 307 rpm and intervals between injections was 500 s. 
Background of titration consisted in injecting the siRNA solution in MilliQ® water. The heats of dilution 
were insignificant compared with the binding interaction heats. 
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Cryo-transmission electron microscopy 
 
10% HA-liposomes and HA-lipoplexes containing siRNA at +/– ratios of 2 and 134 were observed using 
cryo-transmission electron microscopy (cryo-TEM). The preparation of liposome samples was 
performed as follows. 4 µL of liposome concentrated aqueous suspension were placed on Quantifoil 
R2/2 grids (Quantifoil, Germany). The samples were cryofixed in liquid ethane (–180°C) using the Leica 
EMGP (Leica, Austria). For lipoplex samples, grids were pre-treated with 1 mM CaCl2 for 1 min. Grids 
were transferred using a cryo-holder (626 DH Gatan) for observation on a Tecnai F20 electron 
microscope (FEI, USA). Images were recorded under low electron dose conditions at 200 kV on a 
camera Gatan Ultrascan 4000 with Digital Micrograph (Gatan, USA) version 1.83.842. Doses were 
previously quantified using a faraday cup. 
 
Small angle X-ray scattering (SAXS) 
 
Suspensions of liposomes and lipoplexes were loaded into quartz capillaries (diameter 1.5 mm, Glas-
M ller, Berlin, Germany). The top of the capillaries was sealed with a drop of paraffin to prevent water 
evaporation. Small-angle X-ray scattering experiments were performed on the SWING beamline at the 
SOLEIL synchrotron. The energy was set to 11 keV. The scattering intensity was reported as a function 
of scattering vector q = 4π/λ sin θ, where 2θ is the scattering angle and λ is the wavelength of the 
incident beam. Calibration of the q-range (0.008 Å-1 – 0.4 Å-1) was carried out with silver behenate as 
standard. Data were collected with a two-dimensional CCD detector. The acquisition time was 50 s. 
Intensity values were normalized to account for beam intensity, acquisition time, and sample 
transmission. Each scattering pattern was then integrated circularly to yield the intensity as a function 
of q. The scattered intensity from a capillary filled with water was subtracted from the sample 
scattering curves. 
 
HA-lipoplex CD44 receptor affinity by surface plasmon resonance spectroscopy 
 
Interaction of non-coated and HA-lipoplexes with CD44 receptors was monitored by surface plasmon 
resonance (SPR) spectroscopy using a BIAcore T100 (GE Healthcare Life Sciences, Vélizy, France) 
instrument. Human recombinant CD44-Fc receptors were immobilized on a carboxymethylated 
dextran sensor chip (series S CM3, GE Healthcare) using amine coupling. Carboxylic groups were 
activated by a mixture of EDC/NHS during 7 min at 10 µL/min followed by an injection of 17 µg/mL 
CD44-Fc in a 10 mM acetate buffer at pH 4.4 during 5 min at 10 µL/min. The remaining groups were 
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blocked by an injection of ethanolamine. A flow channel blocked by ethanolamine was used as a 
reference surface. The specific interaction of HA-lipoplexes (at the concentrations 0.3, 0.6, 1.2, 2.4 and 
4.8 µM of lipids) with the immobilized CD44-Fc was assessed. All the experiments were conducted at a 
flow rate of 50 μL/min in 150 mM NaCl, with a contact time of 360 s. The surface was washed for 640 s 
and regenerated with a 34 mM octyl‐glucoside solution for 30 s at 50 μL/min and 10 mM NaOH for 30 
s at 100 μL/min after each sample analysis. Free 1600 kDa HA solution was systematically passed 
through the channel to verify the integrity of CD44-Fc receptors. The analyses were performed in 
triplicate using BIAcore T100 evaluation software, version 2.0.2 (GE Healthcare). 
 
Results and discussion 
 
In this study, siRNA-loaded lipoplexes coated with hyaluronic acid (HA) were formulated and 
characterized to investigate their structure and affinity to CD44 receptors, with a view to develop 
effective gene silencing nanomedicines targeting this receptor, a key marker of cancer metastasis. We 
have chosen to coat the lipoplexes with a large molecular weight HA since we have already shown 
that, an increased internalization of siRNA binding these HA-lipoplexes was obtained in CD44 
expressing cells24. SiRNA HA-lipoplexes were here characterized using a combination of light-scattering 
technique, radioactive labeling, diameter and surface charge analyses, capillary electrophoresis, cryo-
TEM microscopy, SAXS and surface plasmon resonance.  
To insert HA on the lipoplex structure, a HA-DOPE conjugate was prepared by a condensation reaction 
between the carboxylic residues of HA and amino groups of DOPE lipids. DOPE within the conjugate 
was used as a lipid anchor. The absence of free DOPE on the conjugate was confirmed by thin layer 
chromatography, and the amount of lipids was quantified as 1.1 ± 0.5% w/w using the Stewart assay28. 
Non-coated liposomes obtained by the ethanol injection method were of 88 ± 8 nm in size (Figure 1). 
The effect of HA-DOPE insertion on the diameter and zeta potential was studied by adding 0, 5, 10 and 
15% (w/w) of conjugate when preparing the liposomes. A gradual increase in diameter with increasing 
HA-DOPE content was observed (Figure 1) indicating the insertion of HA on the liposome structure. 
Liposomes with 15% HA-DOPE reached diameters of 142 ± 19 nm, and higher amounts of conjugate 
resulted in the formation of agglomerates, probably due to bridging interaction between HA molecules 
on lipoplex surface. Non-coated and HA-iposomes maintained their size for at least 4 months when 
stored at 4°C. The absence of vesicles or micelles formed by the HA-DOPE conjugate itself was 
confirmed using light scattering measurements. Zeta potential values were positive in the range of +55 
to +30 mV for liposome preparations due to the presence of amino groups of the cationic lipid DE, 
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gradually decreasing with increasing amounts of HA-DOPE conjugate, again confirming the presence of 
HA on the surface of the particles.  
 
Figure 1. Mean hydrodynamic diameter and zeta potential of cationic liposomes prepared without or 
with 5, 10 or 15% of HA-DOPE (n=3). Data = mean ± SD. 
 
Ten percent of HA-DOPE was chosen for the preparation of lipoplexes. This amount was previously 
shown to be optimal amount for transfection of MDA-MB231 and A549 cancer cells expressing CD4418, 
25. Complexation of liposomes with siRNA at low concentrations (+/– ratios of 200, 100 and 50) 
resulted in lipoplexes with diameters comparable to those of liposomes, around 90 nm for the non-
coated and 120 nm for the HA-liposomes (Figure 2).  
When higher amounts of siRNA were complexed (at ratios 4, 3, 2 and 1), the diameter of non-coated 
and HA-liposome increased to around 140 and 230 nm, respectively (Figure 2). The size distribution in 
these samples was quite large. The PdI of HA-liposomes and HA-lipoplexes was however below 0.23 
for all lipoplex formulations. The zeta potential measurements of lipoplexes clearly confirmed 
differences in the degree of surface modification. Between ratios 200 and 50, all formulations were 
positively charged, with a slight reduction of the zeta potential being observed for the HA-lipoplexes, 
when compared to the non-coated lipoplexes (Figure 2). At lower +/– ratios, a decrease in zeta 
potential was observed for all lipoplexes formulations (Figure 2). The shift from positive to negative 
surface charges for the non-coated liposomes was observed between +/– ratios 2 and 1, which 
demonstrated that the neutralization of surface charges occurs when there is an equimolarity of 
positive and negative charges on the lipoplex structure. Interestingly, this turning point from positive 
to negative surface charge is shifted for the HA-lipoplexes. In this case, the amount of siRNA molecules 
needed to achieve neutrality is smaller, confirming the presence of the negatively charged HA 
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molecules on the liposome structure. The effect of dilution of HA- liposomes/lipoplexes in 
physiological media was studied. Both HA-liposomes and HA-lipoplexes (+/– ratio of 2) maintained 
their size and surface charge when diluted in 0.9% w/v NaCl and 5% w/v glucose (Figure S1). These 
data demonstrate previous results confirming that the HA-lipoplexes are rather stable in different 
medium even in the presence of serum18. 
 
 
Figure 2. Mean hydrodynamic diameter (bars) and zeta potential (lines) of cationic liposomes and 
lipoplexes prepared without (grey) or with 10% HA-DOPE (black) at different +/– ratios (200, 100, 50, 4, 
3, 2, 1). Data = mean ± SD. 
 
The effect of liposome modification by HA-DOPE on the association rate between liposomes and siRNA 
to form lipoplexes was measured after radioactive labeling of siRNA. Interestingly, the presence of HA 
on liposome surface did not compromise the association to the siRNA molecules (Figure 3 A and B). 
More than 90% of the added siRNA was bound to the liposomes for +/– ratios as low as 2 (Figure 3 A) 
while the amount of siRNA bound to lipoplexes increased progressively reaching approximately 
300µg/mg of lipids (Figure 3 B). Maximum entrapment efficiency of nucleotides is commonly described 
for lipoplex-like structures29, 30, 31, 32. The strong interactions between the negative phosphate groups 
on nucleotides and the positive charges of amino groups on cationic lipids leads to such high 
association efficiency 33, 34, 35. However, this binding decreased to 60-70% at a +/– ratio of 1, indicating 
a possible saturation of the available positively charged binding sites on the liposomes occurring 
between +/– ratios of 1 and 2 (Figure 3 A). Lipoplexes at +/– ratio 2 (negative zeta potential) were 
chosen for further experiments while in some cases and to understand lipoplex formation higher +/- 
ratio were used (positively charged close to the initial liposome characteristics). Non-coated liposomes 
and their respective lipoplexes were used for comparison.  
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Figure 3. (A) siRNA association efficiency (%) to liposomes and (B) siRNA loading (µgsiRNA/mglipids) of 
lipoplexes as a function of the +/– ratio and the HA-DOPE content of the parent liposomes. Data = 
mean ± SD. 
 
The heat exchanged during the interaction between DE/DOPE liposomes and siRNA was analyzed by 
isothermal titration calorimetry. Figure 4 shows the cumulative heat curves plotted against the 
siRNA/DE molar ratios for each liposome type, with the raw ITC data processed and fitted to obtain the 
thermodynamic parameters of the interaction. A first negative enthalpy change occurs in the 
interaction of both non-coated and HA-liposomes with siRNA molecules. This exothermic reaction 
represents the interaction between DE lipid molecules and siRNA, and the fact that it occurs almost 
identically for both samples confirms the previous observation that the presence of HA does not 
prevent the interaction between siRNA and DE.  
The exothermic binding of siRNA molecules to liposomes was observed until all of the binding sites in 
the liposomes were occupied at +/– ratio 1, corresponding to a molar ratio of siRNA/DE of 0.025, as 
evidenced by radioactivity measurements. The monotonous decrease of the amount of heat produced 
after each injection suggested that there is only one type of binding site in the liposomes36. These 
observations are in agreement with reports from the literature on thermodynamic studies of DNA 
lipoplexes containing DOPE in their composition37, 19, 39. They are related to the fact that DOPE amine 
groups (pka = 9.5) are unprotonated before binding due to the high surface pH usually measured in 
cationic liposomes (around 11) whereas proton uptake occurs upon lipoplex formation39. Since DOPE 
protonation is an exothermic process, it is suggested, as shown in DOTAP:DOPE-containing lipoplex 37, 
that changes in the protonation state of DOPE account for the exothermic nature of complex 
formation with these lipids. 
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Figure 4. Cumulative heat curves and thermodynamic parameters obtained from calorimetric titration 
of siRNA solution at 19.7 µM (10 µl/injection) into non-coated or HA-liposomes suspension at 98 µM.  
 
Assessment of the HA-DOPE conjugate purity and determination of the HA-DOPE fraction bound to 
liposomes and lipoplexes were carried out by capillary electrophoresis. HA-DOPE migration time was 5 
min and the electrophoretic profile of the conjugate did not display the characteristic peak of 
unconjugated HA expected at 8 min, demonstrating the absence of free HA in the conjugate (Figure 
S2). Large amounts of the HA-DOPE conjugate added to the formulations were found associated to the 
liposomes and lipoplexes +/– ratio 134 (66 and 78%, respectively) (Table 1). A decrease of HA-
conjugate associated to lipoplexes at +/– ratio 2, reaching 36% was observed (Table 1). A similar 
phenomenon was previously observed for lipoplexes prepared using plasmid DNA18. As discussed 
above, the association of nucleotide molecules to cationic lipids is known to be strong, and commonly 
yields stable lipoplexes with high association efficiencies33, 40. We hypothesized that the large and 
concentrated amount of negative charges on the siRNA molecules leads to a competition with the 
negative charges of HA for interaction with the positive charges of cationic lipids, causing some 
displacement of HA-DOPE conjugate molecules from the liposome structure. This implies that HA-
DOPE insertion in the lipoplexes does not only occur through the DOPE moiety but also via 
electrostatic interactions.  
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Table 1. HA-DOPE conjugate association efficiency to liposomes and lipoplexes prepared at +/– ratios 
134 and 2. 
Preparation % HA-DOPE associated 
Liposomes DE:DOPE:DOPE-HA 66.5 ± 3.9 
Lipoplexes DE:DOPE:DOPE-HA:siRNA (+/– 134) 78.8 ± 9.8 
Lipoplexes DE:DOPE:DOPE-HA:siRNA (+/– 2) 36.3 ± 3.9 
 
Cryo-TEM images of cationic liposomes revealed the coexistence of spherical unilamellar and 
oligolamellar vesicles (Figure 5). The diameters observed were in the range of the hydrodynamic 
diameters measured, with some degree of heterogeneity correlated to a measured polydispersity 
index of 0.22. A modification of this morphology was observed after addition of siRNA to liposomes. At 
a +/– ratio of 134, lipoplexes shape was less spherical and homogeneous than the liposomes (Figure 5A 
and B). At a +/– ratio of 2, the structural changes were even more pronounced (Figure 5C). All 
liposomes/lipoplexes appeared as dense multilamellar structures, suggesting a reorganization of lipids 
in presence of siRNA. In particular, the intralamellar distances appeared smaller than those observed 
on the parent oligolamellar liposomes. These observed lipoplexes can be compared to the well-known 
“sandwich” structures41, 42, 43, 29, suggesting the presence of electron-dense siRNA molecules 
intercalated between the cationic lipidic membranes6. The deformation and rearrangement of the 
liposomal membranes are a result of the strong electrostatic interaction between cationic lipid head 
groups and siRNA phosphate groups43, 29. This structural modification is beneficial as far as siRNA 
stability is concerned. Indeed, the bilayer packing around each other promotes the protection of the 
siRNA molecules from degradation better than an exclusive surface-association, in which they would 
be more susceptible to degradation by serum nucleases29, 45. 
 
Figure 5. Cryo-TEM images of HA-modified (A) liposomes, (B) lipoplexes at a +/– ratio of 134 and (C) 
lipoplexes at a +/– ratio of 2. Scale bars = 200 nm. 
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Evidences of the siRNA localization were provided by cryo-TEM analysis. When the particles were 
submitted to the electron beam for acquisition of images, the formation of “bubbles” was observed 
(Figure 6). Micrographs were recorded at approximately 3 electrons/Å2 per exposure, with intervals of 
10 s between exposures. Bubbling started on the second exposure with the appearance of several 
small bubbles, which merge to give fewer and larger ones later in the exposure sequence. This 
occurred for all of the +/– 2 lipoplexes, a few of the +/– 134 lipoplexes and none on the liposomes 
structures, indicating that this event occurred only when siRNA was present. The pattern of the 
bubbles formation inside the vesicles is shown in Figure 6. We hypothesize that bubbling is due to the 
degradation of water molecules associated to the siRNAs, since the pattern of the bubble formation 
observed is characteristic of the formation of hydrogen gas upon electron radiation of samples46, 47. 
Bubblegram imaging has been previously used for structural localization of proteins in vitrified 
specimens and DNA-viruses internal structure investigation48, 49, 50. We report here for the first time 
bubble formation evidencing siRNA localization within the lipoplexes. The uniform localization of the 
bubbles confirms the distribution of siRNA molecules within the lipoplexes, intercalated with the lipid 
membranes.  
 
Figure 6. Cryo-TEM images of HA-modified lipoplexes at a +/– ratio of 2 after exposure to 
approximately (A) 3, (B) 6, (C) 9 and (C) 12 electrons/Å2, evidencing the formation of bubbles where 
siRNA is present. Scale bars = 200 nm. 
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The structure of non-coated and HA-liposomes with 5, 10 and 15% HA-DOPE was further investigated 
using synchrotron small-angle X-ray scattering (SAXS). The pattern of the non-coated liposome 
suspension exhibits a broad bump, consistent with the bilayer form factor of unilamellar vesicles51 
(Figure 7A).  
 
Figure 7. (A) Small-angle X-ray diffraction patterns recorded at room temperature for cationic 
liposomes, either non-coated or prepared with 5, 10 or 15% HA-DOPE. The gradual increase in 
diffraction peak intensity suggests a gradual reorganization of the unilamellar liposomes into 
oligolamellar structures (a.u = arbitrary units). (B) Small-angle X-ray diffraction patterns recorded at 
room temperature for non-coated and HA-lipoplexes prepared at +/– ratio 2 and 20. The well-defined 
Bragg peaks suggest the formation of DOPE/DE-siRNA or HA-DOPE/DE-siRNA complexes, with siRNA 
confined between regularly stacked lipid bilayers. 
 
The SAXS curves of HA-liposomes reveal the gradual increase of the diffraction peak intensities when 
increasing amounts of HA were added to the formulation, indicating the formation of increasingly 
dense multilamellar structures52. This interestingly shined a light on liposome organization in the 
presence of hyaluronic acid. In our method for liposome preparation, HA is present at the moment the 
vesicles are formed. We may therefore assume that a portion of the multiple DOPE units bound to 
each HA molecule intercalates within the DOPE and DE bilayers upon liposome preparation25, 53.  The 
correlation between regularly spaced bilayers gives rise to a Bragg peak. A tiny peak is barely detected 
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in 5% HA-DOPE liposome curve. As HA-DOPE content in the formulation increases, the intensity of the 
Bragg peak increases while its full width at half-maximum decreases, indicative of a higher number of 
bilayers in vesicles and/or of multilamellar vesicles in the preparation. However, the lack of a second-
order peak until 15% of HA-DOPE suggests weakly ordered stacks of bilayers. The characteristic repeat 
spacing (d-spacing), corresponding to the sum of the bilayer thickness and water thickness, is deduced 
from the position of the Bragg peak (d = 2/q). A small increase in d is observed, from d = 60.4 Å (q = 
0.104 Å-1) to d = 63.4 Å (q = 0.099 Å-1) when the HA-DOPE amount increases from 10 to 15%, likely 
reflecting a higher hydration of the lamellar phase and a more important steric repulsion. The 
structural differences between the non-coated and HA-liposomes could be tentatively related to the 
differences of net surface charge between bilayers. Indeed, a net surface charge induces electrostatic 
repulsion between bilayers so that they can swell in excess water. The spontaneous formation of 
unilamellar vesicles in DOPE/DE system may be explained by electrostatic repulsion overwhelming van 
der Waals attraction between bilayers. Addition of HA-DOPE leads to a progressive decrease in the 
bilayer surface charge, and consequently in repulsive forces between bilayers, so that a multilamellar 
structure is formed. Furthermore, negatively charged HA could bridge positively charged lipid bilayers. 
As previously reported, siRNA interacts with cationic DOPE/DE liposomes. The SAXS patterns of non-
coated lipoplexes evidence the reorganization of unilamellar liposomes into oligolamellar vesicles in 
the presence of siRNA, at low +/– ratios. Indeed, at +/– 20 ratio, only a small correlation peak appears 
at q = 0.116 Å-1 (d = 54.1 Å), suggesting that unilamellar liposomes with siRNA absorbed on their 
surface coexist with a few oligolamellar vesicles. In contrast, at +/– ratio 2 a sharp Bragg peak at q = 
0.112 Å-1 and a faint second order, indicative of a lamellar phase with d-spacing 56.1 Å are observed 
(Figure 7B). When HA-liposomes are used for the preparation of lipoplexes (+/– 2 ratio), a sharper 
Bragg peak at q = 0.102 Å-1 and a stronger second order are observed, reflecting a more ordered 
lamellar phase with d-spacing 61.4 Å. This suggests that siRNA is confined between ordered lipid 
bilayers. A similar behavior was observed for HA-lipoplexes. These findings are consistent with the 
existing schematic models of lipoplex formation42, 54 and with the evolution of nanoparticle sizes upon 
complexation. This gradual modification of vesicle morphology after interaction between siRNA and 
cationic liposomes measured by SAXS was confirmed by cryo-TEM microscopy as shown above. 
The binding affinity to CD44 receptors of non-coated and 10% HA-lipoplexes prepared at a +/– ratio of 
2 was determined using surface plasmon resonance (SPR). CD44-Fc were immobilized in a stable and 
suitably oriented manner on the surface, as confirmed by an analysis of the interaction of the 
receptors with HA solution. HA did not show any binding when exposed to the reference surface, 
indicating that binding to the receptors was specific. The immobilization protocol allowed the binding 
of 100-150 RU, corresponding to 0.1-0.15 ng.mm–2 of CD44-Fc per channel. Sensorgrams obtained by 
interaction of different concentrations of HA-lipoplexes and plain lipoplexes with the CD44-Fc-
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immobilized sensor chip were used to analyze the binding affinity. Representative sensorgrams 
obtained in this experiment are shown in Figure 8.  
 
Figure 8. SPR sensorgrams obtained by injection of 10% HA-lipoplexes +/– ratio 2 on CD44-Fc-
immobilized sensor chips. Samples were diluted in NaCl 150 mM to 4.8, 2.4, 1.2, 0.6 and 0.3 µM of 
lipids. Signals of HA-lipoplexes were normalized using signals from non-modified lipoplexes at the 
same concentrations, to eliminate non-specific interactions signals. 
 
Signals of HA-lipoplexes were normalized using signals from non-modified lipoplexes at the same 
concentrations, to eliminate non-specific interactions signals. Considering the molecular weight of the 
CD44-Fc used for these experiments (48.6 kDa), we estimate that 12.3-18.5 receptors were 
immobilized per nm2. The difference between the obtained signals reveals a concentration-dependent 
and preferential affinity of HA-lipoplexes compared to the non-modified lipoplexes (Figure 8), thereby 
confirming both the suitable positioning of HA on the lipoplexes surface and HA ability to specifically 
bind to the CD44 receptors. The CD44-Fc immobilization combined with the surface rinsing protocol 
after HA interactions represent a significant improvement on the SPR techniques to analyze HA binding 
to CD44. First, the low sensor surface capacity was suitable for the interaction studies55. Previously 
reported SPR data on HA-CD44 interaction are based on interaction studies on highly loaded sensor 
surfaces56, 57, 58, which complicates data analysis and may misrepresent the interaction between HA 
and CD4459. Second, the rinsing protocol promoted the detachment of HA-lipoplexes from the CD44-Fc 
surface after each analysis without damaging the receptors. This was an experimental hurdle due to 
the multivalent aspect of this interaction, and required many optimization steps. Little or no 
desorption upon rinsing high molecular weight HA molecules after interaction with its receptors have 
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been described until now60, 59. The kinetic model that best fitted the data obtained was the 
“heterogeneity model” with 4 independent binding sites. Nevertheless, we believe that due to the 
presence of multiple binding sites on each HA, the complexity of the HA-lipoplex structure and re-
binding events during dissociation, a precise kinetic characterization of the HA-lipoplexes-CD44 
interaction cannot be properly resolved. 
 
Conclusion 
 
Lipoplexes are promising siRNA delivery systems that have been studied for gene expression inhibition. 
An accurate and detailed comprehension of their structure and physicochemical characteristics is 
crucial because of their influence in vitro and in vivo efficiency of these nanocarriers. Here, we 
developed and investigated in detail the structure of novel HA-lipoplexes for the delivery of siRNA. 
With the combination of radioactive labeling, diameter and surface charge analyses, capillary 
electrophoresis, cryo-TEM microscopy, SAXS and surface plasmon resonance, the influence of the 
components of the formulation on lipoplex morphology was determined. We demonstrated an 
improvement on SPR method for CD44-HA binding studies and described for the first time evidencing 
of siRNA localization using cryo-TEM microscopy. We provided additional information showing the 
interest of lipoplexes containing the HA-DOPE conjugate, which associated large amounts of siRNA, 
improved stability in physiological media and provided increasing affinity to CD44 receptors with 
increasing HA content. These outputs contribute to the improvement of the siRNA lipoplexes 
development and characterization methods, and give future research directions for the 
characterization of these nanocarriers for successful use in gene delivery. 
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Supporting Information  
 
Figure 1. Electropherogramms obtained by capillary electrophoresis analysis of samples containing HA 
or HA-DOPE at 1 mg/mL: HA solution, HA-DOPE solution, non-modified liposomes, liposomes modified 
with 10% HA-DOPE, liposomes modified with 10% HA-DOPE + internal standard (HA-DOPE solution 1 
mg/mL), lipoplexes +/– ratio 134 modified with 10% HA-DOPE + internal standard (HA-DOPE solution 1 
mg/mL) and lipoplexes modified with 10% HA-DOPE+/– ratio 2 + internal standard (HA-DOPE solution 
1 mg/mL). 
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Travaux expérimentaux - Chapitre 2 
 
Efficient delivery of siRNA by hyaluronic acid-modified lipoplexes targeting 
CD44 receptors 
 
 
Résumé 
 
L'utilisation des nanovecteurs modifiés par de l'acide hyaluronique (HA) est une approche 
prometteuse pour les thérapies ciblant les tumeurs surexpriment des recepteurs CD44. Dans ce 
chapitre, nous avons examiné l'impact de la modification par l’HA sur la capacité de ciblage des 
lipoplexes vecteurs de siRNA. La capture cellulaire et localisation intracellulaire des lipoplexes-HA ont 
été évalués par cytométrie en flux et microscopie de fluorescence, et ont montré que les lipoplexes 
modifies par l’HA sont internalisés plus rapidement que les lipoplexes non modifiés, et une fois dans 
des cellules, ils sont localisés principalement à l’intérieur des endosomes. La capacité des lipoplexes à 
transporter des molécules de siRNA intactes au cytoplasme a été évaluée en testant l'inhibition 
d'expression génique in vitro et in vivo sur la lignée cellulaire de cancer du poumon A549-luc. 81 % 
d'inhibition d'expression de luciferase ont été obtenus in vitro avec lipoplexes-HA à un ratio +/- de 2. In 
vivo, le traitement avec les lipoplexes-HA transportant un siRNA anti-luciferase a mené à une 
diminution statistiquement significative de l’expression de luciferase en comparaison au traitement 
avec du NaCl 0.9 %, ce qui a été confirmé par la réduction de l'expression d’ARNm de la luciferase dans 
le poumon des animaux traités avec les lipoplexes-HA. L'analyse de la distribution des lipoplexes dans 
les poumons a montré que les lipoplexes modifiés par l’HA sont distribués de façon plus importante et 
plus homogène dans le tissu pulmonaire que les lipoplexes non modifiés. Ces résultats confirment le 
potentiel des lipoplexes-HA dans le transport ciblé de siRNA via les récepteurs CD44. 
 
Chapitre rédigé sous forme d’article à être soumis pour publication à Nanomedicine. Auteurs : Thais 
Leite Nascimento, Hervé Hillaireau, Melania Rivano, Claudine Deloménie, Delphine Courilleau, Silvia 
Arpicco, Justin Hanes, Elias Fattal. 
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Experimental work – Chapter 2 
 
Efficient delivery of siRNA by hyaluronic acid-modified lipoplexes targeting 
CD44 receptors 
 
 
Abstract 
 
The use of hyaluronic acid (HA)-modified nancarriers is a promising approach for CD44-overexpressing 
tumor targeting therapies. In the present study, we investigated the impact of HA-modification on the 
targeting capacity of siRNA lipoplexes. Cellular uptake and intracellular localization of HA-lipoplexes 
were evaluated by flow cytometry and fluorescence microscopy, and showed that HA-modified 
lipoplexes are internalized more rapidly than non-modified ones, and once within cells, they are 
localized primarily in endosomes. The ability of the lipoplexes to carry intact siRNA to the cytoplasm 
was assessed by testing gene expression inhibition on the A549-luc lung cancer cell line in vitro and in 
vivo. 81% of luciferase gene expression inhibition was obtained in vitro with HA-lipoplexes at +/– ratio 
2. In vivo, treatment with HA-lipoplexes carrying luc siRNA led to a statistically significant decrease of 
luciferase expression in comparison with treatment with 0.9% NaCl, which was confirmed by the 
reduction of the expression of luciferase mRNA in the lung of animals treated with HA-lipoplexes. 
Analysis of the lipoplexes distribution in the lungs showed that HA-modified lipoplexes are largely and 
more homogenously distributed in the lung tissue after in vivo administration. These results support 
the role of HA-lipoplexes in CD44-targeting siRNA delivery. 
 
Chapter written in the form of a research article to be submitted for publication to Nanomedicine. 
Authors: Thais Leite Nascimento, Hervé Hillaireau, Melania Rivano, Claudine Deloménie, Delphine 
Courilleau, Silvia Arpicco, Justin Hanes, Elias Fattal. 
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Introduction 
 
Downregulation of gene expression is a promising strategy that meets different applications in 
therapeutics. Small interfering RNA (siRNA) molecules present the inherent advantage of nucleic acid 
therapies consisting in the almost unrestricted choice of targets[1]. They also offer a high efficiency 
and selectivity compared to other antisense strategies such as antisense DNA oligonucleotides and 
ribozymes[2]. SiRNA has shown potentialities for the treatment of lung diseases including the 
treatment of inflammatory, immune and infectious diseases, cystic fibrosis (CF) and 
cancer[3].However, their clinical use, even for lung diseases, is still limited due to the same obstacles 
faced by other nucleotide-based therapeutics. Indeed, siRNA are rapidly degraded by nucleases 
showing half-lives in biological fluids of the order of seconds to minutes[4]. Moreover, siRNA lacks 
selectivity for the targeted tissue[1, 3, 5-7]. Within the tissues, they do not cross cell membranes 
readily because of their negative charge, hydrophilicity and molecular size[8, 9]. To overcome these 
limitations and enable siRNA delivery to their site of action, different nanocarriers systems have been 
investigated, including the biocompatible lipid-based liposomes, or lipoplexes. 
Hyaluronic acid (HA) has been extensively used as ligand particularly to design HA-lipid-based 
nanoparticles targeting the CD44 receptor[16][17]. HA is a glycosaminoglycan polymer composed of 
disaccharide units of N-acetylglucosamine and D-glucuronic acid linked together through alternating  -
1,3 and  -1,4 glycosidic bonds[17]. It is biocompatible, being the major component of the extracellular 
matrix. The native high molecular weight HA is non- toxic and non-immunogenic[18]. It does not 
induce expression of genes involved in proliferation or inflammation[19] and counteracts 
proangiogenic effects of the HA oligomers[20, 21]. At last but not least, HA can be utilized as an 
addressing molecule due to the expression of its membrane receptor, CD44, on tumor initiating 
cells[22]. 
It was shown that surface modification of cationic liposomes with high molecular weight HA can 
improve their efficacy by mediating active CD44 targeting in tumors[16, 23-28]. HA can also increase 
liposome circulation time due to possible dysopsonisation effects[24, 29, 30]. In our group, we have 
studied the HA-modification of lipoplexes by the synthesis of a HA-DOPE conjugate and its insertion in 
the DNA lipoplex structure[21, 31, 32]. An improved and receptor-mediated transfection efficiency of 
breast and lung cancer cells overexpressing CD44 receptors was reported[21, 31]. In a preliminary 
report, it was also show that siRNA lipoplexes covered with hyaluronic acid could enter at a larger 
extent into A549 CD44+ cells than Calu-3 CD44- cells[32]. 
In the present study, HA-DOPE modified cationic siRNA lipoplexes were designed using a non-
commercialized cationic lipid that has demonstrated promising transfection efficiency in different cell 
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lines[33, 34], the [2-(2-3didodecyloxypropyl)hydroxyethyl] ammonium bromide (DE). The presence of 
HA on lipoplex surface, and the effects of this modification on cell internalization were evaluated. Also, 
the ability of the lipoplexes to carry intact siRNA to the cytoplasm was assessed by testing gene 
expression inhibition on the A549-luc lung cancer cell line in vitro and in vivo. 
 
Material and methods 
 
Materials 
 
The cationic lipid [2-(2-3didodecyloxypropyl)hydroxyethyl] ammonium bromide (DE) was synthesized 
as described[33]. L-alpha-dioleylphosphatidylethanolamine (DOPE) and phosphatidylethanolamine 
conjugated to rhodamine (PE-rhodamine) were purchased from Avanti Polar Lipids distributed by 
Sigma Aldrich (Saint Quentin Fallavier, France).High molecular weight hyaluronic acid (HA) (sodium 
salt, 1600 kDa, purity of 95%) was provided by Acros organics (Geel, Belgium). pGL3 luciferase (firefly) 
and control siRNA (19bp) were purchased from Eurogentec (Angers, France). The HA-DOPE conjugate 
was synthesized as described previously[31]. 
 
Liposomes and lipoplexes preparation 
 
Liposomes of DOPE/DE at 1:1 w/w ratio were prepared in water by the ethanol injection method[32, 
35]. Separate solutions of DE and DOPE were prepared in chloroform, and then mixed and evaporated 
to dryness under reduced pressure in a rotary evaporator. Following evaporation, the lipid films were 
re-dissolved in absolute ethanol at a concentration of 10 mg/mL. For liposome preparation, the 
ethanolic lipid solution was rapidly injected into RNAse free water under magnetic stirring. HA-
modified liposomes were prepared by diluting an aqueous stock solution of the HA-DOPE conjugate (1 
mg/mL) to different concentrations in RNAse free water before injection. The HA-DOPE content of 
liposomes is expressed as mass ratio of HA-DOPE to other lipids (DE + DOPE) (10% refers to 1:10 
w/w).Liposome suspensions were dialyzed against MilliQ water overnight in Spectra/Por CE dialysis 
tubes with a molecular weight cutoff of 50kDa (Spectrum Laboratories, Breda, Netherlands) to 
eliminate ethanol. Lipoplexes were then prepared at charge ratios (+/– ratios) of 2 and 134 by adding 
one volume of the 3 mM liposome suspension into two volumes of siRNA solution at 11.05 or 0.16 µM, 
respectively, in an Eppendorf tube, and gently homogenizing by pipetting up and down. Suspensions of 
15 µl – 2.5 ml of lipoplexes were usually prepared and incubated for 1 hour at room temperature 
before use.  
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Diameter and zeta potential measurement 
 
Mean diameter and zeta potential were determined with a Zetasizer NanoZs (Malvern Instruments Ltd, 
Malvern, UK). Before each measurement, liposomes and lipoplexes were diluted in 1 mM NaCl. 
Measurements were carried out in triplicate at 25 °C on at least three independent preparations.  
 
Lipoplexes stability in the presence of serum 
 
Non-modified HA-liposomes and lipoplexes at +/– ratios 134 and 2 were prepared as described earlier 
and diluted to 66 μg/mL of lipids with cell culture medium with or without 10% serum. Samples were 
incubated at 37 °C and changes in mean diameter were measured at 0, 35 and 70 min. The accuracy of 
measurements was verified by mixing each suspension thoroughly before each measurement. 
Experiments were performed in triplicate. 
 
Cell culture 
 
A549-luc-C8 Bioware Cell Line, a luciferase-expressing cell line derived from A549 adenocarcinomic 
human alveolar epithelial cells, was purchased from Caliper Life Sciences (Hopkinton, USA). The cells 
were cultured using RPMI-1640 medium supplemented with 10% FBS, 50 units/mL penicillin and 50 
units/mL streptomycin. Cells were maintained at 37°C in a humidified atmosphere with 5% CO2.To 
improve homogeneity of luciferase expression and increase luminescence signals, a protocol for 
selection pressure was optimized. Before each experiment, cells were cultured for 12 days using the 
RPMI medium described previously with addition of 75 µg/ml Geneticin®G418 antibiotic (Gibco, 
Paisley, Scotland).  
 
CD44 expression 
 
A549, A549-luc and G418-selected A549-luc cells were rinsed with PBS FCS 1% and incubated 25 min at 
4 °C with CD44-labeled FITC antibody (Beckman Coulter, Fullerton, USA) according to manufacturer’s 
instructions. Cells were then washed twice in PBS-FCS 1% before being recovered in RPMI-FCS 1%. Cell 
suspensions were analyzed by flow cytometry (Accuri C6, BD Biosciences, Le Pont de Claix, France), 
and mean fluorescence intensities were collected on channel FL-2.Analyses were performed in 
duplicate with 10,000 cells measured in each sample. FITC mouse IgG1 antibody was used as isotype 
control. Results are given as a percentage of cells above fluorescence threshold.   
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Cell viability 
 
Cellular mitochondrial activity was evaluated after incubation with liposomes and lipoplexes using the 
3-[4,5-dimethylthiazol-2-yl]-3,5-diphenyl tetrazolium bromide (MTT) test. Cells were seeded in 96-well 
plates at a density of 70,000 cells/mL and allowed to adhere. After 24 h, cells were rinsed with PBS and 
fresh serum-free medium was added to the wells. Liposomes and lipoplexes were diluted in RPMI 
serum-free medium and added to the wells at various lipid concentrations (0.3-272 µM). Six hours 
after incubation, serum was added to the wells at 10% v/v, and cells were incubated for 48 h. Then, 20 
μL of a 5 mg/mL MTT solution was added to each well. After 2 h of incubation at 37°C, the medium 
was discarded and 100 µl of DMSO was added to lyse the cells and solubilize the formazan crystals. 
The absorbance was measured with a micro-plate reader at 540nm. Each liposome or lipoplex 
concentration was evaluated in triplicate, and the experiment was performed at least three times. Cell 
viability was expressed as the percentage of mitochondrial activity relative to the non-treated cells. 
 
Lipoplexes uptake 
 
Cells were seeded on 12-well plates at a density of 72,000 cells/mL and allowed to adhere. After 24 h, 
cells were rinsed with PBS, and fresh serum-free medium was added to the wells. Rhodamine-labeled 
liposomes and lipoplexes at +/– ratios 2 and 134 were diluted in RPMI serum-free medium and added 
into the wells at a final lipid concentration of 100 µM (67 nM of siRNA for lipoplexes at +/– ratio 2 and 
1 nM of siRNA for lipoplexes 134), and incubated at 37 °C. After 2, 5, 24 or 48 h, supernatants were 
discarded, and cells rinsed twice with PBS and harvested by 1× trypsine. Cell suspensions were 
analyzed by flow cytometry, and mean fluorescence intensities (MFI) were collected on channel FL-2. 
Results were expressed as the ratio of the MFI of each sample to the MFI of non-treated cells. All 
measurements were performed in triplicate. 
 
Subcellular localization of lipoplexes  
 
The intracellular trafficking of lipoplexes +/– ratios 2 and 134 was investigated on A549 cells using 
confocal laser scanning microscopy. A549 cells were seeded at a density of 150,000 cells/mL on 
coverslips and allowed to adhere at 37 °C, 5% CO2. After 24 h, cells were rinsed with PBS and fresh 
serum-free medium was added to the wells. Cells were then treated with rhodamine-labeled 
lipoplexes at a final lipid concentration of 100 µM. After 2 h, 6 h or 24 h of incubation, cells were 
rinsed with PBS and fixed by addition of 800 μL of 4% paraformaldehyde in PBS (w/v) during 20 min. 
After washing with PBS, 10 μL of Vectashield® mounting medium for fluorescence (Vector 
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Laboratories, Inc., Burlingame, USA) was used to prepare the slides. Fluorescence experiments were 
performed with a confocal laser scanning microscope LSM 510-Meta (Zeiss, Germany) using a 63×/1.4 
plan-Apochromat objective lens, a helium neon laser (excitation wavelength 543 nm) and a long pass 
emission filter LP 560 nm. The pinhole was set at 1.0 Airy unit (0.8 μm optical slice thickness). Twelve 
bit numerical images were acquired with LSM 510 software version 3.2. 
 
In vitro luciferase inhibition 
 
The ability of lipoplexes to inhibit luciferase gene expression on A549-luc cells was carried out. For 
that, cells were seeded on 96-well plates at a density of 30,000 cells/mL and allowed to adhere. After 
24 h, cells were rinsed with PBS, and fresh serum-free medium without red phenol was added to the 
wells. Lipoplexes were prepared with control and anti-luciferase siRNA at +/– ratios 134 and 2, with 
non-modified or HA-liposomes. Lipoplexes were diluted in serum-free medium and added into the 
wells at a final lipid concentration of 100 µM. Six hours after incubation, serum was added to the wells 
at 10% v/v and cells were incubated for 48 h. Fifty microliters of BriteLite (Perkin-Elmer Life Sciences, 
Courtaboeuf, France), containing both lysis buffer and luciferin substrate were then added to the 
wells. Plates were vortexed for 3 minutes and luciferase enzyme activity was quantified using the 
Envision Xcite luminometer (Perkin ElmerLife Sciences, Courtaboeuf, France) at ultrasensible mode, 
with measurement time of 0,1 sec/well. Measurements were performed in 8 replicates for each 
sample of lipoplexes. Luciferase activity of untreated cells was measured simultaneously as a baseline 
for comparison. Controls of non-targeting siRNA lipoplexes were used to observe the effect of the 
formulations on luciferase activity. 
 
Distribution of lipoplexes in mouse lung 
 
To investigate the distribution of lipoplexes in the mouse lung, healthy CF mice (female, 6–8 weeks) 
were treated with a single i.v. injection of rhodamine-labeled non-modified or HA-lipoplexes 
containing 20 µg of siRNA. Thirty minutes later, mice were euthanized using an excess of isoflurane. 
Lungs were dissected and flash-frozen with liquid nitrogen in Tissue-Tek O.C.T. Compound. Transverse 
sections of 10 µm of thickness were obtained at various points along the length of the tissue using a 
Leica CM-3050-S cryostat. The sections were stained with ProLong® Gold antifade reagent with DAPI 
(Molecular Probes, Eugene, OR) and images were captured with an inverted epifluorescence 
microscope (Zeiss Axio Observer).   
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A549 intravenous experimental lung metastatic model 
 
Animal studies were carried out in strict accordance to the recommendations in the Guide for the Care 
and Use of Laboratory Animals of the National Institutes of Health. Five-week-old female athymic nude 
mice (Foxn1nu) were purchased from Harlan Laboratories (Gannat, France) and maintained in specific 
pathogen-free conditions throughout the experiment. Animals were kept in sterile cages (maximum of 
four mice/cage) bedded with sterilized soft wood granulate at a 12 h light/dark cycle, and supplied 
with chow and autoclaved water. All manipulations were performed under a laminar flow hood. A459-
luc cells at 80% confluence were harvested, washed 3 times and suspended in PBS. Mice were injected 
in the tail vein with 1.5 million cells suspended in 200 µl of PBS, and tumor growth in the lungs was 
monitored weekly by bioluminescence imaging. 
 
Bioluminescence imaging (BLI) 
 
Bioluminescence from luciferase expressing A549 cells (A549-luc) was measured using IVIS® Lumina 
Series III LT (Perkin Elmer, USA). Firefly luciferin (Perkin Elmer, USA) was injected intraperitoneally6 
minutes before imaging at a concentration of 100 mg/kg. Mice were then anesthetized using 4% 
isoflurane and placed on a warmed stage inside the light-tight camera box with continuous exposure 
to 2.5% isoflurane. Images were made from ventral and dorsal views from 6 to 15 min after luciferin 
injection. Data were analyzed based on total photon emission (photons/sec) in the region of interest 
over the thoracic space.  
 
In vivo luciferase inhibition 
 
The in vivo delivery of luciferase siRNA was tested in female athymic nude mice bearing the A549-luc 
metastatic cancer. Bioluminescence measurements were made before treatment. Each group (8 
animals) was then treated once a day for 3 days by i.v. injection of either NaCl 0.9%, luciferase-siRNA 
solution, HA-lipoplexes prepared with nonspecific control siRNA, HA-lipoplexes prepared with 
luciferase siRNA or non-modified lipoplexes prepared with luciferase siRNA. Total siRNA amount 
injected was 60 µg/mouse. At 24 h post treatment, bioluminescence was quantified, mice were 
euthanized and lungs were removed for siRNA quantification by qPCR. Efficiency of gene expression 
inhibition in vivo was quantified by the comparison of luminescence signals before and after 
treatment.  
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RNA extraction from lung tissues 
 
The lungs from 4 siRNA lipoplex-treated and 3 vehicle-treated mice were frozen in situ with liquid 
nitrogen, and tissue was stored at –80 °C until used for molecular studies. The whole lung tissue from 
each animal was homogenized with ceramic beads in a Precellys®24 (Bertin, France) before extraction 
of total RNA using Trizol® RNA isolation reagent (Life Technologies, France) according to the 
manufacturer’s instructions. RNA purity and quantity was assessed by UV measurement using a 
electrophoresis using RNA 6000 Nano chips and the Bioanalyzer 2100 (Agilent Technologies, USA). 
 
Quantification of luciferase mRNA expression by RT-qPCR 
 
For quantification of mRNA expression, cDNAs were first synthesized by reverse-transcription from 1 
µg of total RNA, with random hexamers and oligo-dT priming using the iSCRIPT enzyme (Bio-Rad 
Laboratories, USA), according to the manufacturer's instructions. PCR primer pairs specific to the 
target and reference genes (Table 1, Supplementary Information) were designed using Primer3Plus 
software. cDNA synthesized from 4 ng of total RNA was amplified in a CFX96 real time thermal cycler 
(Bio-Rad) using the SSoADV Univer SYBR Green Supermix (Bio-Rad) reagent, with 500 nM final 
concentrations of each primer, in duplicates of 10 µl reactions, by 45 two-step cycles (95 °C 5 s ; 60 °C 
30 s). ‘No RT’ controls were amplified on all genes to verify genomic DNA contamination, and melting 
curve analysis was performed to assess the purity of the PCR products. PCR efficiencies, calculated for 
each gene from the slopes of calibration curves generated from the pool of all cDNA samples, were 
above 95%. GeNorm in qBase Plus tool[36] was used to select r18S, HPRT, TBP and ACTB genes as 
references for normalization of mRNA expression results. The normalized relative expression of target 
genes in samples was determined using the   Cq method with correction for PCR efficiencies, where 
NRQ = ETarget 
ΔCq Target / ERef 
ΔCqRef and  ΔCq = Cqsample - Cqcalibrator[37]. Final results were expressed as the n-
fold differences in target gene expression in lipoplex-treated vs vehicle-treated mice. 
 
Statistical analysis 
 
Statistical analysis of data was performed by analysis of variance (ANOVA) followed by Bonferroni or 
Mann-Whitney’s (for qPCR) tests. Differences were considered to be statistically significant at a level of 
P<0.05. 
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Results 
 
Lipoplexes preparation and stability 
 
The mean diameter, polydispersity index (PdI), zeta potential and amount of siRNA associated to the 
obtained non-modified and HA-modified liposomes and lipoplexes are reported on Table 1. Insertion 
of the HA-DOPE conjugate in the liposome structure caused an increase in liposome mean diameter, 
from 90 ± 12 nm for non-modified liposomes to 108 ± 3 nm for HA-liposomes. Surface charge of 
liposomes was positive, as expected due to the presence of the cationic amino groups of the DE lipid. 
The localization of HA moieties on liposome surface was confirmed by the reduction of the surface 
charge compared to the non-modified liposomes. Further decrease in the surface charge upon 
addition of siRNA and formation of lipoplexes confirmed the association of the densely charged siRNA 
molecules. When diluted in cell culture medium a difference between non-modified and HA-lipoplexes 
was observed (Figure 1, Supplementary Information). In the presence of serum proteins, HA-modified 
liposomes and lipoplexes had a lesser tendency to aggregation compared to their non-modified 
counterparts. 
 
Table 1. Mean diameter, polydispersity index (PdI), zeta potential and % of siRNA associated 
measurements for non-modified and HA-liposomes and lipoplexes prepared at ratios +/– 134 and 2.  
Composition Diameter (nm) PdI 
Zeta 
Potential 
(mV) 
% siRNA 
associated 
DE:DOPE 90.4 ± 12.3 0.243 ± 0.06 57 ± 2.2  
DE:DOPE:DOPE-HA 108.6 ± 3.1 0.216 ± 0.04 35.4 ± 0.8  
DE:DOPE:siRNA (134) 76.43 ± 7.3 0.268 ± 0.04 46.5 ± 1.3 99.2 ± 0.7 
DE:DOPE:DOPE-HA:siRNA (134) 93.4 ± 5.1 0.307 ± 0.02 30.1 ± 1.7 99.0 ± 0.4 
DE:DOPE:siRNA (2) 161.7 ± 15.6 0.171 ± 0.06 28 ± 1.9 93.0± 0.6  
DE:DOPE:DOPE-HA:siRNA (2) 233.5 ± 12.6 0.151 ± 0.03 –42.7 ± 3.4 96.0 ± 2.6 
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CD44 expression by A549-luc cells 
 
The presence of CD44 receptors on the surface of A549-luc cells was evaluated by flow cytometry 
before and after cell selection with G418, to confirm that this selection, necessary to improve 
homogeneity of luciferase expression and increase luminescence signals, did not alter cellular 
expression of the receptor. The results show that almost 100% of the cells expressed CD44 receptors 
on their surface, and that the amount of receptors did not change after treatment with G418 (Table 2). 
Figure 1 shows representative histograms of flow cytometry analysis of CD44 in A549, A549-luc and 
G418-selected A549-luc cells.  
 
Table 2. Expression of CD44 receptor on A549, A549-luc and A549-luc selected by G418 cell lines 
reported as RMFI (Relative Median Fluorescence Intensity) and % of analyzed cells (n = 3). 
Cell line RMFI % of analyzed cells 
A549  1081197 ± 3614 99,28% 
A549-luc 1155851 ± 1945 99,86% 
A549-luc sel 1089800 ± 10968 99,24% 
 
Figure 1. Flow cytometry analysis of CD44expression on human cancer cell lines A549 (A), A549-luc (B) 
and A549-luc selected by G418 (C). Cells were incubated with IgG1-FITC isotype control (black) and 
CD44-FITC antibody (blue, red and green), and the mean fluorescence intensity (MFI) was measured.  
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Cytotoxicity 
 
As a first step for in vitro experiments, a comparative cytotoxicity test was performed on A549-luc cells 
using non-modified and HA-modified liposomes and lipoplexes at +/– ratios of 2 and 134. Cells were 
incubated for 48 h with liposomes/lipoplexes formulations at concentrations ranging from 0.1 to 300 
µM lipids. The results show that the modification by HA and the presence of siRNA in the samples did 
not alter their toxicity profiles (Figure 2). To ensure a cell viability above 80%, the lipid concentration 
was maintained at 10 µM for further in vitro experiments. 
 
Figure 2. A549-luc mitochondrial activity as a function of lipid concentration, determined by MTT test 
after incubation with liposomes and lipoplexes. Cells were incubated for 48 h with non-modified and 
HA-liposomes and lipoplexes at +/– ratios 2 and 134, at concentrations from 0.1 to 300 µM lipids/well 
(n=3). 
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Lipoplexes uptake and intracellular distribution 
 
The uptake of liposomes/lipoplexes by A549-luc cells was investigated using fluorescently labeled, 
non-modified and HA-modified liposomes and lipoplexes at +/– ratios of 134 and 2. The uptake was 
quantified by flow cytometry as the cell-associated fluorescence after extensive washing of the cell 
layer (Figure 3). A progressively increasing uptake from 2 to 48 h was observed for liposomes and 
lipoplexes (ratio 134). At all analyzed times, uptake of liposomes and lipoplexes ratio 134 containing 
the HA-DOPE conjugate was higher compared to the non-modified particles, which demonstrated a 
weak cellular uptake. HA-lipoplexes at a ratio of 2 were internalized more rapidly compared to all 
other analyzed particles. At 2 h, a plateau of the uptake of these lipoplexes was already observed, and 
high cellular fluorescence intensity was observed until 48 h, demonstrating the importance of HA-
modification of particle surface when internalization by CD44-expressing cells is desired. 
Figure 3. Uptake kinetics of rhodamine-labeled non-modified (blue) and HA-modified (red) liposomes 
and lipoplexes by A549-luc cells, quantified by flow cytometry as the mean fluorescence intensity 
(MFI). Cells were incubated for 48 h with particles at a lipid concentration of 100 µM (n = 3).  
 
The intracellular distribution of lipoplexes in A549-luc cells was assessed by confocal laser microscopy. 
Non-modified and HA-rhodamine-labeled lipoplexes were prepared at +/– ratios 134 and 2 with 
fluorescently-labeled siRNA. The diffuse fluorescence observed in ortho-images confirmed lipoplex 
localization in the cell cytoplasm, rather than merely bound to the cell membrane (Figure 2, 
Supplementary Information). Images from 2, 6 and 24 h after incubation (Figure 4) show a progressive 
internalization of lipoplexes, as observed by the augmentation of global lipid fluorescence from 2 to 6 
h, after which the fluorescence plateaued. 
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Figure 4. Localization and intracellular distribution of unmodified and HA-DOPE modified lipoplexes 
prepared at +/– ratio 2 with rhodamine-labeled liposomes and FAM-labeled siRNA (arrows). Confocal 
laser microscopy images were obtained after 2, 6 and 24 h (37 °C) incubation. Scale bars = 10 µm. 
 
In vitro luciferase gene expression inhibition 
 
The ability of lipoplexes to carry siRNA into the cell cytoplasm was then evaluated by measuring the 
inhibition of luciferase activity in A549-luc cells. Differences between non-modified and HA-DOPE 
lipoplexes were studied with lipoplexes at +/– ratios 134 and 2 prepared using luciferase-specific siRNA 
and non-specific control siRNA. The results in Figure 5 show that specific inhibition by luciferase siRNA 
was observed compared to control (scramble) siRNA. For a +/– ratio 134, ca. 63% luciferase inhibition 
was observed after incubation with lipoplexes modified by the HA-DOPE conjugate, compared to ca. 
23% for the non-modified lipoplexes. The highest luciferase inhibitions were obtained with lipoplexes 
at +/– ratio 2, with ca. 70% for the non-modified and ca. 81% for the HA-modified vesicles. 
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Figure 5. Luciferase expression inhibition in A549-luc cells by siRNA lipoplexes at +/– ratios 134 and 2 
prepared with non-modified or HA-liposomes. Cells were incubated with lipoplexes for 48h before 
luminescence measurements (n=8). 
 
Lung distribution of lipoplexes 
 
To visualize the influence of HA surface modification of lipoplexes on their distribution in the lungs 
following intravenous administration to mice, fluorescently labeled lipoplexes were prepared at +/– 
ratio 2, HA-modified or not. After i.v. injection to CF mice, particle distribution was observed using 
fluorescence microscopy. Figure 6 shows representative images of the lipoplexes distribution in the 
lungs. A large difference in tissue distribution was observed between these two types of particles 30 
min following administration. The fluorescence related to HA-lipoplexes was homogenously 
distributed throughout the lungs. Meanwhile, weak fluorescence spots were observed for the non-
modified lipoplexes, evidencing the sparse distribution and the formation of aggregates. This indicated 
that the modification of the lipoplex structure with HA promotes a better distribution in the lung 
tissue.  
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Figure 6. Representative image of the lipoplexes distribution in the lungs of mice. Pictures were taken 
with a 10x magnification. From left to right, first frame: image taken using the filter for DAPI staining 
(cells), second frame: image taken using the filter for rhodamine staining (lipoplexes), third frame: 
merge, showing lungs cells in blue and lipoplexes in red. Non-modified lipoplexes +/– ratio 2 and HA-
lipoplexes +/– ratio 2 were administered by intravenous injection. Animals were euthanized and lungs 
were dissected and flash-frozen 30 minutes after treatment. Scale bars = 100 µm. 
 
Tumor growth and in vivo luciferase inhibition 
 
To test the ability of HA-lipoplexes to silence gene expression in vivo, we developed a metastatic 
tumor model using the luciferase-expressing A549-luc cells. 1.5 million cells suspended in 200 µL of 
PBS were injected in the tail vein of athymic nude mice, and tumor growth was monitored weekly by 
bioluminescence imaging. A steady progression of lung tumor growth was measured over the period of 
40 days, which correlated to the finding of tumor nodules on the macroscopic analysis of lungs. No 
changes in the body weight of mice were observed throughout the study. Figure 7 shows tumor 
growth measured by BLI imaging, typical time-dependent ventral images of a mouse with average 
bioluminescence demonstrating lung colonization over time, and a representative image of lungs 
dissected 40 days after cell injection.  
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Figure 7.  A. Tumor growth monitored for 40 days by BLI after intravenous injection of 1.5 million 
A549-luc cells in athymic nude mice (n=50). B. Representative time-dependent ventral images of a 
mouse with average bioluminescence demonstrating lung colonization over time. C. Representative 
image of a lung dissected after 40 days following intravenous injection of 1.5 million A549-luc cells. 
The arrow indicates the tumor metastasis.  
 
The tumor targeting potential and the ability of lipoplex formulations to knockdown luciferase mRNA 
were then investigated on the developed metastatic model of human lung A549 non-small cell lung 
carcinoma. Mice were randomized in 5 groups and treated once a day for 3 days by intravenous 
injections of either NaCl 0.9%, luciferase-siRNA solution, HA-lipoplexes prepared with nonspecific 
control siRNA, HA-lipoplexes prepared with luciferase siRNA or non-modified lipoplexes prepared with 
luciferase siRNA. Tumor growth, calculated as the bioluminescence on the thoracic region after 
treatment relative to the bioluminescence before treatment, is shown in Figure 8. Treatment with HA-
lipoplexes carrying luc siRNA led to a statistically significant decrease of luciferase expression in 
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comparison with controls and non-modified lipoplexes. While tumor luminescence increased to 120 ± 
13% after treatment with vehicle and to 133 ± 27% after treatment with non-modified lipoplexes, it 
decreased to 83 ± 27% after treatment with HA-lipoplexes. 
 
Figure 8. Luciferase expression inhibition in nude athymic mice, calculated as the bioluminescence on 
the thoracic region after treatment compared to the bioluminescence before treatment. Mice were 
inoculated intravenously with 1,5 million A549-luc cells. After 4 weeks, animals were treated once a 
day for 3 days by intravenous injections of NaCl 0.9%, luciferase-siRNA solution, HA-lipoplexes 
prepared with nonspecific control siRNA, HA-lipoplexes prepared with luciferase siRNA or non-
modified lipoplexes prepared with luciferase siRNA. Data represent the mean ± SD (n≥6). *, P < 0.05 
versus vehicle. 
 
Quantification of luciferase mRNA expression by RT-qPCR 
 
The objective of the real-time PCR assays was to determine if the observed decrease in tumor 
luminescence could be identified as the inhibition of luciferase mRNA expression in the lung tissues. 
The transcriptional expression analysis showed a 54% reduction of the expression of PGL3-luc 
transcript in the lung of animals treated with HA-lipoplexes compared to animals treated with NaCl 
0.9% (Figure 9). This result is not statistically significant (p=0.16) considering the number of lungs 
analyzed, and should be confirmed on a higher number of animals. However, combined with the 
results from the luminescence measurements, it confirms the inhibitory activity of siRNA lipoplexes 
upon the expression of PGL3-luc in our model. 
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Figure 9. Relative expression of PGL3-LUC mRNA transcript in nude athymic mice, calculated using 
r18S, HPRT, TBP and ACTB genes as references for normalization of mRNA expression. Results are 
expressed as the n-fold differences in target gene expression in HA-lipoplex-treated vs NaCl 0.9%-
treated mice. Data represent the mean ± SD (n=3;4). 
 
Discussion 
 
The aim of this study was to characterize in vitro and in vivo the potential of HA-modified lipoplexes 
for the targeted delivery of siRNA to CD44-expressing A549 lung cancer cells. As we have previously 
observed that this amount was optimal for the transfection of MDA-MB231 and A549 cancer cells 
expressing CD44[21, 31], 10% (wHA/wtotal lipids) of HA-DOPE conjugate [31] was used to prepare HA-
modified liposomes and lipoplexes, namely HA-liposomes and HA-lipoplexes, in which the DOPE lipid 
served as an anchor for the insertion of HA on the vesicle structure.  
Lipoplexes showed increased diameter with the modification by the conjugate insertion and the 
addition of siRNA, reaching 230 nm for the HA-lipoplexes at +/– ratio 2, that presented the highest 
amounts of siRNA associated to the vesicles. This is frequently described for the modification of lipid 
vesicles with HA[39-41], since HA is a hydrophilic polymer and its placement on nanoparticle surface 
increases nanoparticles mean hydrodynamic diameter. The oligolamellar characteristic of the 
lipoplexes permitted a siRNA entrapment efficacy of 96.0 ± 2.6%. HA lipoplexes were more stable than 
their counterparts with no HA due to a stabilization mechanism being the repulsion between negative 
charges of HA and serum proteins, minimizing their nonspecific interactions and causing a stabilization 
of the particles. 
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The biological activity of HA-lipoplexes was evaluated using the A549-luc human lung carcinoma cell 
line, which proved to be a suitable model for CD44 targeting since the totality of the cell population 
exhibited the CD44 membrane receptor. Measurement of cellular mitochondrial activity of cells 
exposed to liposomes/lipoplexes showed that the modification by HA did not change lipoplex toxicity. 
This biocompatibility is consistent with the ubiquitous and nontoxic characteristics of HA[39], and is in 
agreement with previous studies in which the modification of neutral[23, 27], negatively[39, 43] or 
positively charged[31] liposomes with HA revealed no apparent effect on cellular proliferation of 
CD44-overexpressing cells. Park and co-workers[44]  even observed an increase in MDA-MB-231 cell 
viability from 40 to 106% after incubation with HA-liposomes for 72 h, attributed to the coating of the 
lipid bilayer by HA and its protection against the disruption of cellular membrane caused by the plain 
liposomes. Similar results were described for solid lipid nanoparticles and nanostructured lipid carriers 
[45] and [46], where higher cytotoxicity of non-modified particles is observed when compared with 
their HA-coated counterparts. This difference was explained by the presence of the cationic lipids 
didecyldimethyl ammonium bromide[45]  and hexadecyltrimethyl ammonium bromide[46]  on the 
surface of the nanoparticles, resulting in destruction of the cell membrane, which was prevented by 
coating with HA. The cytotoxicity of cationic lipids and polymers has been investigated in several 
studies, especially due to the increasing interest in these compounds for their ability of forming 
lipoplexes upon incubation with negatively charged nucleic acids[47-49]. When present on 
nanoparticles, these cationic compounds  upon binding to the cell surface, may be recognized as a 
signal of danger for cells (inducing pro-apoptotic or pro-inflammatory reactions) or contribute to 
activate cascades that are classically activated by endogenous cationic compounds[50]. This toxicity 
depends though on several factors besides the particle surface charge, such as the lipid type, amount 
and charge[44], and its ratio in combination with helper lipids[48]. Our results suggest that the 
cytotoxicity profile of HA-lipoplexes is not related to the changes in particle surface charge, since cells 
responded similarly when incubated with all formulations, and that cytotoxicity was observed only 
after incubation with high concentration of vesicles.  
Quantification of lipid-related fluorescence by flow cytometry showed higher internalization in A549 
CD44-overexpressing cells of samples that contained the conjugate, confirming the crucial role of the 
receptor in the endocytosis process, as shown previously by our group and others[29, 32, 38, 51-53]. 
Despite that the  higher fluorescence associated to the uptake of the plain lipoplexes +/– ratio 2 at 48h 
masked the effect of HA presence on the internalization of these lipoplexes, cell fluorescence intensity 
was clearly higher for HA-lipoplexes in all other time points. 
After delivery into the target cells, efficient siRNA vectors must escape endosomes and release siRNA 
into the cytoplasm, allowing the interaction of siRNA with the endogenous RISC[55, 56]. Confocal 
images of cellular uptake and intracellular distribution of lipoplexes confirmed their progressive 
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internalization, with a plateau reached at 6 h. The diffuse cytoplasmic fluorescence observed from 6 h, 
as opposed to a more punctuated fluorescence consistent with the presence of endocytic vesicles 
containing lipoplexes at 2 h[57, 58], indicates that lipoplexes were able to escape endosomes and 
reach the cytosol. 
The efficiency of anti-luc siRNA lipoplexes in promoting gene expression inhibition was tested in vitro 
by measuring the inhibition of the luciferase activity on A549-luc cells. The observed reduction of 
luciferase expression was attributed to the inhibition caused by siRNA that reached cytoplasm after 
being transported into the cells by the lipoplexes. More than 80% luciferase inhibition was achieved 
with HA-lipoplexes at +/– ratio 2 and 65% with HA-DOPE lipoplexes at +/– ratio 134. This corresponds 
to 67 nM and 1 nM siRNA/well, and demonstrates the high siRNA delivery efficiency of the lipoplexes. 
High luc-siRNA specificity was observed by luciferase inhibition after treatment with non-modified 
lipoplexes +/– 2. The luciferase expression inhibition of 70% compared to the cells treated with control 
siRNA showed that even the transport of small amounts of siRNA to the cytoplasm (as shown by 
uptake studies), strong luciferase inhibition can be obtained. This is in agreement with the lipoplexes 
uptake studies. Although higher cellular internalization was observed for all HA-modified particles until 
24 h, after 48 h of incubation the preferential uptake and thus gene expression inhibition effect of the 
HA-lipoplexes +/– ratio 2 is masked by the continuous internalization of the non-modified oligolamellar 
lipoplexes +/–  ratio 2. Taken together, these results confirm that CD44 receptor mediated endocytosis 
plays a role on the uptake of HA-lipoplexes, and that these particles are able to efficiently release 
siRNA within the cell cytoplasm. This is promising when in vivo administration is considered, where 
small amounts of the particle actually reach the targeted cells.  
The modification of nanoparticles with HA has been explored mainly for its ability to specifically bind 
to various cells that overexpress CD44, a common marker for tumor initiating cells-cancer stem cells 
(CSC) in human carcinomas. Since a variety of cells, including breast, ovarian, colon, stomach, and lung 
carcinomas[59] overexpress these receptors, the formulation of HA-modified particles is a promising 
strategy to promote receptor-mediated cellular entry. This strategy has been proved largely efficient in 
vitro[60] . When in vivo activity is tested, though, results are less outstanding. Most of the currently 
developed nanosystems, including the actively targeted ones, exhibit a discrepancy between 
targetability in vitro and in vivo[61]. Long blood circulation is critical for active tumor targeting, and to 
reach the targeted cells after intravenous injection, nanoparticles first have to resist clearance from 
the circulation by the RES. This is not the case for all HA-modified nanoparticles. Even though HA has 
been successfully used as a hydrophilic coating and even proposed as an alternative to PEG to increase 
blood circulation of nanoparticles [23, 24, 43, 61], [62] exemplified that depending on the polymer 
length of HA and on their negative surface charge, HA-liposomes may even suffer a faster clearance. 
Therefore, a case-by-case analysis of the in vivo fate of HA-particles is necessary. To test the 
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hypothesis that HA-lipoplexes can transport siRNA into the cytoplasm of CD44-overexpressing cells in 
vivo, we developed a model of human lung A549 non-small cell lung carcinoma. The bioluminescence 
images and appearance of lung nodules confirmed lung metastasis. Lipoplexes were then administered 
by bolus intravenous injection, at a volume of 0.1 mL per 10 g of body weight, which is normally 
acceptable in human therapy. Results confirmed the advantage of HA-lipoplexes over non-modified 
lipoplexes on the inhibition of luciferase expression by decrease in luminescence and PGL3-LUC 
transcript in the tumors. Tissue analysis after administration of rhodamine-labeled HA-lipoplexes 
revealed diffuse fluorescence corresponding to the HA-lipoplexes in the mouse lung, which was not 
the case with non-modified lipoplexes. Taken together, these results indicate that our HA-lipoplexes 
are able to carry the siRNA molecules to the cytoplasm of CD44-overexpressing cells. These HA-
modified carriers beneficiate of the EPR effect, as consequence of the increase in hydrophilicity and 
longer circulation time caused by the presence of HA on the surface of the particles, and of the CD44-
targeting promoted by HA moieties[44].  
 
Conclusion 
 
The results presented here show the potentialities of HA-lipoplexes as siRNA carriers to CD44-
overexpressing cells. Lipoplexes are stable in the presence of serum, and their structural modification 
with the HA-DOPE conjugate improves cellular internalization mediated by the CD44 receptor. After 
uptake, lipoplexes are distributed in the cytoplasm, where the carried siRNA promotes highly efficient 
gene expression inhibition. The HA-lipoplexes are able to transport in vivo a dose of intact siRNA for 
uptake and ultimately intracellular function, and are thus a promising tool for anticancer therapeutic 
gene expression inhibition. 
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Figure 1. Colloidal stability of non-modified and HA-modified liposomes and lipoplexes at +/- ratios of 
134 and 2 in cell culture medium without serum and containing 10% serum measured over 70 min by 
dynamic light scattering (n = 3). 
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Figure 2. Confocal microscopic ortho-image of cells incubated for 6 h with HA-DOPE lipoplexes +/– 
ratio 2, illustrating siRNA present on the cell cytoplasm. The upper stripe shows the ortho-image along 
the green line and the stripe on the right shows the ortho-image along the red line. Scale bars = 10 µm. 
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Table 1. Primers used for qPCR. 
Gene name Accession Primer Sequence (5’-3’) Amplicon 
size (bp) 
PGL3-LUC U47296 Forward GGAGTTGTGTTTGTGGAC 
75 
  Reverse GAGGATCTCTCTGATTTTTC 
R18S NR_003278 Forward TCATAAGCTTGCGTTGAT 70 
   Reverse ACCATCCAATCGGTAGTAG 
ACTB NM_007393 Forward AGAGGGAAATCGTGCGTGAC 
139 
  Reverse CAATAGTGATGACCTGGCCGT 
HPRT1 NM_013556 Forward AGCTACTGTAATGATCAGTCAACG 
200 
  Reverse AGAGGTCCTTTTCACCAGCA 
TBP NM_013684 Forward ACTTAGCTGGGAAGCCCAAC 
129 
  Reverse ACGGACAACTGCGTTGATTTT 
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Study of the diffusion in respiratory mucus, lung distribution and in vivo gene 
silencing after intrapulmonary administration of hyaluronic acid-modified 
siRNA cationic lipoplexes 
 
Résumé 
 
L'administration locale de composés thérapeutiques aux poumons offre la possibilité d'améliorer le 
traitement de maladies pulmonaires grâce à un l'accès instantané, de fortes concentrations locales et 
donc moins de risques de la toxicité. Dans ce travail, nous avons étudié la diffusion des lipoplexes-HA 
de siRNA dans le mucus, afin d’évaluer la faisabilité de l’administration pulmonaire fr ces particules. 
Des liposomes cationiques ont été préparés par la méthode d'injection d'éthanol et les lipoplexes ont 
été obtenus en mélangeant la dispersion de liposomes avec la solution de siRNA. Les études utilisant la 
technique de « multiple particle tracking (MPT) » ont montré que la présence d’HA combinée à l'ajout 
de siRNA ont permis l’obtention de deux formulations de lipoplexes présentant un pénétration efficace 
dans le mucus, les lipoplexes-HA and les lipoplexes-PEG/HA. Ces particules ont présenté des 
déplacements moyens quadratiques (mean squared displacement, MSD) seulement 3.5 et 2.4 fois plus 
petits que les particules contrôle de polystyrène, et des fractions importantes des populations ont 
rapidement pénétré dans le mucus respiratoire. Après administration pulmonaire chez la souris, les 
lipoplexes modifiées par l’HA ont été distribués de façon plus importante dans les poumons, comparé 
aux lipoplexes non modifiés, tandis que les lipoplexes-PEG/HA ont montré des distributions 
plulmonaires les plus intenses et uniformes parmi les formulations testées. L'inhibition de l'expression 
de luciferase après administration intrapulmonaire a aussi été testée utilisant le modèle métastatique 
A549-luc, mais aucun effet du traitement avec lipoplexes n’a été observé, probablement en raison de 
la différente localisation des cellules tumorales et des lipoplexes dans les poumons. Des études plus 
approfondies de l'administration locale des lipoplexes-HA et lipoplexes-PEG/HA devront être 
effectuées, afin de tirer profit des capacités mucopénétrantes de ces vecteurs de siRNA. 
 
Chapitre rédigé sous forme d’article à être soumis pour publication. Auteurs : Thais Leite Nascimento, 
Gregg Duncan, Hervé Hillaireau, Jung Soo Suk, Justin Hanes, Elias Fattal. 
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Experimental work - Chapter 3 
 
Study of the diffusion in respiratory mucus, lung distribution and in vivo gene 
silencing after intrapulmonary administration of hyaluronic acid-modified 
siRNA cationic lipoplexes 
 
Abstract 
 
Local administration of therapeutic compounds to the lungs offers the possibility to improve the 
treatment of lung diseases by means of instant access, high local concentrations and therefore less risk 
of toxicity. In this work, we studied the mucus diffusion of hyaluronic acid (HA)-modified siRNA 
lipoplexes in order to evaluate the feasibility of pulmonary administration of these particles to treat 
lung diseases. Cationic liposomes were prepared by the ethanol injection method and lipoplexes were 
prepared by mixing the liposome dispersion with siRNA solution. Multiple particle tracking (MPT) 
technique studies showed that the presence of HA together with the addition of siRNA allowed the 
preparation of two efficient mucus-penetrating lipoplexes formulations, HA-lipoplexes and PEG/HA-
lipoplexes. These particles presented mean squared displacements only 3.5 and 2.4-fold smaller than 
the mucus-penetrating polystyrene control nanoparticles, and high fractions of population that rapidly 
penetrated respiratory mucus. After intrapulmonary administration, HA-modified siRNA lipoplexes 
were largely distributed in the lungs of mice, compared to the non-modified lipoplexes, while PEG/HA-
lipoplexes showed the most intense and uniform distribution of the samples analyzed. In vivo 
luciferase expression inhibition after intrapulmonary administration was also tested using an A549-luc 
lung metastatic model, but no effect of the treatment with lipoplexes was observed, probably due to 
the different localization of tumor cells and lipoplexes in the lungs. Further investigation of local 
administration of HA and PEG/HA-modified lipoplexes should be carried out, since these siRNA carriers 
showed a promising mucus penetrating ability. 
 
The work described in this chapter was performed in collaboration with the laboratory of Prof. Justin 
Hanes, at the Center for Nanomedicine of the Department of Ophthalmology at the Johns Hopkins 
Hospital, in Baltimore, Maryland, United States. It is written in the form of a research article to be 
submitted for publication. Authors: Thais Leite Nascimento, Gregg Duncan, Hervé Hillaireau, Jung Soo 
Suk, Justin Hanes, Elias Fattal. 
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Introduction 
 
Small interfering RNAs (siRNAs) are potent molecules able to block gene expression after entering cell 
cytoplasm. The possibility of controlling disease-associated genes makes RNA interference an 
attractive choice for future therapeutics against cancer, autoimmune diseases, dominant genetic 
disorders and viral infections [1, 2].  
Administration of siRNA targeting the lungs has been studied for the down-regulation of a variety of 
targets including heme-oxygenase [3, 4], interleukin-5 [5], Fas [6], macrophage inflammatory protein 
(MIP)-2 [7] and p38 MAP kinase [8]. The utility of siRNA for treating respiratory viral infections has 
been also explored [9, 10]. In most of these cases, siRNA has been administered using delivery vectors 
including polymeric nanoparticles, liposomes and chitosan nanoparticles. For lung cancer therapy, 
increasing efforts have focused on the development of local administration of gene therapy because it 
has mainly two advantages: instant access and a high ratio of the gene deposited non-invasively within 
the lung [11]. Local delivery directly to the lungs could increase siRNA transport efficiency and 
therefore improve the treatment of lung diseases [12, 13]. Local administration offers also the 
advantage of achieving higher pulmonary concentrations of the therapeutic agent with a total dose 
considerably lower than that required for systemic administration, resulting in less risk of toxicity and 
adverse effects [14, 15]. Moreover, the lungs possess a great absorption surface area (100 m²), 
extensive vascularization, thin alveolar epithelium (0,1 – 0,2 µm) and a small air-blood exchange 
passage distance [16], which facilitates the local and systemic treatment of diseases. 
Despite the great potential applications for targeted local delivery, siRNAs still face pharmacokinetic 
and cell penetration limitations. As a result of their small size, they are rapidly eliminated by the 
kidneys and show circulating half-lives of the order of seconds to minutes [17]. They are also 
susceptible to degradation by nucleases in the plasma, and tend to accumulate mainly in the liver and 
kidney and to a lesser extent in the heart, spleen and lungs [18]. Within the tissues, they do not cross 
cell membranes readily because of their negative charge, hydrophilicity and molecular size. Also, 
siRNAs are not taken up by most mammalian cells in a way that preserves their activity [1]. Therefore, 
an effective delivery system is considered almost as a prerequisite for effective siRNA-mediated gene 
silencing [19, 20].  
The potential of hyaluronic acid (HA)-modified cationic liposomes as siRNA carriers and their targeting 
to CD44-overexpressing cells were explored during the PhD thesis in which this chapter is included. 
Cationic liposomes of L-alpha-dioleylphosphatidyl ethanolamine  (DOPE)  and the cationic  lipid [2-(2-3-
didodecyloxypropyl)hydroxyethyl] ammonium bromide (DE) [21] containing different amounts of  
hyaluronic acid were obtained and their interaction with siRNA, forming lipoplexes, was characterized. 
Specific interaction of HA-modified lipoplexes with CD44 receptors was observed using the Surface 
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Plasmon Resonance technique. In vitro studies were performed using the A549-luc lung cancer cell 
model, with which luciferase expression inhibition was demonstrated using an anti-luciferase specific 
siRNA. Preferential internalization of HA-lipoplexes was observed, as well as cytoplasm localization. 
Also, effective luciferase inhibition was observed on an A549 experimental lung metastatic model in 
mice after administration by intravenous administration of HA-modified lipoplexes.  
The work presented in this chapter aimed at studying the mucus diffusion of HA and PEG-modified 
siRNA lipoplexes in order to evaluate the viability of administering these particles by the pulmonary 
route to treat lung diseases. This study was motivated by the hydrophilic and “bioinert” characteristics 
of high-molecular weight HA [22], and the fact that coating particles with hydrophilic polymers (e.g., 
PEG, pluronic) is the strategy used to develop “mucus-penetrating particles” (MPP). Interestingly, HA 
has been proposed as an alternative to PEG for the preparation of targeted liposomes encapsulating 
small molecules [23, 24] or lipoplexes [25, 26]. Cationic liposomes were prepared by the ethanol 
injection method and lipoplexes were prepared by mixing the liposome dispersion with siRNA solution. 
The diffusion of lipoplexes in mucus was studied using the multiple particle tracking (MPT) technique, 
and distribution of HA-modified siRNA lipoplexes in the mouse lung after pulmonary administration 
was analyzed. In vivo gene expression inhibition after intrapulmonary administration was also tested 
using the tumor model described in Chapter 2. 
 
Materials and Methods 
 
Materials 
 
The cationic lipid [2-(2-3didodecyloxypropyl)hydroxyethyl] ammonium bromide (DE) was synthesized 
as described previously [21]. L-alpha-dioleylphosphatidylethanolamine (DOPE), 
phosphatidylethanolamine conjugated to rhodamine (PE-rhodamine) and N-(carbonyl-
methoxypolyethyleneglycol 2000)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE-
PEG2000) were purchased from Avanti Polar Lipids distributed by Sigma Aldrich (Saint Quentin 
Fallavier, France). High molecular weight hyaluronic acid (HA) (sodium salt, 1600 kDa, purity of 95%) 
was provided by Acros organics (Geel, Belgium). Control siRNA (19 bp) was purchased from Eurogentec 
(Angers, France). The DOPE-HA conjugate was synthesized and characterized as described previously 
[25]. 
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Liposomes and lipoplexes preparation 
 
Liposomes of DOPE/DE at 1:1 w/w ratio were prepared in water by the ethanol injection method [27, 
28]. Separate solutions of DE and DOPE were prepared in chloroform, and then mixed and evaporated 
to dryness under reduced pressure in a rotary evaporator. Following evaporation, the lipid films were 
re-dissolved in absolute ethanol at a concentration of 10 mg/mL. For liposome preparation, the 
ethanolic lipid solution was rapidly injected into RNAse free water under magnetic stirring. HA and 
PEG-modified liposomes were prepared by diluting an aqueous stock solution of the HA-DOPE 
conjugate (1 mg/mL) and PEG to different concentrations in RNAse free water before injection. The 
HA-DOPE/PEG content of liposomes is expressed as mass ratio of HA-DOPE/PEG to other lipids (DE + 
DOPE) (10% refers to 1:10 w/w). Liposome suspensions were dialyzed against 1 L of MilliQ water 
overnight in Spectra/Por CE dialysis tubes with a molecular weight cutoff of 50kDa (Spectrum 
Laboratories, Breda, Netherlands) to eliminate ethanol. Fluorescent  rhodamine-labeled liposomes 
were prepared by substituting 1% of DOPE lipid by phosphatidylethanolamine conjugated to 
rhodamine (PE-rhodamine) in the formulations. Lipoplexes were then prepared at different charge 
ratios (+/– ratios) by adding one volume of the 3 mM liposome suspension into two volumes of siRNA 
solution at different concentrations (0.11, 0.16, 0.22, 0.44, 5.52, 7.36, 11.05 and 22.10 µM for +/– 
ratios of 200, 134, 100, 50, 4, 3, 2 and 1 respectively) in an Eppendorf tube, and gently homogenizing 
by pipetting up and down. Suspensions of 15 µL – 2.5 mL of lipoplexes were usually prepared and 
incubated for 1 hour at room temperature before use. 
 
Diameter and zeta potential measurement 
 
Diameter and zeta potential were determined with a Zetasizer Nano Zs (Malvern Instruments Ltd, 
Malvern, UK). Before each measurement, liposomes and lipoplexes were diluted in 1 mM NaCl. 
Measurements were carried out in triplicate at 25 °C.  
 
siRNA labeling with Cy3 
 
siRNA was labeled using the Mirus Label-IT Cy3 labeling kit (Fisher Scientific) according to the 
manufacturer’s protocol. Cy3-labeled lipoplexes were prepared by mixing 2 volumes of siRNA solution 
with 1 volume of liposome suspension. Lipoplexes at +/– ratios 2 and 8 were used for the experiments. 
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Mucus sample collection 
 
The method used in this section was described by Schuster et al [29]. Human airway mucus samples 
were collected in accordance with a protocol approved by the Johns Hopkins Medicine Institutional 
Review Board (study number NA_00038606). Patients who required intubation as part of general 
anesthesia for elective, non-cardiothoracic surgery at the Johns Hopkins Hospital were identified. Only 
patients with no cardiopulmonary or respiratory comorbidities and no smoking history were included 
in this study. At the end of surgery, the endotracheal tube was removed from the patient, and the 
distal 10 cm portion, including the balloon cuff, was cut and placed in a 50 mL centrifuge tube. The 
specimens were then spun at 1000 rpm (220 × g) for 30 s, yielding an average mucus volume of 0.5 mL. 
Mucus with visible blood contamination was not included in the analysis. Mucus samples were stored 
at 4 °C and analyzed within 24 h of collection. 
 
Multiple particle tracking (MPT) of lipoplexes 
 
Cy3-labeled lipoplexes were added in custom-made 30 μL microwells to 30 μL (3% dilution) of water or 
lung mucus, and equilibrated for 1 h prior to microscopy. Twenty second movies at 66.7 ms temporal 
resolution were acquired via Evolve 512 EMCCD camera (Photometrics, Tucson, AZ) equipped on an 
inverted epifluorescence microscope (Axio Observer D1, Zeiss; Thornwood, NY) with a 100×/1.4NA 
objective. Movies were analyzed with Metamorph software (Universal Imaging, Glendale, WI) to 
extract x, y-coordinates of lipoplexes centroids over time. Time-averaged mean square displacement 
(MSD) for individual gene carriers were calculated as a function of time scale(τ) [32]. Bulk transport 
properties were calculated by geometric ensemble-averaging of individual MSD. Exposure time of 66.7 
ms was used to capture fluorescent snapshots of lipoplexes, and MSD values are presented at a time 
scale of 1 s [30]. 
 
Distribution of lipoplexes in mouse lung 
 
Female CF-1 mice of 6-8 weeks (CF-1 mice, strain code 023, Charles River Laboratories, Wilmington, 
MA) were anesthetized using 2,2-2-tribomoethanol (Sigma-Aldrich) diluted with PBS (1:80 v/v). 600 µL 
of the anesthetic were injected intraperitoneally and mice were monitored until the loss of pedal 
reflex. Cy3 and rhodamine-labeled liposomes and lipoplexes were then administered in the lungs using 
a microsprayer (PennCentury). Thirty minutes later, mice were euthanized using an excess of 
isoflurane. Lungs were dissected and flash-frozen with liquid nitrogen in Tissue-Tek O.C.T. Compound. 
Transverse sections of 10 µm of thickness were obtained at various points along the length of the 
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tissue using a Leica CM-3050-S cryostat. The sections were stained with ProLong® Gold antifade 
reagent with DAPI (Molecular Probes, Eugene, OR) and images were captured with an inverted 
epifluorescence microscope (Zeiss Axio Observer). HA-liposomes, HA-lipoplexes at a +/– ratio of 2, 
non-modified lipoplexes at a +/– ratio of 2, PEG/HA-lipoplexes at a +/– ratio of 8, HA-lipoplexes at a 
+/– ratio of 2 and non-modified lipoplexes at a +/– ratio of 2 were analyzed. Each animal was treated 
with a single dose of lipoplexes containing 20 µg of siRNA. Lipoplexes were concentrated to final 
volumes of 50 µL/mouse for pulmonary administration. 
 
A549 intravenous experimental lung metastatic model 
 
Animal studies were carried out in strict accordance to the recommendations in the Guide for the Care 
and Use of Laboratory Animals of the National Institutes of Health. Five-week-old female athymic nude 
mice (Foxn1nu) were purchased from Harlan Laboratories (Gannat, France) and maintained in specific 
pathogen-free conditions throughout the experiment. Animals were kept in sterile cages (maximum of 
four mice/cage) bedded with sterilized soft wood granulate at a 12 h light/dark cycle, and supplied 
with chow and autoclaved water. All manipulations were performed under a laminar flow hood. A459-
luc cells at 80% confluence were harvested, washed 3 times and suspended in PBS. Mice were injected 
in the tail vein with 1.5 million cells suspended in 150 µL of PBS, and tumor growth in the lungs was 
monitored weekly by bioluminescence imaging. 
 
Bioluminescence imaging (BLI) 
 
Bioluminescence from luciferase expressing A549 cells (A549luc) was measured using IVIS® Lumina 
Series III LT (Perkin Elmer, USA). Firefly luciferin (Perkin Elmer, USA) was injected intraperitoneally 6 
minutes before imaging at a concentration of 100 mg/kg. Mice were then anesthetized using 4% 
isoflurane and placed on a warmed stage inside the light-tight camera box with continuous exposure 
to 2.5% isoflurane. Images were made from ventral and dorsal views from 6 to 15 min after luciferin 
injection. Data were analyzed based on total photon emission (photons/sec) in the region of interest 
over the thoracic space.  
 
In vivo luciferase inhibition 
 
Mice were randomized in 5 groups of treatment with 8 animals/group. 50 µL of either NaCl 0.9%, 
luciferase-siRNA solution, HA-lipoplexes prepared with nonspecific control siRNA, HA-lipoplexes 
prepared with luciferase siRNA or non-modified lipoplexes prepared with luciferase siRNA were 
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administered using a microsprayer (PennCentury) once a day for 3 days. The study was double-
blinded. Total siRNA amount injected was 60 µg/mouse. Tumor imaging was performed before and 
after the treatment.  
 
Statistical analysis 
 
Statistical analysis of data was performed by analysis of variance (ANOVA) followed by Bonferroni test. 
Differences between groups were considered to be statistically significant at a level of P< 0.05. 
 
Results 
 
Physicochemical properties of lipoplexes 
 
To test the ability of HA-lipoplexes to move through human airway mucus, we first modified the HA-
lipoplexes formulations in attempt to obtain particles that were as hydrophilic as possible with a zeta 
potential being the closest to neutrality. For that reason, 10% and 12% mol of DPPE-PEG were added 
to plain and HA-modified liposomes, and the obtained liposomes were used to prepare lipoplexes at 
+/– ratios of 2, 4 and 8. The particles obtained were characterized in terms of mean diameter, 
polydispersity index (PdI) and zeta potential (Table 1). 
Liposomes mean diameter ranged from 106 nm to 132 nm, without significant differences between 
the plain and HA-modified particles (p>0.05). PEGylated vesicles were slightly smaller, but the 
diameter decrease did not depend on the amount of PEG present on the formulation. Zeta potentials 
changes were significant with liposome surface modification, HA-liposomes having a decreased surface 
charge compared to the non-modified and PEGylated cationic liposomes. 
Upon addition of siRNA to prepare the lipoplexes, a gradual decrease in the surface charge with 
increasing concentrations of complexed siRNA molecules was observed. Moreover, surface charge of 
PEGylated lipoplexes was significantly reduced, indicating the shielding of the siRNA and HA negative 
charges by the presence of neutrally charged PEG. An ‘optimized formulation’, in terms of surface 
neutrality, was obtained when siRNA was complexed to 10% PEG/HA-lipoplexes at a +/– ratio of 8 
(Table 1).  
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Table 1. Characterization of non-modified, HA-modified, PEG-modified and HA/PEG-modified DE:DOPE 
liposomes and lipoplexes in terms of particle mean diameter (nm), polydispersity index (PdI), and zeta 
potential (mV).  
Preparation Mean diameter (nm) PdI Zeta Potential (mV) 
Liposomes    
Non-modified  132.1 ± 2.4 0.263 ± 0,009 39.7 ± 1.3 
HA-modified  130.3 ± 1.9 0.113 ± 0,006 29.6 ± 1.8 
10% PEG liposomes  126.8 ± 2.6 0.371 ± 0.015 45.5 ± 1.2 
10% PEG HA liposomes  106.4 ± 2.4 0.431 ± 0.032 21.1 ± 3.4 
12% PEG HA liposomes 120.9 ± 3.9 0.284 ± 0.005 24.5 ± 0.7 
Lipoplexes    
Non-modified +/- 2 158.1 ± 2.1 0.155 ± 0,020 33.6 ± 2.4 
HA-lipoplexes +/- 2 154.5 ± 1.7 0.147 ± 0,028 –39.7 ± 0.5 
10% PEG lipoplexes +/- 2 78.3 ± 1.5 0.386 ± 0.020 –13.1 ± 1.3 
10% PEG lipoplexes +/- 4 126.6 ± 2.4 0.271 ± 0.004 12.9 ± 0.4 
10% PEG lipoplexes +/- 8 116.8 ± 0.5 0.308 ± 0.042 18.5 ± 1.0 
10% PEG HA lipoplexes +/- 2 86.3 ± 1.2 0.348 ± 0.014 –17.2 ± 2.9 
10% PEG HA lipoplexes +/- 4 90.1 ± 1.4 0.341 ± 0.044 –15.8 ± 4.1 
10% PEG HA lipoplexes +/- 8 97.4 ± 1.3 0.340 ± 0.042 –1.4 ± 0.6 
12% PEG lipoplexes +/- 2 85.4 ± 1.4 0.381 ± 0.010 –24.7 ± 4.0 
12% PEG HA lipoplexes +/- 2 92.4 ± 1.2 0.299 ± 0.033 –24.0 ± 1.7 
 
Diffusion of lipoplexes in respiratory mucus 
 
The movement of non-modified liposomes, non-modified lipoplexes (+/– ratio of 2), HA-liposomes and 
HA-lipoplexes (+/– ratio of 2) in respiratory mucus was studied. The formulation PEG/HA-lipoplexes 
(+/– ratio of 8) was also analyzed, since this was the preparation that presented the surface charge 
closest to neutrality and was therefore more likely to move through the mucus. Polystyrene 
nanoparticles (PS) of 100 nm internally labeled with a fluorescent dye, which were densely coated with 
PEG to minimize mucus adhesion and have neutral surface charge [31, 32], were used as a control for 
the mucus tracking experiments. Tracked trajectories over 20 s, distribution of individual particle mean 
squared displacement at a time scale of 1 s and the ensemble-averaged geometric mean squared 
displacement are illustrated in Figures 1 and 2. 
As expected from their positive surface charge and reduced stability in physiological medium, the 
motion of HA-liposomes in mucus was strongly hindered, as was evidenced by their highly constrained, 
non-Brownian time-lapse traces (Figure 1). The geometric averaged mean square displacement (MSD) 
of HA-liposomes in four different mucus samples was 1.03 × 10−3 μm2 at a time scale (τ) of 1 s (Fig. 2); 
which was ~1200-fold lower than the MSD of the control PS nanoparticles (1.2 μm2). Non-modified 
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liposomes moved more freely in mucus compared to the HA-modified; with MSD only 20-fold lower 
than PS.  
Interestingly, addition of siRNA to the formulations increased the mobility of particles, as was 
observed for lipoplex formulations, which displayed time-lapse trajectories that spanned markedly 
greater distances. Non-modified lipoplexes moved with a MSD 6.04-fold smaller than PS nanoparticles, 
while PEG/HA-lipoplexes and HA-lipoplexes moved with MSDs only 3.49 and 2.40-fold smaller than PS 
nanoparticles. These findings suggest that the presence of HA alone does not provide a muco-inert 
surface coating of cationic liposomes for efficient diffusion in respiratory mucus, but it is an important 
factor that increases the diffusion of the particles. HA presence together with the addition of siRNA 
allowed the preparation of two efficient mucus-penetrating lipoplexes formulations, the HA-lipoplexes 
and PEG/HA-lipoplexes. Also, modification of lipoplexes with HA allowed the preparation of more 
homogenous vesicles. The distribution of individual MSD for all samples was monomodal, but unlike 
non-modified formulations, HA-lipoplexes and PEG/HA-lipoplexes presented high fractions of 
population that rapidly penetrated respiratory mucus (Figure 3). 
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Figure 1. Representative trajectories of non-modified liposomes, non-modified lipoplexes (+/– ratio of 
2), HA-liposomes, HA-lipoplexes (+/– ratio of 2), PEG-HA-lipoplexes (+/– ratio of 8) and the control 
PEG-polystyrene nanoparticles in airway mucus. Trajectories show 20 s of motion. Scale bar = 7 µm. 
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Figure 2. Ensemble-averaged geometric mean squared displacement (MSD) as a function of timescale 
for non-modified liposomes, non-modified lipoplexes (+/– ratio of 2), HA-liposomes, HA-lipoplexes (+/– 
ratio of 2), PEG-HA-lipoplexes (+/– ratio of 8) and control PEG-polystyrene nanoparticles in airway 
mucus. 
Figure 3. Distribution of individual particle mean squared displacements at a time scale of 1 s for the 
formulations: non-modified liposomes, non-modified lipoplexes (+/– ratio of 2), HA-liposomes, HA-
lipoplexes (+/– ratio of 2), PEG-HA-lipoplexes (+/– ratio of 8) and the control PEG-polystyrene 
nanoparticles.  
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Distribution of lipoplexes in mucus of mouse lung 
 
Liposomes and lipoplexes were administered to CF mice by the intrapulmonary route with a 
microsprayer, and particle distribution in the lungs was observed using fluorescence microscopy. 
Figure 4 shows representative images of the nanoparticles distribution in the lungs. 
Thirty minutes following administration, HA-liposomes were found sparsely distributed in the lung 
airways, with the weakest fluorescence spots compared to the other analyzed samples. Increased 
fluorescence intensity on the lung tissue was observed for the non-modified lipoplexes, while HA-
modified lipoplexes were even more intensely distributed. A different distribution pattern along the 
airway epithelium throughout the lungs was observed for the 10% PEG/HA-lipoplex formulation, for 
which an intense fluorescence was present and uniformly distributed. 
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Figure 4. Representative image of distribution of nanoparticles in the lungs of mice. Pictures were 
taken with a 10x magnification. From left to right: on the first column, images recorded using the filter 
for DAPI staining (cells); second column, images recorded using the filter for rhodamine staining 
(lipoplexes); third column, merged images, showing lungs cells in blue and lipoplexes in red. Non-
modified lipoplexes (+/– ratio of 2), HA-lipoplexes (+/– ratio of 2), PEG-HA-lipoplexes (+/– ratio of 8) 
and HA-liposomes were administered to the lungs using a microsprayer. Animals were euthanized and 
lungs were dissected and flash-frozen 30 minutes after treatment. Scale bars = 100 µm. 
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In vivo luciferase inhibition 
 
The ability of lipoplexes to carry siRNAs into the cell cytoplasm of cancer cells after intratracheal 
administration was evaluated by measuring the inhibition of luciferase activity of A549-luc-bearing 
mice (Figure 5). Treatment with non-modified or HA-modified lipoplexes did not inhibit the lung 
expression of luciferase, contrarily to what was observed previously after intravenous administration 
of HA-lipoplexes. To efficiently deliver siRNA on the cytoplasm of targeted lung cells after 
intrapulmonary administration, lipoplexes have several obstacles to transpose. Their site of deposition 
after administration, their ability to efficiently penetrate the mucus layer while protecting siRNA from 
degradation and their cell targeting properties will influence their success as a siRNA delivery system. 
To further understand which of these steps HA-lipoplexes are not overcoming, a detailed study of each 
of them is needed.  
 
Figure 5. A. Luciferase expression inhibition in lungs of nude athymic mice. Representative image of a 
mouse with lung bioluminescence. B. Mice were inoculated intravenously with 1.5 million A549-luc 
cells. After 4 weeks, animals were treated once a day for 3 days by intrapulmonary administrations of 
NaCl 0.9%, luciferase-siRNA solution, HA-lipoplexes prepared with nonspecific control siRNA, HA-
lipoplexes prepared with luciferase siRNA or non-modified lipoplexes prepared with luciferase siRNA. 
Data represent the mean ± SD (n ≥ 6). 
 
30 
25 
2 0 
10 
5 
15   
Color scale   
min = 5.00e3 
Max = 3.00e4 
Na
Cl
 0
.9
%
lu
c s
iR
NA
 so
lu
tio
n
ct
r s
iR
NA
 H
A-
lip
op
le
xe
s
lu
c s
iR
NA
 li
po
pl
ex
es
lu
c s
iR
NA
 H
A-
lip
op
le
xe
s
0.0
0.5
1.0
1.5
2.0
Lu
ci
fe
ra
se
 e
xp
re
ss
io
n
 in
h
ib
it
io
n
in
 t
u
m
o
r 
ti
ss
u
e
A B 
Travaux expérimentaux – Chapitre 3 
 
158 
 
Discussion 
 
Local administration of siRNA to the lungs is a promising strategy for the treatment of lung diseases. To 
reach the cell cytoplasm where they will enter the pathway that leads to gene silencing, these small 
molecules have to overcome the mucus barrier, the primary defense mechanism of mucosal tissues, 
which traps and removes nano- and micron-sized objects. Mucus is a highly entangled, viscoelastic 
polymer network composed of secreted mucin proteins, cells, bacteria, nutrients, protective factors 
and waste [33]. The percentage of the components in the mucus varies between the different tissues 
and health conditions [13], as do the mesh spacing (~340 nm for human cervicovaginal mucus, ~145 
nm for cystic fribotic sputum, and ~150 nm for human chronic rhinosinusitis, for example) [29, 34, 35], 
but the major components of healthy human mucus are basically water (95%) and mucins (2%) [36].  
To be able to cross these mucosal barriers, nanoparticles have to be small enough to pass through the 
mucus mesh spaces, and possess appropriate surface characteristics to avoid interaction with mucins. 
Surface-modified nanoparticles that undergo extensive interaction with negatively charged mucins and 
are able to cross the mucus barrier have been studied [37, 38]. For example, coating solid lipid 
nanoparticles (SLN) with poloxamer (Pluronic) increased their movement in cystic fibrosis sputum by 5 
and 100 folds compared to tween- and PVA-coated SLNs, allowing efficient lung mucus penetration 
[39]. Pluronic-coated liposomes were able to penetrate the mucus layers to reach the intestinal 
epithelial surface and deliver encapsulated active substances [41, 42]. Imidazole-modified chitosan and 
trimethyl chitosan nanoparticles were also able to overpass the gastric mucus layer and deliver siRNA 
to the gastrointestinal mucosa [43]. Notably, polymeric PEGylated nanoparticles have shown 
significant progress as mucus-penetrating nucleotide delivery systems [44]. Coating polymeric PSA 
[45], PLGA [46], PCL [46] and latex [31] nanoparticles with PEG minimized protein adhesion at 
biomaterial surfaces. The hydrated PEG layer enthalpically resists the release of water molecules and 
entropically resists compression [47], thereby drastically increasing the ability of these nanoparticles to 
move through the mucus mesh.  
The use of HA as a hydrophilic coating material has also been explored for the carrying of cargo 
through the mucus layer [48]. Modification of siRNA carriers with HA has been used for targeting and 
controlling particle surface properties [23-26]. In our previous work, we describe the structure of an 
optimized HA-lipoplex formulation, and its in vitro and in vivo applications for the targeting of CD44-
overexpressing cells. Here, we investigate the impact of HA on lipoplexes fate in the lungs, especially 
regarding interaction with mucus, and the effect of PEG incorporation to improve this properties. To 
do so, we prepared HA-lipoplexes, notably negatively charged, and by modifying their formulation with 
PEG and different ratios of siRNA, we obtained 10% PEG/HA-lipoplexes with +/– ratio of 8 that had a 
global surface charge of –1.4 mV.  
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To visualize the diffusion of lipoplexes in human mucus, we labeled liposomes and lipoplexes with a 
fluorescent probe and quantified the translational motion of hundreds of particles in mucus freshly 
collected from patients using multiple particle tracking (MPT). HA-liposomes were almost completely 
immobilized in the mucus, which correlated with the results obtained for stability studies in 
physiological medium (Supplementary information, Chapter 2). The MSD of non-modified liposomes 
was slightly lower than that of the non-modified lipoplexes, implying that the addition of siRNA 
negative charges reduced adhesive (hydrophobic, electrostatic) interactions with mucus. Contrary to 
what could be expected [35], PEG-shielding was not fundamental for effective lipoplex diffusion in 
respiratory mucus. Rapid diffusion was observed for PEG/HA-lipoplexes as well as HA-lipoplexes, 
whose mean MSD values were very close to each other and to that of the mucus-penetrating PEG-
polystyrene control nanoparticles [31]. This indicated that the presence of HA in the lipoplexes 
structure was able to reduce interactions with the mucus components. The modification of lipoplexes 
with HA also decreased vesicles heterogeneity, and allowed higher fractions of population to rapidly 
penetrate respiratory mucus. We hypothesize that, as for muco-inert viruses, that have high density of 
both cationic and anionic surface coating [37, 49], the presence of both densely negative siRNA 
molecules and HA moieties and positive DE charges on the surface of the HA-lipoplexes, together with 
the hydrophilic character of HA, are responsible for preventing adhesion to mucus constituents. It is 
important to note that particle movement in the mucus depends on multiple factors, and not only on 
their mean diameter and surface charge. Exact threshold of hydrophilic coverage needed to achieve 
mucoresistance depends on the specific system of interest [33].  
We then compared the distribution of the particles in the lungs of CF-1 mice after intrapulmonary 
administration. Increasing amount of particles were observed in the lungs after administration of HA-
liposomes < non-modified lipoplexes < HA-modified lipoplexes < 10% PEG/HA-lipoplexes, in agreement 
with the observations of their movement in lung mucus, confirming the importance of siRNA and HA 
presence in particle mobility. Instead of defined fluorescent regions, as observed for the other 
formulations, lungs of mice treated with PEGylated HA-lipoplexes showed intense fluorescence all over 
the tissue, evidencing that the in vivo mucus penetration of these particles was indeed more efficient 
compared to the non-PEGylated HA-lipoplexes. Thus, the similarity of the mucus-penetrating 
properties of HA-lipoplexes and PEG/HA-lipoplexes observed in MPT experiments was not confirmed in 
vivo, and the larger vesicle heterogeneity of the PEG/HA-lipoplexes may be the cause of this 
difference. PEG/HA lipoplexes had the highest PdI index of all preparations (0.340). We can thus 
assume that although there is a part of this population that is not efficiently penetrating through the 
mucus mesh, the part that is actually moving in the mucus is able to travel greater distances, as 
evidenced in vivo and also on the tracked trajectories image. Dense PEG grafting on the lipoplexes 
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surface have been previously shown to effectively shield them against adhesive hydrophobic and 
electrostatic interactions and minimized protein binding [29]. 
To reach lung cells after administration in the respiratory system, nanoparticles have several obstacles 
to transpose, including coughing, dissolution, mucociliarly clearance and phagocytosis by macrophages 
[50]. Already their site of deposition in the lungs will depend on the entry pathway. Considering that 
our HA-modified lipoplexes were administered directly to the lungs, we expect that their deposition 
extends from the bronchial to the alveolar region. Since they had reasonable mucus penetrating 
properties, as observed by MPT experiments, a reasonable mobility could also be expected for the 
alveolar lining fluid. It is possible, though, that their movement wasn’t fast enough to reach the cells 
before being cleared. Also, it is possible that while crossing the mucus layer lipoplexes were removed 
by mucociliary clearance, especially in the case of HA-(non-PEGylated) lipoplexes. Although in vitro [51-
56] and in vivo [57, 58] evidences suggest that cell-to-cell transfer of RNAs occurs, particles reaching 
the lung tissue through the intratracheal route will first encounter cells from the respiratory 
epithelium. In our tumor model, in which the lung carcinoma formation was observed after 
intravenous and not intratracheal administration of A549 cells, it is expected that the metastatic tumor 
is localized preferentially in the endothelial region of the lungs. Therefore, the fact that the possible 
main localization of the lipoplexes that reach the tissue after mucus penetration does not coincide 
with the tumor localization, is also a reason that could explain why gene silencing was not observed.  
 
Conclusion and perspectives 
 
HA-modified siRNA lipoplexes showed a promising mucus penetrating ability. The presence of HA and 
siRNA on the vesicles structure were equally important to prevent particle hindrance in the mucus and 
increase particle homogeneity and stability. Modification of lipoplexes with both HA and PEG 
increased showed the best results in improving particle diffusion in airway mucus, as confirmed in the 
lung distribution study using fluorescently-labeled lipoplexes. Further investigation regarding the 
macromolecular structure and siRNA stability could shine a light on the formation process of these 
lipoplexes. The investigation of the in vivo gene expression inhibition by this formulation would also be 
interesting, since PEG/HA-lipoplexes showed good potential as carriers for localized delivery of siRNA 
to the lungs.  
 
  
Travaux expérimentaux – Chapitre 3 
 
161 
 
References 
 
1. Aagaard, L. and J.J. Rossi, RNAi therapeutics: Principles, prospects and challenges. Adv Drug 
Deliv Rev, 2007. 59(2-3): p. 75-86. 
2. Nascimento, T., H. Hillaireau, and E. Fattal, Nanoscale particles for lung delivery of siRNA. 
Journal of drug delivery science and technology, 2012. 22(1): p. 99-108. 
3. Zhang, X., et al., Cucumber mosaic virus-encoded 2b suppressor inhibits Arabidopsis 
Argonaute1 cleavage activity to counter plant defense. Genes Dev, 2006. 20(23): p. 3255-68. 
4. Siner, J.M., et al., VEGF-induced heme oxygenase-1 confers cytoprotection from lethal 
hyperoxia in vivo. The FASEB Journal, 2007. 21(7): p. 1422-1432. 
5. Huang, H., C. Lee, and B. Chiang, Small interfering RNA against interleukin-5 decreases airway 
eosinophilia and hyper-responsiveness. Gene therapy, 2008. 15(9): p. 660-667. 
6. Perl, M., et al., Silencing of Fas, but not caspase-8, in lung epithelial cells ameliorates 
pulmonary apoptosis, inflammation, and neutrophil influx after hemorrhagic shock and sepsis. 
The American journal of pathology, 2005. 167(6): p. 1545-1559. 
7. Lomas-Neira, J.L., et al., In vivo gene silencing (with siRNA) of pulmonary expression of MIP-2 
versus KC results in divergent effects on hemorrhage-induced, neutrophil-mediated septic acute 
lung injury. Journal of leukocyte biology, 2005. 77(6): p. 846-853. 
8. Moschos, S.A., et al., Targeting the lung using siRNA and antisense based oligonucleotides. 
Current pharmaceutical design, 2008. 14(34): p. 3620-3627. 
9. Koli, U., et al., siRNA-Based Therapies for Pulmonary Diseases. Journal of Biomedical 
Nanotechnology, 2014. 10(9): p. 1953-1997. 
10. Vicentini, F., et al., Delivery Systems and Local Administration Routes for Therapeutic siRNA. 
Pharmaceutical Research, 2013. 30(4): p. 915-931. 
11. Gautam, A., J.C. Waldrep, and C.L. Densmore, Aerosol gene therapy. Mol Biotechnol, 2003. 
23(1): p. 51-60. 
12. Griesenbach, U., et al., In vivo imaging of gene transfer to the respiratory tract. Biomaterials, 
2008. 29(10): p. 1533-40. 
13. Sanders, N., et al., Extracellular barriers in respiratory gene therapy. Advanced Drug Delivery 
Reviews, 2009. 61(2): p. 115-127. 
14. Koshkina, N.V., et al., Biodistribution and pharmacokinetics of aerosol and intravenously 
administered DNAâ€“polyethyleneimine complexes: optimization of pulmonary delivery and 
retention. Molecular therapy, 2003. 8(2): p. 249-254. 
15. Sham, J.O.H., et al., Formulation and characterization of spray-dried powders containing 
nanoparticles for aerosol delivery to the lung. International journal of pharmaceutics, 2004. 
269(2): p. 457-467. 
16. Patton, J.S., Mechanisms of macromolecule absorption by the lungs. Advanced Drug Delivery 
Reviews, 1996. 19(1): p. 3-36. 
17. Soutschek, J., et al., Therapeutic silencing of an endogenous gene by systemic administration of 
modified siRNAs. Nature, 2004. 432(7014): p. 173-8. 
18. Braasch, D.A., et al., Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg 
Med Chem Lett, 2004. 14(5): p. 1139-43. 
19. Dykxhoorn, D.M. and J. Lieberman, Knocking down disease with siRNAs. Cell, 2006. 126(2): p. 
231-5. 
20. Fattal, E. and G. Barratt, Nanotechnologies and controlled release systems for the delivery of 
antisense oligonucleotides and small interfering RNA. British Journal of Pharmacology, 2009. 
157(2): p. 179-194. 
21. Arpicco, S., et al., Synthesis, characterization and transfection activity of new saturated and 
unsaturated cationic lipids. Farmaco, 2004. 59(11): p. 869-78. 
22. Pardue, E.L., S. Ibrahim, and A. Ramamurthi, Role of hyaluronan in angiogenesis and its utility 
to angiogenic tissue engineering. Organogenesis, 2008. 4(4): p. 203-214. 
Travaux expérimentaux – Chapitre 3 
 
162 
 
23. Peer, D. and R. Margalit, Tumor-targeted hyaluronan nanoliposomes increase the antitumor 
activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. 
Neoplasia, 2004. 6(4): p. 343-53. 
24. Peer, D. and R. Margalit, Loading mitomycin C inside long circulating hyaluronan targeted 
nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer, 2004. 
108(5): p. 780-9. 
25. Surace, C., et al., Lipoplexes Targeting the CD44 Hyaluronic Acid Receptor for Efficient 
Transfection of Breast Cancer Cells. Molecular Pharmaceutics, 2009. 6(4): p. 1062-1073. 
26. Wojcicki, A.D., et al., Hyaluronic Acid-Bearing Lipoplexes: Physico-Chemical Characterization 
And In Vitro Targeting Of The CD44 Receptor. Journal of Controlled Release, 2012. 
27. Batzri, S. and E.D. Korn, Single bilayer liposomes prepared without sonication. Biochim. 
Biophys. Acta, 1973. 298: p. 1015-1019. 
28. Taetz, S., et al., Hyaluronic Acid-Modified DOTAP/DOPE Liposomes for the Targeted Delivery of 
Anti-Telomerase siRNA to CD44-Expressing Lung Cancer Cells. Oligonucleotides, 2009. 19(2): p. 
103-115. 
29. Schuster, B.S., et al., Nanoparticle diffusion in respiratory mucus from humans without lung 
disease. Biomaterials, 2013. 34(13): p. 3439-3446. 
30. Suk, J.S., et al., Lung gene therapy with highly compacted DNA nanoparticles that overcome the 
mucus barrier. Journal of Controlled Release, 2014. 178: p. 8-17. 
31. Lai, S.K., et al., Rapid transport of large polymeric nanoparticles in fresh undiluted human 
mucus. Proceedings of the National Academy of Sciences, 2007. 104(5): p. 1482-1487. 
32. Suk, J.S., et al., The penetration of fresh undiluted sputum expectorated by cystic fibrosis 
patients by non-adhesive polymer nanoparticles. Biomaterials, 2009. 30(13): p. 2591-2597. 
33. Wang, Y.Y., et al., Addressing the PEG Mucoadhesivity Paradox to Engineer Nanoparticles that 
“Slip” through the Human Mucus Barrier. Angewandte Chemie International Edition, 2008. 
47(50): p. 9726-9729. 
34. Lai, S.K., et al., Nanoparticles reveal that human cervicovaginal mucus is riddled with pores 
larger than viruses. Proceedings of the National Academy of Sciences, 2010. 107(2): p. 598-
603. 
35. Yu, T., et al., Liposome-based mucus-penetrating particles (MPP) for mucosal theranostics: 
Demonstration of diamagnetic chemical exchange saturation transfer (diaCEST) magnetic 
resonance imaging (MRI). Nanomedicine: Nanotechnology, Biology and Medicine, 2014. 11(2): 
p. 401-405 
36. Bansil, R. and B.S. Turner, Mucin structure, aggregation, physiological functions and biomedical 
applications. Current Opinion in Colloid & Interface Science, 2006. 11(2): p. 164-170. 
37. Lai, S.K., Y.Y. Wang, and J. Hanes, Mucus-penetrating nanoparticles for drug and gene delivery 
to mucosal tissues. Advanced drug delivery reviews, 2009. 61(2): p. 158-171. 
38. Lam, J.K.-W., W. Liang, and H.-K. Chan, Pulmonary delivery of therapeutic siRNA. Advanced 
Drug Delivery Reviews, 2012. 64(1): p. 1-15. 
39. Nafee, N., et al., Antibiotic-free nanotherapeutics: Ultra-small, mucus-penetrating solid lipid 
nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum 
sensing inhibitors. Journal of Controlled Release, 2014. 192(0): p. 131-140. 
41. Chen, D., et al., Comparative study of Pluronic< sup>®</sup> F127-modified liposomes and 
chitosan-modified liposomes for mucus penetration and oral absorption of cyclosporine A in 
rats. International Journal of Pharmaceutics, 2013. 449(1): p. 1-9. 
42. Li, X., et al., Novel mucus-penetrating liposomes as a potential oral drug delivery system: 
preparation, in vitro characterization, and enhanced cellular uptake. International Journal of 
Nanomedicine, 2011. 6: p. 3151. 
43. Sadio, A., et al., Modified-Chitosan/siRNA Nanoparticles Downregulate Cellular CDX2 
Expression and Cross the Gastric Mucus Barrier. PloS one, 2014. 9(6): p. e99449. 
44. de la Fuente, M., B. Seijo, and M.J. Alonso, Novel hyaluronic acid-chitosan nanoparticles for 
ocular gene therapy. Invest Ophthalmol Vis Sci, 2008. 49(5): p. 2016-24. 
Travaux expérimentaux – Chapitre 3 
 
163 
 
45. Tang, B.C., et al., Biodegradable polymer nanoparticles that rapidly penetrate the human 
mucus barrier. Proceedings of the National Academy of Sciences, 2009. 106(46): p. 19268-
19273. 
46. Yang, M., et al., Biodegradable nanoparticles composed entirely of safe materials that rapidly 
penetrate human mucus. Angewandte Chemie International Edition, 2011. 50(11): p. 2597-
2600. 
47. Valentine, M.T., et al., Colloid Surface Chemistry Critically Affects Multiple Particle Tracking 
Measurements of Biomaterials. Biophysical Journal, 2004. 86(6): p. 4004-4014. 
48. Sandri, G., et al., Mucoadhesive and penetration enhancement properties of three grades of 
hyaluronic acid using porcine buccal and vaginal tissue, Caco‐2 cell lines, and rat jejunum. 
Journal of Pharmacy and Pharmacology, 2004. 56(9): p. 1083-1090. 
49. Cone, R.A., Barrier properties of mucus. Advanced Drug Delivery Reviews, 2009. 61(2): p. 75-
85. 
50. Carafa, M., et al., Novel Concept in Pulmonary Delivery. In Chronic Obstructive Pulmonary 
Disease - Current Concepts and Practice, Chapter 16, InTech, 2012. 484 pages.  
51. Dunoyer, P., et al., Small RNA duplexes function as mobile silencing signals between plant cells. 
Science, 2010. 328(5980): p. 912-916. 
52. Molnar, A., et al., Small silencing RNAs in plants are mobile and direct epigenetic modification 
in recipient cells. Science, 2010. 328(5980): p. 872-875. 
53. Valiunas, V., et al., Connexin-specific cell-to-cell transfer of short interfering RNA by gap 
junctions. The Journal of physiology, 2005. 568(2): p. 459-468. 
54. Hosoda, T., et al., Human cardiac stem cell differentiation is regulated by a mircrine 
mechanism. Circulation, 2011. 123(12): p. 1287-1296. 
55. Lim, P.K., et al., Gap Junction–Mediated Import of MicroRNA from Bone Marrow Stromal Cells 
Can Elicit Cell Cycle Quiescence in Breast Cancer Cells. Cancer Research, 2011. 71(5): p. 1550-
1560. 
56. Katakowski, M., et al., Functional microRNA is transferred between glioma cells. Cancer 
Research, 2010. 70(21): p. 8259-8263. 
57. Pan, Q., et al., Hepatic cell-to-cell transmission of small silencing RNA can extend the 
therapeutic reach of RNA interference (RNAi). Gut, 2012. 61(9), p. 1330-1339. 
58. McCaskill, J., et al., Efficient biodistribution and gene silencing in the lung epithelium via 
intravenous liposomal delivery of siRNA. Molecular Therapy-Nucleic Acids, 2013. 2(6): p. e96. 
 
Discussion générale 
 
164 
 
  
 
 
 
 
 
 
  
Discussion générale 
 
165 
 
 
 
 
 
 
 
 
 
 
Discussion générale 
  
Discussion générale 
 
166 
 
 
  
Discussion générale 
 
167 
 
General discussion 
 
Context 
 
The increasing knowledge of the molecular mechanisms related to the pathogenesis of cancers has 
allowed the development of new strategies to improve the treatment of these diseases. Due to their 
high selectivity and efficiency, much effort has been made on using siRNAs as a therapeutic tool in the 
treatment of cancer and other severe diseases. These small molecules can be designed to specifically 
interfere with the production of mRNA and consequently with the translation of proteins. Presently, 
specific delivery of siRNA molecules to target cells remains the major handicap for the use of these 
small hydrophilic molecules in cancer therapy, since they lack stability in serum and targeting 
properties. Various delivery systems have been developed to overcome these obstacles and to 
promote an efficient delivery of siRNA to diseased cells. These nanocarriers are designed to protect 
siRNA from degradation, access to the tumor cells and deliver siRNA molecules to the cytoplasm. They 
are broadly divided into two categories, viral and non-viral. In part due to the potential toxicities 
associated with viral vectors, non-viral vectors have become increasingly popular alternatives. Non-
viral siRNA vectors typically involve complexing siRNA with a positively charged vector (e.g., cationic 
cell penetrating peptides, cationic polymers and dendrimers, and cationic lipids); conjugating siRNA 
with small molecules (e.g., cholesterol, bile acids, and lipids), polymers, antibodies, and RNAs; and 
encapsulating siRNA in nanoparticulate formulations[1].  
A high molecular weight HA-modified lipoplex formulation has been developed in our laboratory which 
allowed the selective in vitro delivery of DNA plasmids to CD44-overexpressing MDA breast cancer 
cells[2] and A549-luc cells[3]. These particles were prepared by conjugating DOPE lipid molecules to 
high molecular weight HA, followed by the preparation of lipoplexes by the incubation with DNA. The 
formulation strategy of these particles relies on the overexpression of the CD44 receptor in various 
cancer cells, particularly metastasis-developing primary tumors. These tumors include a larger fraction 
of cancer stem cells, which are rare cells with indefinite proliferative potential that dictate the 
formation and growth of tumors[4] and present a CD44+ overexpressing phenotype[5, 6]. The 
constitutive binding between HA and CD44 would give HA-lipoplexes the ability to enter the cells via 
the interaction with these receptors. Also, the modification of the lipoplexes surface with the long 
hydrophilic chains of HA would promote particle stealth properties, increasing plasmatic circulation 
time and passive targeting to the tumor region by the EPR effect. 
In this thesis, the hypotheses regarding the applicability of the lipoplex system to the targeted delivery 
of siRNA molecules to CD44-overexpressing cells were tested. We first studied the formation of siRNA 
lipoplexes and analyzed the influence of the HA-modification on the particle structure combining 
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particle diameter and surface charge analysis, capillary electrophoresis, cryo-TEM microscopy, surface 
plasmon resonance and small angle X-ray scattering techniques. The effects of the modification of 
lipoplexes with HA on cell internalization were then evaluated. The cellular viability, uptake kinetics, 
lipoplexes cellular localization and in vitro gene expression inhibition were studied using a luciferase-
expressing A549 cell model. Then, the ability of the lipoplexes to carry intact siRNA to the cytoplasm of 
cancer cells in vivo was studied. For this, an A549 luciferase-expressing metastatic cancer model was 
developed. Bioluminescence signals from the lungs of animals before and after treatment were 
compared to evaluate expression inhibition. At last, we studied the diffusion of the HA-modified siRNA 
lipoplexes in human airway mucus, in order to evaluate the viability of administering these particles by 
the pulmonary route to treat lung diseases. The diffusion of lipoplexes was studied using the multiple 
particle tracking (MPT) technique, and the distribution of HA-modified siRNA lipoplexes in the mouse 
lung after pulmonary administration was analyzed.  
 
The HA-DOPE conjugate 
 
In order to insert HA on liposome structure, we used a conjugate of HA and DOPE lipid molecules, 
which act as anchors of HA on the bilayer structure. The choice of high molecular weight HA for the 
preparation of the conjugate was based on literature reports that indicate that these large molecules, 
being ubiquitous, do not induce expression of genes involved in proliferation or inflammation[7] and 
counteract proangiogenic effects of the HA oligomers[8]. The HA-DOPE conjugate preparation was 
based on a reaction described by Yerushalmi and Margalit[9]. In this reaction, the carboxylic groups of 
hyaluronic acid are activated to react with the amine groups from the DOPE lipid molecules (Figure 1). 
The efficiency of the conjugation reaction was calculated by the Stewart assay [32] as 1.1 + 0.5%, 
meaning that each HA molecule (composed of 6320 D-glucuronic acid and N-acetyl-D-glucosamine 
dimers) had 250 molecules of DOPE attached to its structure. 
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Hyaluronic acid 
 
 
DOPE 
Figure 1. Structures of hyaluronic acid (HA) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
(DOPE). 
 
Preparation and structure of HA-modified liposomes and lipoplexes 
 
The cationic lipid [2-(2-3didodecyloxypropyl)hydroxyethyl]ammonium bromide (DE, Figure 2), which 
has demonstrated improved transfection efficiency in different cell lines[10], was used for the 
preparation of the cationic liposomes.  
DE 
Figure 2. Structure of [2-(2-3didodecyloxypropyl)hydroxyethyl]ammonium bromide (DE) lipid. 
 
DOPE was used as helper lipid on account of its well documented ability to adopt an inverted 
hexagonal phase and attach itself to and rapidly fuse with anionic membranes, resulting in the release 
of the liposome content into the cytoplasm[11-13], and to destabilize the endosomal membrane at 
acidic pH and assist liposomes in delivering their contents into the cytoplasm[14].  
The obtained liposomes presented a variable polydispersity index (PdI) as a consequence of using the 
ethanol injection for their preparation without a subsequent size calibration using extrusion. As 
observed by Cryo-TEM microscopy, the population of liposomes was composed mainly, but not 
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exclusively, of unilamellar vesicles. The presence of HA on the surface of these particles was indicated 
by the increase of liposomes diameter proportionally to the amount of HA added to the formulation, 
from around 90 for non-modified liposomes to around 140 nm for liposomes containing 15% (w/w) 
HA-DOPE. Zeta potential measurements confirmed the presence of HA dimers on the surface of 
liposomes, observed as a proportional reduction from +55 mV to +30 mV for non-modified to 
liposomes containing 15% HA-DOPE.  
Previous studies by Wojcicki et al.[3] using differential scanning calorimetry (DSC) had already revealed 
a different behavior between unconjugated HA and HA conjugated to DOPE upon interaction with the 
liposomes membrane. The analysis of DOPE demonstrated that the endotherm of gel to liquid crystal 
phase transition shifted from −10.30 °C with water or unconjugated HA to −8.97 °C with HA-DOPE 
(Figure 3). This suggested that DOPE covalently linked to HA interacts with DOPE in the liposomes, 
being therefore able to play the role of anchor in the lipid membrane.  
Figure 3. Study of the transition temperature from gel to liquid crystalline phase of DOPE hydrated by 
different solutions (HA-DOPE, unconjugated HA and water) by differential scanning calorimetry. The 
first peak of each thermogram corresponds to the transition temperature (Tm) of hydrated DOPE and 
the second to the water melting. The three curves correspond (from top to bottom) to DOPE film 
hydrated by an aqueous solution of HA-DOPE 10%, DOPE film hydrated by an aqueous solution of 
unconjugated HA 10% and to DOPE film hydrated by water. Adapted from Wojcicki et al.[15]. 
 
We searched for further evidences of the interaction between the HA-DOPE conjugate and the lipid 
bilayers in our studies using SAXS. Analysis of liposomes modified with different concentrations of the 
conjugate revealed that its presence causes the reorganization of unilamellar vesicles into 
oligolamellar ones. Between 10 and 15% HA-DOPE, an increase in hydration of the lamellar phase was 
observed, indicating a more important steric repulsion between bilayers caused by the presence of HA 
molecules. Because multiple DOPE molecules are linked to one chain of HA, conjugate insertion by 
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multiple lipid anchors favors the presence of HA between lipids bilayers of the liposomes. The 
structures obtained are therefore different from the previously suggested brush or mushroom 
conformations [16]. 
The complexation with siRNA for the formation of lipoplexes originated vesicles with, as for the HA 
modification, increasing diameters and decreasing surface charges. The rearrangement of lipid vesicles 
resulted in the formation of a more homogeneous population of oligolamellar structures of around 
230 nm and –40 mV for lipoplexes of +/– charge ratios of 1 and 2. This was evidenced by Cryo-TEM 
microscopy and SAXS analysis, and is in agreement with the multiple small unilamellar vesicles fusion 
observed for DNA lipoplexes [17-19]. This is a favorable characteristic when siRNA stability is 
considered, since the packing of the bilayers around siRNA molecules represent a barrier from 
degradation of plasmatic RNAses. This lipoplex structure could furthermore increase lipoplex 
efficiency, since as it has been described in the literature that MLV lipoplexes are generally better 
transfecting agents than SUV lipoplexes [20-22]. It was evidenced by ITC experiments that lipoplexes 
contained no more lipid than the necessary for a complete neutralization of siRNA charges. Therefore, 
the maximal +/– ratio possible for complexation was 1. At this siRNA concentration, the maximal 
capacity of the lipids for siRNA binding was reached. Revealed by the end point of the ITC titration, this 
value is in agreement with the maximal possible final +/– ratio obtained in the association studies 
using radiolabeled siRNA for liposome binding. The complete association of siRNA to liposomes at +/– 
ratio 2 was also visualized by gel electrophoresis. As shown in Figure 4, complete siRNA association 
was confirmed for lipoplexes diluted in water and in cell culture medium. 
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Figure 4. Agarose gel electrophoresis of siRNA lipoplexes at +/– ratios 134 and 2. Lipoplexes were 
prepared and diluted in water or cell culture medium before analysis. 1. Free siRNA correspondent to 
the +/– ratio 2 concentration; 2. Lipoplexes 0% HA-DOPE +/– ratio 134 diluted in cell culture medium; 
3. Lipoplexes 0% HA-DOPE +/– ratio 134 diluted in water; 4. Lipoplexes 0% HA-DOPE +/– ratio 2 diluted 
in cell culture medium; 5. Lipoplexes 0% HA-DOPE +/– ratio 2 diluted in water; 6. Lipoplexes 10% HA-
DOPE +/– ratio 134 diluted in cell culture medium; 7. Lipoplexes 10% HA-DOPE +/– ratio 134 diluted 
water; 8. Lipoplexes 10% HA-DOPE +/– ratio 2 diluted in cell culture medium; 9. Lipoplexes 10% HA-
DOPE +/– ratio 2 diluted in water; 10. Free siRNA correspondent to the +/– ratio 134 concentration 
diluted in cell culture medium; 11. Free siRNA correspondent to the +/– ratio 2 concentration diluted 
in cell culture medium; 12. Free siRNA correspondent to the +/– ratio 134 concentration diluted in 
water. 
 
Based on the liposome concentration (estimated from lipid concentration and liposome size) and 
siRNA loading (13.84%), each lipoplex at +/– ratio 2 would have approximately 1054 siRNA molecules. 
This estimation considers that all vesicles are unilamelar. In the case of our oligolamellar HA-modified 
lipoplexes, the cargo capacity is more important since vesicles have a much higher lipid density. This is 
comparable to highly charged and efficient siRNA carriers described in the literature[23]. As far as HA 
is concerned, the concentration of the polymer in the liposome suspension (that has a conjugate 
association of 71%) is 0.14 mg/ml, corresponding to 5.9 HA molecules/liposome. When siRNA is added 
at +/– ratio 2, charge competition with strongly interacting siRNA molecules and steric hindrance 
caused by the bilayers rearrangement decrease the HA-DOPE concentration to 37%, that represents 
0.024 mg/ml and 2.21 HA molecules/lipoplex. Despite the fact that this concentration is smaller than 
the ones described by Quattal et al.[16] and Landesman-Milo et al.[24], for example, it was proven 
effective for CD44 binding using surface plasmon resonance experiments and in vitro binding and 
internalization and gene expression inhibition experiments.  
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In vitro activity of lipoplexes 
 
The A549-luc human lung carcinoma cell line was used to evaluate the biological activity of HA-
lipoplexes. This cell line is commonly used as a CD44-targeting cell model because of the high and 
homogeneous CD44 membrane receptor expression, as we confirmed by flow cytometry. The 
luminescence analysis revealed, on the other hand, that these cells did not homogenously express 
luciferase. Therefore, a selection protocol using gentamicine (G418, Geneticin®, Thermo Fisher 
Scientific Inc., USA) was optimized, and cells were treated with 75 µg/ml for 12 days before each 
experiment. 
A549-luc viability studies showed that the modification by hyaluronic acid did not change lipoplex 
toxicity, as expected due to the well know biocompatibility of HA[25]. The low cytotoxicity observed 
after incubation with high concentrations of lipoplexes regardless of the +/– ratio suggested that this 
effect was not related to the changes in particle surface charge, but probably to the type and amount 
of lipids in the formulation[26, 27]. Nevertheless, the uptake and gene silencing inhibition of the 
lipoplexes was not compromised. Flow cytometry experiments showed a progressive uptake, with 
lipoplexes containing the HA-DOPE conjugate being taken up by the cells at a higher rate when 
compared to the plain lipoplexes. This difference was clearly observed for the ratio +/– 134. Lipoplexes 
at +/– 2 were internalized more rapidly compared to all other analyzed particles, and a plateau of the 
uptake of these lipoplexes was reached after 2 h. Confocal laser microscopy confirmed that the 
lipoplexes were localized at the cell cytoplasm, as were siRNA molecules.  
After identifying the cellular localization of the siRNA, it was important to check if these molecules 
were intact and able to bind RISC and form the RNA-induced silencing complex that would lead to gene 
silencing. With this aim, we tested the lipoplexes luminescence inhibition using a luciferase-targeted 
siRNA. Previous studies of Surace et al.[2] and Wojcicki et al.[15] demonstrated that 10% HA-DOPE 
(w/w) is the optimal concentration for transfection of CD44-overexpressing MDA-MB231 and A549 
cells with plasmid DNA lipoplexes. We performed a gene expression inhibition test with lipoplexes at 
+/– ratio 2 modified with 5, 10 and 15% of conjugate, in which we confirmed this result for the siRNA 
lipoplexes formulation (Figure 5). 
Specific inhibition by the luciferase-siRNA compared to the control siRNA was observed, which 
validated the model chosen. Higher luciferase expression was observed for lipoplexes modified by HA, 
at both +/– ratios 134 and 2, in agreement with the uptake experiments, being the highest luciferase 
expression observed after treatment with HA-lipoplexes at +/– ratio 2.  
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Figure 5. Luciferase expression inhibition in A549-luc cells by siRNA lipoplexes at +/– ratio 2 prepared 
with 0, 5, 10 or 15% HA-DOPE conjugate and scramble (scr) or luciferase-siRNA (luc). Cells were 
incubated with lipoplexes for 48 h before luminescence measurements (n=8). 
 
In vivo activity of lipoplexes 
 
The results obtained using the A549-luc model in vitro demonstrated the relevance of the siRNA 
delivering system that we developed. The increased internalization of the lipoplexes, cytoplasm 
localization and luciferase inhibition results encouraged the evaluation of the in vivo activity of the HA-
lipoplexes. It was our interest to use a model that could mimic as best as possible the biological 
conditions of a tumor, and with this in mind, we developed a metastatic lung tumor model using the 
A549-luc cell line. Tumor-bearing mice were treated for 3 consecutive days with HA-lipoplexes +/– 
ratio 2, and luminescence signals were quantified using the In Vivo Image System (IVIS), an instrument 
that allows the measurement of the bioluminescence in living animals. This feature brings the 
important advantage of sensibly reducing the number of animals and following the behavior on the 
same individual at any time point. Images of the thoracic region of each animal before and after 
treatment were compared. The effect of HA-lipoplexes on luciferase expression inhibition, although 
modest, was clearly demonstrated in comparison to the controls. At this point we were interested in 
observing the effect of the modification of lipoplexes with HA in the lung distribution after intravenous 
administration of the lipoplexes. For this, we treated healthy CF-1 mice with fluorescently labeled 
lipoplexes, and analyzed by microscopy the lung distribution of both plain and HA-lipoplexes at +/– 
ratio 2. A clear difference in tissue distribution was observed between these two types of particles, 
which evidenced the advantage of the HA modification of the lipoplexes. While a more intense and 
homogenous lipoplex-related fluorescence was found in the airway tissue of animals treated with HA-
lipoplexes, only weak fluorescence spots were observed for the non-modified lipoplexes. This clearly 
showed that the presence of HA on the surface of lipoplexes improved the distribution in the lung 
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tissue. This result correlates with the siRNA expression inhibition measured by the decrease in 
luminescence and in the expression of luciferase mRNA in the lungs. They indicate that after 
intravenous administration, the increase in hydrophilicity of lipoplexes promoted by their modification 
with HA favors a prolonged circulation time and accumulation in the lungs, where lipoplexes can 
interact with tumor CD44 receptors. Together, these results demonstrate the ability of HA-lipoplexes 
of carrying siRNA in vivo to tumor cells, being therefore relevant candidates for CD44-targeted siRNA 
therapy. 
 
Mucus diffusion of lipoplexes after endotracheal administration 
 
This last part of my thesis was motivated by many studies that discuss the possibility of using HA as an 
alternative to PEG[27-30] as biocompatible hydrophilic coating of nanoparticles, and the coating of 
particles with hydrophilic polymers (e.g., PEG, pluronic) as a strategy to develop mucus-penetrating 
particles (MPP). We were interested in evaluating the viability of administering our lipoplexes through 
the endotracheal route for the eventual targeting of CD44 overexpressing lung cancerous cells. The 
direct administration of lipoplexes to the lungs could allow a higher efficiency of the treatment with 
possibly less amount of particles and siRNA being administered. With this aim, we studied the diffusion 
of lipoplexes in mucus using the multiple particle tracking (MPT) technique. A PEGylated formulation 
of the lipoplexes, PEG/HA-lipoplexes (10% HA, +/– ratio 8), with a neutral surface charge and therefore 
theoretically more prone to move through the mucus mesh, was also studied. Both HA-lipoplexes (10% 
HA-DOPE, +/– 2) and PEG/HA-lipoplexes (10% HA, +/– 8) presented a rapid diffusion in the mucus 
compared to the non-modified particles, which indicated that the presence of HA on lipoplex surface 
reduced the interactions with mucus components. The analysis of the distribution of these lipoplexes 
in the mouse lung after pulmonary administration showed that HA-lipoplexes had a larger distribution 
than the plain lipoplexes, with defined fluorescent regions being observed, while PEG/HA-lipoplexes 
were intensely distributed in a homogenous pattern throughout the lung tissue. Contrarily to the 
results after intravenous administration, a luciferase expression inhibition was not observed after the 
in vivo administration of HA-lipoplexes through the endotracheal route. We hypothesized several 
explanations that could be likely related to this observation, including particle clearance, phagocytosis 
by mucus macrophages and the impossibility to reach endothelial lungs cells, since the distribution of 
airway-instilled lipoplex may involve different regions of the lung than that of intravenously injected 
material [31]. Nevertheless, we believe that the further investigation of the PEGylated HA-lipoplex 
formulation is of interest, since they showed promising mucus penetrating properties and in vivo lung 
distribution, and can thus offer a combination of both CD44-targeting and mucus penetration 
properties. 
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Conclusions and Perspectives 
 
An efficient CD44-targeting lipoplex system for gene expression inhibition using siRNA was developed. 
Lipoplexes modified with HA were easy to prepare, and thanks to their oligolamellar structure, they 
were able to achieve high siRNA loading. The interest of the HA-DOPE conjugate for the modification 
of the lipoplexes was demonstrated in terms of improving stability in physiological media and 
providing affinity to CD44 receptors. Receptor-mediated internalization was confirmed in vitro, as 
lipoplexes were shown to effectively transport siRNA to the cytoplasm of the targeted cells, where 
they actively inhibited gene expression. HA-lipoplexes were also able to deliver in vivo a dose of intact 
siRNA to the CD44-overexpressing lung cancer cells, and promote gene silencing in the tumor.  
HA-modified siRNA lipoplexes showed promising mucus penetrating ability and the addition of PEG to 
their structure further improved lipoplexes diffusion in the lungs. Taken together, these results 
confirm that HA-lipoplexes are able to efficiently release siRNA within the cell cytoplasm in vitro and in 
vivo. 
Capillary electrophoresis studies allowed the quantification of the HA-DOPE conjugate attached to the 
lipoplexes. A further exploration of the supramolecular structure of these particles could be 
performed, with the quantification of the amount of HA present on the surface of the particles. The 
distinction between the HA portion on the surface and the portion inside the lipoplexes would be of 
interest and could be related to the binding to CD44 receptors. This measurement would be possible 
after exposure of HA-lipoplexes to hyaluronidases, which would separate the portion of the HA 
localized at the surface of the lipoplexes. 
An important future goal would be to study lipoplexes biodistribution after intravenous 
administration. This analysis would elucidate the contribution of the active CD44-targeting promoted 
by HA and of the furtivity promoted by the hydrophilic coating of the lipoplexes to the gene silencing 
effect observed.  
The PEGylated HA-lipoplexes showed promising mucus diffusion in vitro and after endotracheal 
administration. Therefore, an investigation of their macromolecular structure and organization in 
comparison to (non-PEGylated) HA-lipoplexes should be carried out, as well as their in vivo gene 
expression inhibition. This further modification of the lipoplex surface could also represent an 
improvement in terms of particle stability when the intravenous administration of the particles is 
considered. PEGylation would help decrease HA-lipoplexes interaction with plasma components and 
improve tumor accumulation and receptor targeting, and consequently gene silencing activity.   
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